

ZY 1234 320

ELI LILLY AND COMPANY
 FID-MC-HGAJ (ALL PHASES)

FDA cutoffs used

ANALYTCD	ANALYTE	GENDER	LOLIM	HILIM	UNIT
A01	HEMATOCRIT	F	0.32	0.5	1
		M	0.37	0.55	1
A02	HEMOGLOBIN	F	5.8957	10.2399	mmL/L-Fe
		M	7.1369	11.4811	mmL/L-Fe
A03	ERYTHROCYTE COUNT	F	3	6	TI/L
		M	3	6	TI/L
A10	LEUCOCYTE COUNT	F	2.8	16	GI/L
		M	2.8	16	GI/L
A13	NEUTROPHILS, SEGMENTED	F	15	.	% WBC
		M	15	.	% WBC
A16	EOSINOPHILS	F	.	10	% WBC
		M	.	10	% WBC
A20	PLATELET COUNT	F	75	700	GI/L
		M	75	700	GI/L
C01	UA-SPECIFIC GRAVITY	F	1.001	1.035	NO UNITS
		M	1.001	1.035	NO UNITS
C03	UA-PH	F	4.6	8	U
		M	4.6	8	U
C07	UA-GLUCOSE	F	.	3	NO UNITS
		M	.	3	NO UNITS
C11	UA-RBC	F	.	3	NO UNITS
		M	.	3	NO UNITS
C15	UA-WBC	F	.	3	NO UNITS
		M	.	3	NO UNITS
C21	UA-PROTEIN	F	.	3	NO UNITS
		M	.	3	NO UNITS
C26	UA-CASTS, GRANULAR	F	.	3	NO UNITS
		M	.	3	NO UNITS
C58	UA-KETONES	F	.	3	NO UNITS
		M	.	3	NO UNITS
C80	UA-CASTS, HYALINE	F	.	3	NO UNITS
		M	.	3	NO UNITS

ZY 1234 321

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

FDA cutoffs used

ANALYTCD	ANALYTE	GENDER	LOLIM	HILIM	UNIT
C84	UA-CASTS, MAXY	F M	. .	3 3	NO UNITS NO UNITS
C86	UA-CASTS, RBC	F M	. .	3 3	NO UNITS NO UNITS
E01	AST/SGOT	F M	. .	150 150	U/L U/L
E03	ALT/SGPT	F M	. .	165 165	U/L U/L
E12	CREATINE PHOSPHOKINASE	F M	. .	507 594	U/L U/L
E13	ALKALINE PHOSPHATASE	F M	. .	420 420	U/L U/L
E17	GGT(GGPT/SGGT/YGGT)	F M	. .	135 195	U/L U/L
F01	UREA NITROGEN	F M	. .	10.71 10.71	mmol/L mmol/L
F02	CREATININE	F M	. .	176.8 176.8	umol/L umol/L
F04	CALCIUM	F M	1.7465 1.7465	2.994 2.994	mmol/L mmol/L
F06	PHOSPHORUS	F M	0.48435 0.48435	1.77595 1.77595	mmol/L mmol/L
F07	SODIUM	F M	129 129	160 160	mmol/L mmol/L
F10	TOTAL PROTEIN	F M	50 50	. .	g/L g/L
F11	ALBUMIN	F M	25 25	. .	g/L g/L
F31	GLUCOSE, NON-FASTING	F M	2.4975 2.4975	13.875 13.875	mmol/L mmol/L
F40	URIC ACID	F M	. .	505.58 624.54	umol/L umol/L

13:18 Wednesday, July 5, 1995 3

ELI LILLY AND COMPANY
F1D-MC-HGAJ (ALL PHASES)

FDA cutoffs used

ANALYTCD	ANALYTE	GENDER	LOLIM	HILIM	UNIT
F50	CHOLESTEROL	F	.	15.516	mmol/L
		M	.	15.516	mmol/L
G01	BILIRUBIN, TOTAL	F	.	34.2	umol/L
		M	.	34.2	umol/L

ZY 1234 322

RMP.F1DSTSS1.SASPGM(LABNTJX)

85266

ZY 1234 323

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

ABNORMAL LABS INCIDENCE
USING FDA LIMITS

Name of Lab Test	Lab Test	DIRECTN	Therapy												
			Hal	Olz	ALL	MAX	MAX	MAX	N	n	(%)	N	n	(%)	
ALBUMIN	F11	LOW	634	0	0.00	1544	0	0.00	2178	0					
ALKALINE PHOSPHATASE	E13	HIGH	635	0	0.00	1546	1	0.00	2181	1					
ALT/SGPT	E03	HIGH	634	4	0.01	1540	33	0.02	2174	37					
AST/SGOT	E01	HIGH	634	2	0.00	1546	2	0.00	2180	4					
BILIRUBIN, TOTAL	G01	HIGH	631	1	0.00	1541	1	0.00	2172	2					
CALCIUM	F04	HIGH	635	0	0.00	1546	0	0.00	2181	0					
CHOLESTEROL	F50	HIGH	635	0	0.00	1546	0	0.00	2181	0					
CREATINE PHOSPHOKINASE	E12	HIGH	607	14	0.02	1490	54	0.04	2097	68					
CREATININE	F02	HIGH	633	2	0.00	1542	2	0.00	2175	4					
EOSINOPHILS	A16	HIGH	624	2	0.00	1527	23	0.02	2151	25					
ERYTHROCYTE COUNT	A03	HIGH	620	4	0.01	1529	12	0.01	2149	16					
GGT(GGT)/SGGT(YGT)	E17	HIGH	630	1	0.00	1535	22	0.01	2165	23					

(CONTINUED)

RMP.FIDSISS1.SASPGM(LABNTJX)

85266

ZY 1234 324

ELI LILLY AND COMPANY
 FID-MC-HGAJ (ALL PHASES)
 ABNORMAL LABS INCIDENCE
 USING FDA LIMITS

Name of Lab Test	Lab Test	DIRECTN	Therapy											
			Hal				Olz				ALL			
			N	n	(%)	N	n	(%)	N	n	(%)	N	n	(%)
GLUCOSE, F31	HIGH		628	2	0.00	1536	27	0.02	2164	29				
NON-FASTING	LOW		633	1	0.00	1542	1	0.00	2175	2				
HEMATOCR-IA01	HIGH		618	5	0.01	1512	11	0.01	2130	16				
IT	LOW		624	7	0.01	1526	18	0.01	2150	25				
HEMOGLOB-IA02	HIGH		622	5	0.01	1533	10	0.01	2155	15				
IN	LOW		631	2	0.00	1542	4	0.00	2173	6				
LEUCOCYTE-IA10	HIGH		616	5	0.01	1526	21	0.01	2142	26				
COUNT	LOW		631	2	0.00	1546	2	0.00	2177	4				
NEUTROPH-IA13	LOW													
ILS, SEGMENTED			632	0	0.00	1546	0	0.00	2178	0				
PHOSPHOR-IF06	HIGH		633	0	0.00	1540	2	0.00	2173	2				
US	LOW		634	0	0.00	1543	0	0.00	2177	0				
PLATELET-IA20	HIGH		632	0	0.00	1543	1	0.00	2175	1				
COUNT	LOW		632	0	0.00	1544	1	0.00	2176	1				
SODIUM F07	HIGH		635	0	0.00	1546	0	0.00	2181	0				
	LOW		626	3	0.00	1531	6	0.00	2157	9				
TOTAL PROTEIN	LOW		634	0	0.00	1546	0	0.00	2180	0				
UA-CASTS, IC26	INC2													
GRANULAR			631	0	0.00	1534	2	0.00	2165	2				

(CONTINUED)

RMP.FIDSISS1.SASPGM(LABNTJX)

85266

ZY 1234 325

ELI LILLY AND COMPANY
 FID-MC-HGAJ (ALL PHASES)
 ABNORMAL LABS INCIDENCE
 USING FDA LIMITS

Name of Lab Test	Lab Test	DIRECTN	Therapy											
			Hal			Olz			ALL			MAX		
			N	n	(%)	N	n	(%)	N	n	(%)	N	n	(%)
UA-CASTS, C80	INC2		631	0	0.00	1534	0	0.00	2165	0				
UA-CASTS, C86	INC2		631	0	0.00	1535	0	0.00	2166	0				
UA-CASTS, C84	INC2		631	0	0.00	1535	0	0.00	2166	0				
UA-GLUCOSE	INC2		627	2	0.00	1528	27	0.02	2155	29				
UA-KETONES	INC2		629	0	0.00	1532	2	0.00	2161	2				
UA-PH	C03	HIGH	630	0	0.00	1529	1	0.00	2159	1				
UA-PROTEIN	C21	INC2	631	1	0.00	1533	1	0.00	2164	2				
UA-RBC	C11	INC2	621	12	0.02	1507	34	0.02	2128	46				
UA-SPECIFIC GRAVITY	C01	HIGH	625	3	0.00	1519	13	0.01	2144	16				
UA-MBC	C15	INC2	625	8	0.01	1514	15	0.01	2139	23				
UREA NITROGEN	F01	HIGH	635	1	0.00	1542	2	0.00	2177	3				
URIC ACID	F40	HIGH	633	4	0.01	1540	11	0.01	2173	15				
ALL			28323	93	0.00	69077	362	0.01	97400	455				

13:18 Wednesday, July 5, 1995 7

ZY 1234 326

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

Number of notable patients
USING FDA LIMITS

Therapy	
Hal	01z
N	N
N	N
	75
	278
	353

85266

RNP.FIDSISSI.SASPGM(LABNTJX)

NOTABLE PATIENTS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

ZY 1234 327

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVIS	NOTERSLT	UNIT	LOLIM	HILIM
001	306	M	Ha1	HEMATOCRIT SODIUM	A01 F07	LOW LOW	6 6	0.33 124	1 mmol/L	0.37 129	0.55 160
001	306	M	01z	SODIUM	F07	LOW	22	128	mmol/L	129	160
001	608	M	01z	ALT/SGPT	E03	HIGH	5	194	U/L	.	165
001	614	F	01z	UA-SPECIFIC GRAVITY	C01	HIGH	26	1.037	NO UNITS	1.001	1.035
001	805	F	01z	UA-GLUCOSE GLUCOSE, NON-FASTING	C07 F31	INC2 HIGH	5 16	3 16.1534	NO UNITS mmol/L	.	3 13.875
001	1579	M	01z	URIC ACID	F40	HIGH	8	630.488	umol/L	.	624.54
001	1585	M	01z	UA-SPECIFIC GRAVITY	C01	HIGH	18	1.037	NO UNITS	1.001	1.035
001	1663	F	Ha1	URIC ACID	F40	HIGH	6	535.32	umol/L	.	505.58
003	15	M	01z	SODIUM	F07	LOW	6	121	mmol/L	129	160
003	467	F	01z	UA-RBC	C11	INC2	28	4	NO UNITS	.	3
003	469	F	01z	URIC ACID	F40	HIGH	20	517.476	umol/L	.	505.58
003	470	M	01z	EOSINOPHILS	A16	HIGH	8	18.2146	% WBC	.	10
003	688	F	01z	UA-RBC	C11	INC2	8	4	NO UNITS	.	3
003	695	M	01z	ALT/SGPT	E03	HIGH	5	312	U/L	.	165
003	800	M	01z	EOSINOPHILS ALT/SGPT	A16 E03	HIGH HIGH	16 11	10.5263 216	% WBC U/L	.	10 165
003	801	M	Ha1	CREATINE PHOSPHOKINASE	E12	HIGH	21	1280	U/L	.	594
003	891	F	01z	EOSINOPHILS	A16	HIGH	8	12.874	% WBC	.	10
003	1116	M	01z	CREATINE PHOSPHOKINASE	E12	HIGH	15	1623	U/L	.	594
003	1386	F	01z	EOSINOPHILS	A16	HIGH	4	14.8235	% WBC	.	10
003	1426	F	01z	UA-RBC	C11	INC2	16	4	NO UNITS	.	3
003	1429	M	01z	CREATINE PHOSPHOKINASE	E12	HIGH	11	1226	U/L	.	594
003	1507	M	01z	CREATINE PHOSPHOKINASE	E12	HIGH	18	728	U/L	.	594

ZY 1234 328

ELI LILLY AND COMPANY
FLD-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVIS	NOTERSLT	UNIT	LOLIM	HILIM
006	815	F	Olz	GGT(GGPT/SGGT/YGGT) GLUCOSE, NON-FASTING	E17 F31	HIGH HIGH	7 8	282 30.1974	U/L mmol/L	. 2.4975	135 13.875
006	816	M	Olz	UA-SPECIFIC GRAVITY	C01	HIGH	6	1.055	NO UNITS	1.001	1.035
006	817	M	Hal	UA-RBC CREATINE PHOSPHOKINASE	C11 E12	INC2 HIGH	5 6	4 945	NO UNITS U/L	. .	3 594
006	821	M	Olz	ALT/SGPT	E03	HIGH	7	215	U/L	.	165
007	341	M	Hal	GLUCOSE, NON-FASTING	F31	LOW	6	2.44244	mmol/L	2.4975	13.875
007	343	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	20	1298	U/L	.	594
007	346	F	Olz	UA-RBC	C11	INC2	28	4	NO UNITS	.	3
008	46	M	Olz	GGT(GGPT/SGGT/YGGT)	E17	HIGH	17	245	U/L	.	195
008	48	M	Hal	HEMATOCRIT	A01	LOW	5	0.35	1	0.37	0.55
008	913	M	Olz	UA-GLUCOSE GLUCOSE, NON-FASTING	C07 F31	INC2 HIGH	22 22	3 16.4865	NO UNITS mmol/L	. 2.4975	3 13.875
008	918	M	Hal	SODIUM	F07	LOW	7	128	mmol/L	129	160
009	51	M	Olz	UA-GLUCOSE GLUCOSE, NON-FASTING	C07 F31	INC2 HIGH	4 4	3 24.2024	NO UNITS mmol/L	. 2.4975	3 13.875
009	52	M	Olz	EOSINOPHILS	A16	HIGH	13	11.5966	% WBC	.	10
009	625	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	8	678	U/L	.	594
009	629	F	Olz	UA-RBC	C11	INC2	5	4	NO UNITS	.	3
012	459	M	Hal	CREATINE PHOSPHOKINASE	E12	HIGH	5	3100	U/L	.	594
012	460	F	Olz	UA-GLUCOSE GLUCOSE, NON-FASTING	C07 F31	INC2 HIGH	14 10	3 18.0408	NO UNITS mmol/L	. 2.4975	3 13.875
013	74	M	Olz	LEUCOCYTE COUNT	A10	HIGH	18	16.33	GI/L	2.8	16
013	364	M	Olz	GGT(GGPT/SGGT/YGGT)	E17	HIGH	7	196	U/L	.	195
013	923	M	Olz	ERYTHROCYTE COUNT	A03	HIGH	18	6.2	TI/L	3	6
014	84	F	Olz	UA-PH	C03	HIGH	3	9	U	4.6	8

ZY 1234 329

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVTS	NOTERSLT	UNIT	LOLIM	HILIM
016	485	F	01z	UA-SPECIFIC GRAVITY	C01	HIGH	28	1.036	NO UNITS	1.001	1.035
				UA-GLUCOSE	C07	INC2	20	3	NO UNITS		3
				GLUCOSE, NON-FASTING	F31	HIGH	28	14.8767	mmol/L	2.4975	13.875
016	491	M	01z	ALT/SGPT	E03	HIGH	22	176	U/L		165
016	932	F	Ha1	GLUCOSE, NON-FASTING	F31	HIGH	20	13.8775	mmol/L	2.4975	13.875
016	934	M	01z	LEUCOCYTE COUNT	A10	HIGH	14	18.77	GI/L	2.8	16
016	935	F	01z	UA-GLUCOSE	C07	INC2	20	3	NO UNITS		3
				GGT(GGPT/SGGT/UGGT)	E17	HIGH	18	178	U/L		135
				GLUCOSE, NON-FASTING	F31	HIGH	20	17.4857	mmol/L	2.4975	13.875
016	939	F	01z	UA-RBC	C11	INC2	18	4	NO UNITS		3
017	97	M	01z	LEUCOCYTE COUNT	A10	LOW	3	2.67	GI/L	2.8	16
017	98	M	01z	CREATINE PHOSPHOKINASE	E12	HIGH	14	872	U/L		594
017	773	M	Ha1	CREATININE	F02	HIGH	4	185.64	umol/L		176.8
017	775	M	01z	HEMATOCRIT	A01	LOW	5	0.34	1	0.37	0.55
				HEMOGLOBIN	A02	LOW	6	7.07484	mmL/L-Fe	7.1369	11.4811
020	833	M	01z	UA-GLUCOSE	C07	INC2	4	3	NO UNITS		3
				GLUCOSE, NON-FASTING	F31	HIGH	4	14.3771	mmol/L	2.4975	13.875
020	1134	F	01z	HEMATOCRIT	A01	LOW	13	0.29	1	0.32	0.5
021	1247	F	01z	AST/SGOT	E01	HIGH	23	336	U/L		150
				ALT/SGPT	E03	HIGH	23	245	U/L		165
				GGT(GGPT/SGGT/UGGT)	E17	HIGH	22	592	U/L		135
021	1651	M	01z	EOSINOPHILS	A16	HIGH	18	10.6931	% WBC		10
023	1213	F	Ha1	LEUCOCYTE COUNT	A10	HIGH	6	16.24	GI/L	2.8	16
024	140	M	01z	LEUCOCYTE COUNT	A10	HIGH	6	17.08	GI/L	2.8	16
024	1219	F	01z	SODIUM	F07	LOW	18	126	mmol/L	129	160
024	1222	M	Ha1	AST/SGOT	E01	HIGH	3	748	U/L		150
				ALT/SGPT	E03	HIGH	3	239	U/L		165
				CREATINE PHOSPHOKINASE	F12	HIGH	3	65900	U/L		594
025	148	M	01z	LEUCOCYTE COUNT	A10	HIGH	20	17.35	GI/L	2.8	16

NOTABLE PATIENTS
 ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

ZY 1234 330

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVTS	NOTERSLT	UNIT	LOLIM	HILIM
025	499	F	Olz	UA-GLUCOSE GLUCOSE, NON-FASTING	C07 F31	INC2 HIGH	16 5	3 14.9322	NO UNITS mmol/L	2.4975	13.875
025	500	M	Hal	HEMATOCRIT HEMOGLOBIN	A01 A02	LOW LOW	8 4	0.35 7.01278	1 mmol/L-Fa	0.37 7.1369	0.55 11.4811
025	942	M	Olz	UA-KETONES	C58	INC2	8	3	NO UNITS	.	3
026	153	M	Olz	UA-GLUCOSE GLUCOSE, NON-FASTING	C07 F31	INC2 HIGH	19 12	3 18.2073	NO UNITS mmol/L	2.4975	13.875
026	154	M	Olz	LEUCOCYTE COUNT	A10	HIGH	16	16.16	GI/L	2.8	16
027	331	M	Olz	EOSINOPHILS	A16	HIGH	14	13.3333	% WBC	.	10
027	334	M	Olz	HEMATOCRIT	A01	LOW	28	0.35	1	0.37	0.55
027	335	M	Olz	LEUCOCYTE COUNT	A10	HIGH	13	16.17	GI/L	2.8	16
027	337	F	Olz	UA-RBC	C11	INC2	4	4	NO UNITS	.	3
027	592	M	Olz	LEUCOCYTE COUNT	A10	HIGH	17	19.3	GI/L	2.8	16
027	593	M	Olz	SODIUM	F07	LOW	9	124	mmol/L	129	160
027	597	F	Olz	UA-MBC	C15	INC2	8	3	NO UNITS	.	3
027	949	M	Olz	UA-SPECIFIC GRAVITY	C01	HIGH	6	1.036	NO UNITS	1.001	1.035
027	951	F	Hal	URIC ACID	F40	HIGH	4	612.644	umol/L	.	505.58
028	164	F	Olz	UA-RBC	C11	INC2	18	4	NO UNITS	.	3
028	168	M	Hal	AST/SGOT CREATINE PHOSPHOKINASE	E01 E12	HIGH HIGH	4 4	195 15420	U/L U/L	.	150 594
028	677	M	Olz	ALT/SGPT	E03	HIGH	6	229	U/L	.	165
028	678	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	15	8150	U/L	.	594
028	961	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	4	970	U/L	.	594
029	169	F	Hal	UA-RBC	C11	INC2	4	4	NO UNITS	.	3
029	172	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	19	3700	U/L	.	594
029	173	M	Olz	ALT/SGPT	E03	HIGH	16	396	U/L	.	165

ZY 1234 331

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVIS	NOTERSLT	UNIT	LOLIM	HILIM
029	421	F	Olz	HEMATOCRIT	A01	LOW	9	0.31	1	0.32	0.5
029	428	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	23	1288	U/L	.	594
029	739	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	4	11980	U/L	.	594
029	967	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	16	649	U/L	.	594
029	969	M	Olz	ERYTHROCYTE COUNT	A03	HIGH	13	6.1	TI/L	3	6
029	974	M	Olz	GGT(GGPT/SGGT/YGGT)	E17	HIGH	6	248	U/L	.	195
031	482	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	17	5865	U/L	.	594
031	984	M	Olz	ALT/SGPT	E03	HIGH	14	176	U/L	.	165
031	1644	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	5	876	U/L	.	594
032	189	F	Olz	LEUCOCYTE COUNT	A10	HIGH	16	17.1	GI/L	2.8	16
032	448	M	Olz	PHOSPHORUS	F06	HIGH	27	1.90511	mmol/L	0.48435	1.77595
032	449	F	Olz	EOSINOPHILS	A16	HIGH	14	14.91	% WBC	.	10
032	451	F	Ha1	HEMOGLOBIN	A02	HIGH	22	10.6743	mmol/L-Fe	5.8957	10.2399
032	453	F	Olz	UA-RBC	C11	INC2	18	4	NO UNITS	.	3
033	752	F	Olz	UA-GLUCOSE GGT(GGPT/SGGT/YGGT) GLUCOSE, NON-FASTING	C07 E17 F31	INC2 HIGH HIGH	26 6 26	3 259 15.4318	NO UNITS U/L mmol/L	.	3 135 13.875
034	204	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	5	1114	U/L	.	594
035	205	M	Olz	EOSINOPHILS	A16	HIGH	12	10.665	% WBC	.	10
035	208	M	Olz	LEUCOCYTE COUNT CREATINE PHOSPHOKINASE	A10 E12	HIGH HIGH	7 7	18.77 659	GI/L U/L	2.8	16 594
035	716	M	Olz	UA-SPECIFIC GRAVITY UA-GLUCOSE GLUCOSE, NON-FASTING	C01 C07 F31	HIGH INC2 HIGH	26 22 24	1.036 3 15.6538	NO UNITS NO UNITS mmol/L	1.001	1.035 3 13.875
035	720	M	Ha1	HEMATOCRIT	A01	LOW	9	0.36	1	0.37	0.55
036	211	M	Ha1	CREATININE	F02	HIGH	3	185.64	umol/L	.	176.8

RMP.FIDSTSL.SASPGM(LABNTJX) 85266

NOTABLE PATIENTS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVIS	NOTERSLT	UNIT	LOLIM	HILIM
036	212	F	01z	HEMATOCRIT	A01	LOW	10	0.31	1	0.32	0.5
036	323	F	01z	ALT/SGPT	E03	HIGH	5	234	U/L	.	165
038	224	M	01z	UA-GLUCOSE GLUCOSE, NON-FASTING	C07 F31	INC2 HIGH	22 29	3 16.1534	NO UNITS mmol/L	.	13.875
038	412	M	01z	EOSINOPHILS	A16	HIGH	8	18.1704	% WBC	.	10
038	681	M	01z	UA-RBC	C11	INC2	8	4	NO UNITS	.	3
038	684	M	01z	ERYTHROCYTE COUNT	A03	HIGH	22	6.2	TI/L	3	6
039	389	M	01z	UA-RBC	C11	INC2	17	4	NO UNITS	.	3
039	392	M	01z	ALT/SGPT	E03	HIGH	6	285	U/L	.	165
040	239	F	01z	UA-RBC	C11	INC2	24	4	NO UNITS	.	3
040	240	F	Ha1	GLUCOSE, NON-FASTING	F31	HIGH	8	15.7093	mmol/L	2.4975	13.875
040	851	M	Ha1	LEUCOCYTE COUNT	A10	HIGH	8	18.11	GI/L	2.8	16
041	242	M	Ha1	HEMATOCRIT	A01	LOW	27	0.35	1	0.37	0.55
041	245	F	01z	UA-RBC	C11	INC2	19	4	NO UNITS	.	3
041	397	M	01z	AST/SGOT CREATINE PHOSPHOKINASE	E01 E12	HIGH HIGH	20 20	249 24880	U/L U/L	.	150 594
041	401	M	01z	ALT/SGPT	E03	HIGH	14	416	U/L	.	165
041	1025	M	01z	GLUCOSE, NON-FASTING	F31	HIGH	4	19.9281	mmol/L	2.4975	13.875
042	247	M	Ha1	CREATINE PHOSPHOKINASE	E12	HIGH	7	2160	U/L	.	594
042	248	M	01z	GLUCOSE, NON-FASTING	F31	HIGH	4	24.7575	mmol/L	2.4975	13.875
042	1465	M	01z	CREATINE PHOSPHOKINASE	E12	HIGH	14	1112	U/L	.	594
043	1095	M	01z	LEUCOCYTE COUNT	A10	HIGH	19	19.37	GI/L	2.8	16
044	1446	F	01z	UA-GLUCOSE	C07	INC2	20	3	NO UNITS	.	3
044	1448	M	Ha1	CREATINE PHOSPHOKINASE	E12	HIGH	3	818	U/L	.	594
044	1572	M	01z	UA-GLUCOSE	C07	INC2	6	3	NO UNITS	.	3

NOTABLE PATIENTS
 ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVIS	NOTERSLT	UNIT	LOLIM	HILIM
044	1572	M	Olz	GLUCOSE, NON-FASTING	F31	HIGH	7	14.8767	mmol/L	2.4975	13.875
045	267	F	Ha1	UA-SPECIFIC GRAVITY UA-GLUCOSE	C01 C07	HIGH INC2	26 4	1.04 3	NO UNITS NO UNITS	1.001	1.035 3
045	787	M	Olz	LEUCOCYTE COUNT	A10	HIGH	3	20.69	GI/L	2.8	16
045	794	M	Olz	ALT/SGPT	E03	HIGH	7	187	U/L	.	165
045	1279	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	3	736	U/L	.	594
045	1281	F	Olz	UA-RBC	C11	INC2	16	4	NO UNITS	.	3
045	1408	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	4	5640	U/L	.	594
045	1409	F	Olz	LEUCOCYTE COUNT	A10	HIGH	11	18.13	GI/L	2.8	16
045	1414	M	Olz	HEMATOCRIT EOSINOPHILS	A01 A16	LOW HIGH	5 8	0.36 19.7464	1 % WBC	0.37	0.55 10
047	279	M	Olz	UA-GLUCOSE	C07	INC2	6	3	NO UNITS	.	3
047	282	M	Ha1	URIC ACID	F40	HIGH	5	660.228	umol/L	.	624.54
048	283	M	Ha1	LEUCOCYTE COUNT	A10	HIGH	6	16.14	GI/L	2.8	16
048	286	M	Olz	HEMATOCRIT	A01	LOW	9	0.35	1	0.37	0.55
048	352	M	Ha1	EOSINOPHILS	A16	HIGH	8	10.3982	% WBC	.	10
048	353	M	Olz	ALT/SGPT	E03	HIGH	6	224	U/L	.	165
049	290	F	Olz	UA-RBC	C11	INC2	28	3	NO UNITS	.	3
049	291	F	Olz	UA-GLUCOSE GLUCOSE, NON-FASTING	C07 F31	INC2 HIGH	20 20	3 28.3101	NO UNITS mmol/L	2.4975	13.875
049	763	F	Olz	UA-GLUCOSE	C07	INC2	26	3	NO UNITS	.	3
049	767	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	3	3785	U/L	.	594
049	1259	M	Ha1	ALT/SGPT	E03	HIGH	6	168	U/L	.	165
049	1259	M	Olz	HEMOGLOBIN CREATINE PHOSPHOKINASE	A02 E12	HIGH HIGH	20 20	11.4811 865	mmol/L-Fe U/L	7.1369	11.4811 594
049	1260	M	Olz	HEMATOCRIT	A01	LOW	6	0.36	1	0.37	0.55

NOTABLE PATIENTS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

ZY 1234 334

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVIS	NOTERSLT	UNIT	LOLIM	HILIM
049	1260	M	01z	CREATINE PHOSPHOKINASE	E12	HIGH	6	2320	U/L	.	594
050	556	F	Ha1	HEMATOCRIT	A01	LOW	6	0.31	1	0.32	0.5
050	556	F	01z	HEMATOCRIT	A01	LOW	11	0.31	1	0.32	0.5
				UA-MBC	C15	INC2	16	4	NO UNITS	.	3
				ALKALINE PHOSPHATASE	E13	HIGH	16	542	U/L	.	420
				GGT(GGPT/SGGT/YGGT)	E17	HIGH	16	677	U/L	.	135
				GLUCOSE, NON-FASTING	F31	HIGH	16	20.4277	mmol/L	2.4975	13.875
050	558	M	01z	ERYTHROCYTE COUNT	A03	HIGH	18	6.1	TI/L	3	6
050	1039	M	Ha1	ERYTHROCYTE COUNT	A03	HIGH	16	6.2	TI/L	3	6
050	1040	M	01z	CREATINE PHOSPHOKINASE	E12	HIGH	4	3835	U/L	.	594
051	313	M	01z	LEUCOCYTE COUNT	A10	HIGH	28	17.71	GI/L	2.8	16
051	314	M	01z	CREATINE PHOSPHOKINASE	E12	HIGH	18	1238	U/L	.	594
				GGT(GGPT/SGGT/YGGT)	E17	HIGH	20	572	U/L	.	195
052	514	M	01z	CREATINE PHOSPHOKINASE	E12	HIGH	6	10060	U/L	.	594
052	517	M	01z	CREATINE PHOSPHOKINASE	E12	HIGH	13	639	U/L	.	594
053	520	M	01z	HEMATOCRIT	A01	LOW	6	0.34	1	0.37	0.55
053	527	M	01z	GGT(GGPT/SGGT/YGGT)	E17	HIGH	4	340	U/L	.	195
054	535	M	01z	HEMOGLOBIN	A02	HIGH	27	11.4811	mmol/L-Fe	7.1369	11.4811
054	536	M	01z	CREATININE	F02	HIGH	16	176.8	umol/L	.	176.8
055	542	M	01z	HEMOGLOBIN	A02	LOW	13	7.07484	mmol/L-Fe	7.1369	11.4811
				UA-GLUCOSE	C07	INC2	4	3	NO UNITS	.	3
				GLUCOSE, NON-FASTING	F31	HIGH	6	13.933	mmol/L	2.4975	13.875
056	1266	F	01z	UA-GLUCOSE	C07	INC2	18	3	NO UNITS	.	3
				GLUCOSE, NON-FASTING	F31	HIGH	16	16.875	mmol/L	2.4975	13.875
056	1267	F	01z	ALT/SGPT	E03	HIGH	22	195	U/L	.	165
056	1270	M	01z	LEUCOCYTE COUNT	A10	HIGH	20	17.42	GI/L	2.8	16
057	569	F	Ha1	HEMATOCRIT	A01	HIGH	7	0.54	1	0.32	0.5
				HEMOGLOBIN	A02	HIGH	7	10.302	mmol/L-Fe	5.8957	10.2399

ZY 1234 335

ELI LILLY AND COMPANY
 FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS
 ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVIS	NOTERSLT	UNIT	LOLIM	HILIM
057	569	F	01z	HEMATOCRIT HEMOGLOBIN	A01 A02	HIGH HIGH	10 10	0.57 10.9226	1 mmL/L-Fe	0.32 5.8957	0.5 10.2399
057	1060	M	Ha1	LEUCOCYTE COUNT	A10	HIGH	4	18.85	GI/L	2.8	16
057	1061	F	01z	UA-GLUCOSE GLUCOSE, NON-FASTING	C07 F31	INC2 HIGH	5 5	3 20.7607	NO UNITS mmol/L	. 2.4975	3 13.875
057	1503	M	Ha1	CREATINE PHOSPHOKINASE	E12	HIGH	4	753	U/L	.	594
058	598	F	01z	UA-GLUCOSE	C07	INC2	16	3	NO UNITS	.	3
058	600	M	01z	CREATINE PHOSPHOKINASE	E12	HIGH	22	1378	U/L	.	594
059	620	M	01z	HEMOGLOBIN ERYTHROCYTE COUNT	A02 A03	HIGH HIGH	26 26	11.5432 6.2	mmL/L-Fe TI/L	7.1369 3	11.4811 6
				UA-GLUCOSE GLUCOSE, NON-FASTING	C07 F31	INC2 HIGH	6 6	3 16.0424	NO UNITS mmol/L	. 2.4975	3 13.875
059	1121	F	01z	UA-RBC	C11	INC2	5	4	NO UNITS	.	3
059	1122	M	01z	HEMATOCRIT HEMOGLOBIN	A01 A02	LOW LOW	4 9	0.36 7.01278	1 mmL/L-Fe	0.37 7.1369	0.55 11.4811
059	1243	M	01z	CREATINE PHOSPHOKINASE	E12	HIGH	4	1636	U/L	.	594
060	644	M	Ha1	ERYTHROCYTE COUNT	A03	HIGH	9	6.1	TI/L	3	6
060	650	M	Ha1	HEMATOCRIT	A01	HIGH	7	0.6	1	0.37	0.55
061	1084	M	Ha1	CREATINE PHOSPHOKINASE	E12	HIGH	3	621	U/L	.	594
062	1078	F	01z	CREATINE PHOSPHOKINASE	E12	HIGH	22	610	U/L	.	507
062	1079	F	Ha1	HEMATOCRIT HEMOGLOBIN	A01 A02	LOW LOW	4 4	0.3 5.5854	1 mmL/L-Fe	0.32 5.8957	0.5 10.2399
062	1080	F	01z	GGT(GGPT/SGGT/YGGT)	E17	HIGH	18	169	U/L	.	135
066	1183	F	01z	UA-WBC	C15	INC2	10	4	NO UNITS	.	3
066	1188	M	01z	ALT/SGPT GGT(GGPT/SGGT/YGGT)	F03 E17	HIGH HIGH	12 12	411 219	U/L U/L	..	165 195
068	1304	M	01z	UA-WBC CREATINE PHOSPHOKINASE	C15 E12	INC2 HIGH	17 17	3 940	NO UNITS U/L	..	3 594

NOTABLE PATIENTS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVIS	NOTERSLT	UNIT	LOLIM	HILIM
068	1307	M	Olz	ALT/SGPT	E03	HIGH	4	281	U/L	.	165
068	1608	M	Olz	HEMATOCRIT SODIUM	A01 F07	LOW LOW	13 12	0.36 114	1 mmol/L	0.37 129	0.55 160
068	1609	M	Olz	SODIUM	F07	LOW	20	128	mmol/L	129	160
068	1611	M	Olz	ALT/SGPT	E03	HIGH	6	265	U/L	.	165
068	1612	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	20	1564	U/L	.	594
070	1319	M	Olz	GLUCOSE, NON-FASTING	F31	HIGH	6	14.9877	mmol/L	2.4975	13.875
070	1320	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	12	855	U/L	.	594
070	1322	M	Olz	HEMATOCRIT CREATINE PHOSPHOKINASE	A01 E12	LOW HIGH	5 6	0.34 1884	1 U/L	0.37	0.55 594
074	1355	M	Olz	CREATINE PHOSPHOKINASE URIC ACID	E12 F40	HIGH HIGH	22 22	939 648.332	U/L umol/L	.	594 624.54
074	1357	M	Hal	HEMOGLOBIN	A02	HIGH	4	11.6673	mmL/L-Fe	7.1369	11.4811
074	1535	M	Olz	HEMATOCRIT CREATINE PHOSPHOKINASE	A01 E12	LOW HIGH	11 11	0.36 13720	1 U/L	0.37	0.55 594
102	2013	M	Hal	CREATINE PHOSPHOKINASE	E12	HIGH	3	703	U/L	.	594
106	2037	F	Olz	GGT(GGPT/SGGT/YGGT)	E17	HIGH	5	179	U/L	.	135
108	2052	M	Olz	ERYTHROCYTE COUNT	A03	HIGH	16	6.1	TI/L	3	6
110	2065	M	Olz	UA-SPECIFIC GRAVITY	C01	HIGH	7	1.036	NO UNITS	1.001	1.035
200	2402	F	Hal	UA-MBC	C15	INC2	8	4	NO UNITS	.	3
200	2404	F	Olz	HEMOGLOBIN	A02	HIGH	15	10.2399	mmL/L-Fe	5.8957	10.2399
200	2406	F	Olz	LEUCOCYTE COUNT	A10	HIGH	16	21.72	GI/L	2.8	16
200	2464	M	Olz	HEMATOCRIT HEMOGLOBIN	A01 A02	HIGH HIGH	26 26	0.55 11.5432	1 mmL/L-Fe	0.37 7.1369	0.55 11.4811
200	2465	F	Hal	UA-RBC	C11	INC2	4	4	NO UNITS	.	3
201	2408	F	Olz	UA-RBC	C11	INC2	3	4	NO UNITS	.	3

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVTS	NOTERSLT	UNIT	LOLIM	HILIM
202	2417	M	Olz	UA-WBC	C15	INC2	7	4	NO UNITS	.	3
203	2421	F	Olz	UA-RBC	C11	INC2	4	4	NO UNITS	.	3
203	2424	M	Olz	ALT/SGPT	E03	HIGH	13	215	U/L	.	165
204	2427	F	Olz	GGT(GGPT/SGGT/YGGT)	E17	HIGH	27	144	U/L	.	135
204	2428	F	Olz	HEMATOCRIT HEMOGLOBIN	A01 A02	LOW LOW	21 21	0.3 5.83364	1 mmL/L-Fe	0.32 5.8957	0.5 10.2399
205	2432	M	Olz	GGT(GGPT/SGGT/YGGT)	E17	HIGH	23	307	U/L	.	195
205	2434	F	Olz	URIC ACID	F40	HIGH	26	568	umol/L	.	505.58
205	2436	F	Olz	EOSINOPHILS	A16	HIGH	4	14.6067	% WBC	.	10
205	2452	F	Olz	EOSINOPHILS UREA NITROGEN	A16 F01	HIGH HIGH	15 13	10.1322 11.1	% WBC mmol/L	.	10 10.71
206	2439	M	Olz	UA-GLUCOSE GLUCOSE, NON-FASTING	C07 F31	INC2 HIGH	28 28	3 15.2	NO UNITS mmol/L	.	3 13.875
206	2441	F	Olz	EOSINOPHILS	A16	HIGH	5	11.8545	% WBC	.	10
240	2552	M	Olz	LEUCOCYTE COUNT	A10	HIGH	19	17.74	GI/L	2.8	16
280	7326	F	Olz	EOSINOPHILS	A16	HIGH	7	26.793	% WBC	.	10
300	2994	F	Olz	UA-RBC UA-WBC	C11 C15	INC2 INC2	24 24	4 4	NO UNITS NO UNITS	.	3 3
300	3003	F	Olz	UA-SPECIFIC GRAVITY CREATINE PHOSPHOKINASE	C01 E12	HIGH HIGH	3 3	1.036 5490	NO UNITS U/L	1.001	1.035 507
302	2813	M	Olz	HEMATOCRIT	A01	HIGH	28	0.56	1	0.37	0.55
303	2820	F	Olz	URIC ACID	F40	HIGH	5	608	umol/L	.	505.58
304	2825	F	Olz	GGT(GGPT/SGGT/YGGT)	E17	HIGH	4	156	U/L	.	135
304	2827	M	Hal	UA-GLUCOSE	C07	INC2	7	3	NO UNITS	.	3
304	2827	M	Olz	ECSINOPHILS	A16	HIGH	15	10.0125	% WBC	.	10
304	2829	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	5	778	U/L	.	594

NOTABLE PATIENTS
 ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVIS	NOTERSLT	UNIT	LOLIM	HILIM
305	2831	F	Olz	UA-MBC	C15	INC2	28	3	NO UNITS	.	3
306	2838	M	Olz	LEUCOCYTE COUNT	A10	HIGH	3	26.91	GI/L	2.8	16
306	2839	F	Ha1	UA-RBC	C11	INC2	8	4	NO UNITS	.	3
306	2841	M	Olz	ALT/SGPT	E03	HIGH	4	179	U/L	.	165
306	3074	F	Olz	EOSINOPHILS	A16	HIGH	7	12.2424	% WBC	.	10
307	2844	M	Ha1	UREA NITROGEN	F01	HIGH	8	11.2	mmol/L	.	10.71
307	2847	F	Ha1	UA-MBC	C15	INC2	6	4	NO UNITS	.	3
307	2848	F	Olz	URIC ACID	F40	HIGH	27	520	umol/L	.	505.58
307	3046	F	Olz	GGT(GGPT/SGGT/YGGT)	E17	HIGH	27	160	U/L	.	135
307	3048	M	Olz	HEMATOCRIT	A01	LOW	6	0.34	1	0.37	0.55
308	2849	M	Olz	HEMATOCRIT	A01	HIGH	28	0.55	1	0.37	0.55
308	2852	M	Olz	UA-GLUCOSE	C07	INC2	4	3	NO UNITS	.	3
312	2877	F	Olz	PLATELET COUNT	A20	HIGH	26	735	GI/L	75	700
312	3193	M	Olz	UA-RBC	C11	INC2	12	4	NO UNITS	.	3
				UA-MBC	C15	INC2	12	4	NO UNITS	.	3
312	3194	F	Olz	UA-MBC	C15	INC2	7	4	NO UNITS	.	3
315	2893	F	Ha1	HEMOGLOBIN	A02	HIGH	18	10.4881	mmL/L-Fe	5.8957	10.2399
315	2894	F	Ha1	ALT/SGPT	E03	HIGH	4	345	U/L	.	165
315	3146	M	Olz	HEMATOCRIT	A01	LOW	8	0.36	1	0.37	0.55
				UA-RBC	C11	INC2	8	4	NO UNITS	.	3
				UA-MBC	C15	INC2	8	4	NO UNITS	.	3
				UA-PROTEIN	C21	INC2	8	3	NO UNITS	.	3
				UREA NITROGEN	F01	HIGH	8	23.9	mmol/L	.	10.71
				PHOSPHORUS	F06	HIGH	8	1.82	mmol/L	0.48435	1.77595
315	3147	F	Ha1	CREATINE PHOSPHOKINASE	E12	HIGH	5	1820	U/L	.	507
316	2899	M	Olz	ALT/SGPT	E03	HIGH	18	198	U/L	.	165
318	2913	M	Olz	UA-GLUCOSE	C07	INC2	24	3	NO UNITS	.	3

ZY 1234 339

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVTS	NOTERSLT	UNIT	LOLIM	HILIM
318	2913	M	Olz	GLUCOSE, NON-FASTING	F31	HIGH	26	18.1	mmol/L	2.4975	13.875
319	2915	F	Olz	UA-SPECIFIC GRAVITY	C01	HIGH	28	1.036	NO UNITS	1.001	1.035
				UA-GLUCOSE	C07	INC2	22	3	NO UNITS	.	3
				GLUCOSE, NON-FASTING	F31	HIGH	20	15.4	mmol/L	2.4975	13.875
320	2922	F	Olz	GLUCOSE, NON-FASTING	F31	LOW	23	1.7	mmol/L	2.4975	13.875
321	2930	M	Olz	EOSINOPHILS	A16	HIGH	5	11.0283	% WBC	.	10
321	3136	F	Ha1	HEMATOCRIT	A01	HIGH	6	0.51	1	0.32	0.5
321	3138	F	Ha1	UA-RBC	C11	INC2	9	4	NO UNITS	.	3
				UA-WBC	C15	INC2	7	4	NO UNITS	.	3
				UA-PROTEIN	C21	INC2	9	3	NO UNITS	.	3
				ALT/SGPT	E03	HIGH	8	389	U/L	.	165
322	3011	M	Olz	UA-CASTS, GRANULAR	C26	INC2	25	3	NO UNITS	.	3
				UA-KETONES	C58	INC2	25	3	NO UNITS	.	3
				URIC ACID	F40	HIGH	25	932	umol/L	.	624.54
				BILIRUBIN, TOTAL	G01	HIGH	25	36	umol/L	.	34.2
322	3283	M	Olz	UA-SPECIFIC GRAVITY	C01	HIGH	16	1.036	NO UNITS	1.001	1.035
325	2951	F	Ha1	UA-RBC	C11	INC2	6	4	NO UNITS	.	3
				UA-WBC	C15	INC2	6	4	NO UNITS	.	3
325	2955	F	Olz	HEMOGLOBIN	A02	HIGH	17	10.302	mmL/L-Fe	5.8957	10.2399
				ALT/SGPT	E03	HIGH	17	337	U/L	.	165
325	3026	F	Olz	UA-RBC	C11	INC2	26	4	NO UNITS	.	3
325	3029	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	4	1731	U/L	.	594
327	2965	M	Olz	UA-SPECIFIC GRAVITY	C01	HIGH	28	1.036	NO UNITS	1.001	1.035
327	3106	M	Olz	ERYTHROCYTE COUNT	A03	HIGH	18	6.2	TI/L	3	6
328	3063	F	Olz	UA-RBC	C11	INC2	27	4	NO UNITS	.	3
331	2990	F	Olz	UA-SPECIFIC GRAVITY	C01	HIGH	10	1.036	NO UNITS	1.001	1.035
332	3115	M	Ha1	CREATINE PHOSPHOKINASE	E12	HIGH	3	966	U/L	.	594
332	3190	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	12	997	U/L	.	594
332	3244	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	19	835	U/L	.	594

NOTABLE PATIENTS
 ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTES	NOTESLT	UNIT	LOLIM	HILIM
333	3287	M	01z	LEUCOCYTE COUNT	A10	LOW	7	2.73	GI/L	2.8	16
334	3170	F	01z	UA-RBC	C11	INC2	16	4	NO UNITS	.	3
334	3236	F	01z	GGT (GGPT/SGGT/YGGT)	E17	HIGH	4	215	U/L	.	135
334	3251	F	01z	UA-RBC	C11	INC2	17	4	NO UNITS	.	3
				UA-MBC	C15	INC2	17	4	NO UNITS	.	3
336	3211	F	01z	CREATINE PHOSPHOKINASE	E12	HIGH	9	597	U/L	.	507
337	3246	F	Ha1	UA-RBC	C11	INC2	7	4	NO UNITS	.	3
401	4111	F	01z	ALT/SGPT	E03	HIGH	7	269	U/L	.	165
401	4168	M	01z	ALT/SGPT	E03	HIGH	6	205	U/L	.	165
				CREATINE PHOSPHOKINASE	E12	HIGH	8	632	U/L	.	594
401	4175	M	Ha1	EOSINOPHILS	A16	HIGH	22	12.7451	% WBC	.	10
401	4214	M	Ha1	LEUCOCYTE COUNT	A10	HIGH	9	16.67	GI/L	2.8	16
402	4116	F	Ha1	HEMATOCRIT	A01	HIGH	19	0.52	1	0.32	0.5
404	4229	M	Ha1	UA-SPECIFIC GRAVITY	C01	HIGH	3	1.036	NO UNITS	1.001	1.035
407	4145	M	01z	ERYTHROCYTE COUNT	A03	HIGH	5	6.1	TI/L	3	6
407	4146	F	01z	HEMOGLOBIN	A02	HIGH	16	10.2399	mmL/L-Fe	5.8957	10.2399
				UA-RBC	C11	INC2	16	4	NO UNITS	.	3
408	4194	M	01z	URIC ACID	F40	HIGH	20	725	umol/L	.	624.54
502	4514	M	01z	CREATINE PHOSPHOKINASE	E12	HIGH	4	1053	U/L	.	594
502	4516	M	01z	HEMATOCRIT	A01	HIGH	5	0.56	1	0.37	0.55
503	4520	M	01z	UA-RBC	C11	INC2	10	4	NO UNITS	.	3
				ALT/SGPT	E03	HIGH	5	222	U/L	.	165
503	4523	M	01z	ALT/SGPT	E03	HIGH	4	195	U/L	.	165
600	4882	M	01z	HEMATOCRIT	A01	HIGH	21	0.57	1	0.37	0.55
600	4933	M	01z	LEUCOCYTE COUNT	A10	HIGH	15	22.33	GI/L	2.8	16
602	4893	F	01z	UA-RBC	C11	INC2	6	4	NO UNITS	.	3

ZY 1234 341

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVIS	NOTERSLT	UNIT	LOLIM	HILIM
602	4896	M	Olz	ERYTHROCYTE COUNT CREATINE PHOSPHOKINASE	A03 E12	HIGH HIGH	27 27	6.3 4670	TI/L U/L	3 .	6 594
602	4931	M	Olz	ALT/SGPT	E03	HIGH	13	267	U/L	.	165
602	4960	M	Olz	PLATELET COUNT UA-RBC	A20 C11	LOW INC2	4 5	61 4	GI/L NO UNITS	75 .	700 3
602	4965	M	Olz	HEMATOCRIT	A01	HIGH	8	0.55	1	0.37	0.55
605	4912	M	Olz	ALT/SGPT	E03	HIGH	6	187	U/L	.	165
606	4920	M	Olz	HEMATOCRIT	A01	HIGH	5	0.55	1	0.37	0.55
606	4921	M	Olz	ERYTHROCYTE COUNT	A03	HIGH	19	6.3	TI/L	3	6
606	4922	M	Hal	BILIRUBIN, TOTAL	G01	HIGH	20	39	umol/L	.	34.2
606	4941	F	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	24	843	U/L	.	507
700	5261	M	Hal	CREATINE PHOSPHOKINASE	E12	HIGH	4	1801	U/L	.	594
722	5535	M	Hal	LEUCOCYTE COUNT	A10	LOW	6	2.56	GI/L	2.8	16
723	5540	F	Hal	UA-SPECIFIC GRAVITY	C01	HIGH	19	1.036	NO UNITS	1.001	1.035
723	5544	F	Olz	EOSINOPHILS	A16	HIGH	8	11.4563	% WBC	.	10
723	5547	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	3	646	U/L	.	594
723	5550	F	Olz	UA-RBC	C11	INC2	12	4	NO UNITS	.	3
752	6056	F	Olz	URIC ACID	F40	HIGH	6	507	umol/L	.	505.58
752	6065	F	Olz	UA-CASTS, GRANULAR	C26	INC2	20	3	NO UNITS	.	3
752	6066	F	Hal	UA-RBC	C11	INC2	20	4	NO UNITS	.	3
800	6304	M	Olz	HEMATOCRIT HEMOGLOBIN ERYTHROCYTE COUNT	A01 A02 A03	HIGH HIGH HIGH	20 20 20	0.6 11.6673 6.2	1 mmL/L-Fe TI/L	0.37 7.1369 3	0.55 11.4811 6
801	6308	M	Hal	HEMOGLOBIN	A02	HIGH	4	11.4811	mmL/L-Fe	7.1369	11.4811
807	6346	F	Hal	UA-RBC UA-WBC	C11 C15	INC2 INC2	9 9	4 4	NO UNITS NO UNITS	.	3 3

ZY 1234 342

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVIS	NOTERSLT	UNIT	LOLIM	HILIM
807	6347	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	3	817	U/L	.	594
809	6355	M	Olz	UA-SPECIFIC GRAVITY	C01	HIGH	22	1.036	NO UNITS	1.001	1.035
809	6433	M	Olz	EOSINOPHILS	A16	HIGH	5	12.4101	% WBC	.	10
809	6434	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	4	848	U/L	.	594
809	6435	M	Ha1	UA-MBC	C15	INC2	4	4	NO UNITS	.	3
809	6437	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	6	2031	U/L	.	594
809	6440	M	Olz	ALT/SGPT	E03	HIGH	6	279	U/L	.	165
811	6368	F	Ha1	UA-MBC	C15	INC2	5	4	NO UNITS	.	3
813	6381	M	Olz	CREATINE PHOSPHOKINASE	E12	HIGH	24	2496	U/L	.	594
813	6410	F	Olz	CREATININE URIC ACID	F02 F40	HIGH HIGH	5 19	196 537	umol/L umol/L	.	176.8 505.58
813	6414	F	Olz	UA-GLUCOSE GLUCOSE, NON-FASTING	C07 F31	INC2 HIGH	13 4	3 15.4	NO UNITS mmol/L	2.4975	13.875
814	6389	M	Olz	ALT/SGPT	E03	HIGH	24	208	U/L	.	165
816	6514	M	Ha1	ERYTHROCYTE COUNT	A03	HIGH	4	6.2	TI/L	3	6
816	6514	M	Olz	GGT(GGPT/SGGT/YGGT)	E17	HIGH	11	328	U/L	.	195
816	6557	M	Olz	HEMATOCRIT CREATINE PHOSPHOKINASE	A01 E12	LOW HIGH	10 10	0.36 3910	l U/L	0.37	0.55 594
817	6521	M	Ha1	LEUCOCYTE COUNT	A10	LOW	4	2.68	GI/L	2.8	16
850	7065	M	Olz	ERYTHROCYTE COUNT	A03	HIGH	18	6.3	TI/L	3	6
850	7080	M	Ha1	ERYTHROCYTE COUNT CREATINE PHOSPHOKINASE SODIUM	A03 E12 F07	HIGH HIGH LOW	4 4 6	6.1 1070 128	TI/L U/L mmol/L	3 .	6 594 160
850	7081	F	Olz	ALT/SGPT	E03	HIGH	14	200	U/L	.	165
851	7072	F	Olz	LEUCOCYTE COUNT	A10	HIGH	19	16.43	GI/L	2.8	16
851	7090	F	Olz	HEMOGLOBIN GGT(GGPT/SGGT/YGGT)	A02 E17	HIGH HIGH	19 12	10.302 166	mmL/L-Fe U/L	5.8957	10.2399 135

RMP.FIDSISS1.SASPM(LABNTJX) 85266

ZY 1234 343

ELI LILLY AND COMPANY
 FLD-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS
 ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVIS	NOTERSLT	UNIT	LOLIM	HILIM
851	7107	M	OLZ	LEUCOCYTE COUNT	A10	HIGH	20	17.06	GI/L	2.8	16
990	7724	F	OLZ	UA-RBC	C11	INC2	21	4	NO UNITS	.	3
990	7727	F	Ha1	UA-RBC UA-MBC	C11 C15	INC2 INC2	8 8	4 4	NO UNITS NO UNITS	.	3 3
990	7754	M	OLZ	EOSINOPHILS	A16	HIGH	7	18.6589	% WBC	.	10
991	7748	F	OLZ	UA-RBC UA-MBC	C11 C15	INC2 INC2	16 16	4 4	NO UNITS NO UNITS	.	3 3
992	7745	F	OLZ	CREATINE PHOSPHOKINASE	E12	HIGH	5	1091	U/L	.	507
992	7774	F	OLZ	EOSINOPHILS UA-RBC UA-MBC	A16 C11 C15	HIGH INC2 INC2	7 6 5	11.619 4 4	% WBC NO UNITS NO UNITS	.	10 3 3
993	7761	M	Ha1	GGT(GGPT/SGGT/YGGT)	E17	HIGH	6	246	U/L	.	195
994	7792	F	OLZ	HEMATOCRIT	A01	HIGH	4	0.51	1	0.32	0.5
994	7793	F	OLZ	LEUCOCYTE COUNT	A10	HIGH	16	18.85	GI/L	2.8	16
994	7796	M	OLZ	CREATINE PHOSPHOKINASE	E12	HIGH	4	1682	U/L	.	594
994	7797	F	Ha1	HEMATOCRIT URIC ACID	A01 F40	HIGH HIGH	8 16	0.51 511	1 umol/L	0.32	0.5 505.58
994	7827	F	OLZ	HEMATOCRIT	A01	HIGH	6	0.51	1	0.32	0.5
996	7872	F	OLZ	UA-RBC	C11	INC2	7	4	NO UNITS	.	3
996	7901	F	Ha1	UA-RBC	C11	INC2	18	3	NO UNITS	.	3
997	7882	F	OLZ	UA-MBC	C15	INC2	5	4	NO UNITS	.	3
997	7883	M	Ha1	UA-RBC	C11	INC2	6	4	NO UNITS	.	3
997	7891	F	OLZ	UA-MBC ALT/SGPT GGT(GGPT/SGGT/YGGT)	C15 E03 E17	INC2 HIGH HIGH	19 19 19	4 234 168	NO UNITS U/L U/L	.	3 165 135
997	7914	F	OLZ	URIC ACID	F40	HIGH	9	537	umol/L	.	505.58
997	7925	M	OLZ	EOSINOPHILS	A16	HIGH	11	31.0367	% WBC	.	10

RMP.FLDISS1.SASPGN(LABNTJX) 85266

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

13:18 Wednesday, July 5, 1995 25

NOTABLE PATIENTS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

ZY 1234 344

INV	PATIENT	GENDER	THERAPY	ANALYTE	ANALYTCD	DIRECTN	NOTEVIS	NOTERSLT	UNIT	LOLIM	HILIM
997	7936	F	01z	GGT(GGPT/SGGT/YGGT)	E17	HIGH	4	149	U/L	.	135
997	7938	M	01z	ALT/SGPT	E03	HIGH	7	222	U/L	.	165

ZY 1234 345

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
001	306	M	Ha1	A01	HEMATOCRIT	LOW	1	S	-2	0.44	1	0.37	0.55
							2	S	0	0.39	1	0.37	0.55
							3	S	7	0.37	1	0.37	0.55
							4	S	14	0.38	1	0.37	0.55
							5	S	22	0.36	1	0.37	0.55
							6	S	30	0.33	1	0.37	0.55
001	306	M	Ha1	F07	SODIUM	LOW	1	S	-2	140	mmol/L	129	160
							2	S	0	135	mmol/L	129	160
							3	S	7	135	mmol/L	129	160
							4	S	14	133	mmol/L	129	160
							5	S	22	134	mmol/L	129	160
							6	S	30	124	mmol/L	129	160
001	306	M	Olz	F07	SODIUM	LOW	1	S	33	133	mmol/L	129	160
							10	S	42	132	mmol/L	129	160
							11	S	51	133	mmol/L	129	160
							12	S	60	134	mmol/L	129	160
							14	S	75	136	mmol/L	129	160
							15	S	82	138	mmol/L	129	160
							16	S	93	132	mmol/L	129	160
							18	S	154	134	mmol/L	129	160
							20	S	217	124	mmol/L	129	160
							22	S	279	128	mmol/L	129	160
							24	S	331	132	mmol/L	129	160
							26	S	369	127	mmol/L	129	160
001	608	M	Olz	E03	ALT/SGPT	HIGH	1	S	-2	30	U/L	.	165
							2	S	0	26	U/L	.	165
							3	S	8	35	U/L	.	165
							4	S	15	268	U/L	.	165
							5	S	22	194	U/L	.	165
							6	S	29	285	U/L	.	165
							7	S	35	229	U/L	.	165
							8	S	42	139	U/L	.	165
							16	S	113	41	U/L	.	165
							18	S	190	35	U/L	.	165
							20	S	246	33	U/L	.	165
							22	S	313	33	U/L	.	165
001	614	F	Olz	C01	UA-SPECIFIC GRAVITY	HIGH	1	S	-2	1.021	NO UNITS	1.001	1.035
							2	S	0	1.025	NO UNITS	1.001	1.035
							3	S	9	1.035	NO UNITS	1.001	1.035
							4	S	16	1.03	NO UNITS	1.001	1.035
							5	S	21	1.029	NO UNITS	1.001	1.035
							6	S	30	1.025	NO UNITS	1.001	1.035
							7	S	38	1.03	NO UNITS	1.001	1.035

RMP.FIDSTSSL.SASPCN(LABNTJX) 85266

ZY 1234 346

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
001	614	F	01z	C01	UA-SPECIFIC GRAVITY	HIGH	8	S	45	NO UNITS	1.001	1.035	0
							16	S	101	NO UNITS	1.001	1.035	0
							18	S	157	NO UNITS	1.001	1.035	0
							20	S	214	NO UNITS	1.001	1.035	0
							22	S	269	NO UNITS	1.001	1.035	1
							24	S	326	NO UNITS	1.001	1.035	0
							26	S	376	NO UNITS	1.001	1.035	1
001	805	F	01z	C07	UA-GLUCOSE	INC2	1	S	-2	NO UNITS	.	.	3
							2	S	0	NO UNITS	.	.	3
							3	S	12	NO UNITS	.	.	3
							4	S	20	NO UNITS	.	.	3
							5	S	27	NO UNITS	.	.	3
							6	S	36	NO UNITS	.	.	3
							7	S	43	NO UNITS	.	.	3
							8	S	50	NO UNITS	.	.	3
							16	S	106	NO UNITS	.	.	3
							18	S	162	NO UNITS	.	.	3
							20	S	217	NO UNITS	.	.	3
							22	S	281	NO UNITS	.	.	3
							24	S	349	NO UNITS	.	.	3
							26	S	407	NO UNITS	.	.	3
001	805	F	01z	F31	GLUCOSE, NON-FASTING	HIGH	1	S	-2	10.4914 mmol/L	2.4975	13.875	0
							2	S	0	10.8245 mmol/L	2.4975	13.875	0
							3	S	12	7.60487 mmol/L	2.4975	13.875	0
							4	S	20	12.8783 mmol/L	2.4975	13.875	0
							5	S	27	8.10446 mmol/L	2.4975	13.875	0
							6	S	36	8.60405 mmol/L	2.4975	13.875	0
							7	S	43	8.99262 mmol/L	2.4975	13.875	0
							8	S	50	15.8759 mmol/L	2.4975	13.875	1
							16	S	106	16.1534 mmol/L	2.4975	13.875	1
							18	S	162	12.6008 mmol/L	2.4975	13.875	1
							20	S	217	17.7077 mmol/L	2.4975	13.875	1
							22	S	281	17.0416 mmol/L	2.4975	13.875	1
							24	S	349	18.8179 mmol/L	2.4975	13.875	1
							26	S	407	16.653 mmol/L	2.4975	13.875	1
001	1579	M	01z	F40	URIC ACID	HIGH	1	S	-14	481.788 umol/L	.	624.54	0
							2	S	0	499.632 umol/L	.	624.54	0
							3	S	8	600.748 umol/L	.	624.54	0
							4	S	16	624.54 umol/L	.	624.54	1
							5	S	22	440.152 umol/L	.	624.54	0
							6	S	28	523.424 umol/L	.	624.54	0
							7	S	38	654.28 umol/L	.	624.54	1
							8	S	42	630.488 umol/L	.	624.54	1
							16	S	133	481.788 umol/L	.	624.54	0

ZY 1234 347

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

001 1585	M	Olz	C01	UA-SPECIFIC GRAVITY	DIRECTN VISIT UNVISIT RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
001 1663	F	Ha1	F40	URIC ACID	-7	386.62 umol/L	1.001	505.58	0
					0	422.308 umol/L	1.001	505.58	0
					7	392.568 umol/L	1.001	505.58	0
					14	452.048 umol/L	1.001	505.58	0
					21	463.944 umol/L	1.001	505.58	0
					28	535.32 umol/L	1.001	505.58	1
003 15	M	Olz	F07	SODIUM	-3	139 mmol/L	129	160	0
					0	142 mmol/L	129	160	0
					7	146 mmol/L	129	160	0
					14	140 mmol/L	129	160	0
					21	144 mmol/L	129	160	0
					28	121 mmol/L	129	160	1
003 467	F	Olz	C11	UA-RBC	31	0 NO UNITS	.	3	0
					38	0 NO UNITS	.	3	0
					45	0 NO UNITS	.	3	0
					52	0 NO UNITS	.	3	0
					59	0 NO UNITS	.	3	0
					66	0 NO UNITS	.	3	0
					73	3 NO UNITS	.	3	1
					87	0 NO UNITS	.	3	0
					144	0 NO UNITS	.	3	0
					202	0 NO UNITS	.	3	0
					258	0 NO UNITS	.	3	0
					356	0 NO UNITS	.	3	0
					410	0 NO UNITS	.	3	0
					469	4 NO UNITS	.	3	1
003 469	F	Olz	F40	URIC ACID	-2	404.464 umol/L	1.001	505.58	0
					0	362.828 umol/L	1.001	505.58	0
					14	452.048 umol/L	1.001	505.58	0
					21	457.996 umol/L	1.001	505.58	0
					28	457.996 umol/L	1.001	505.58	0
					35	487.736 umol/L	1.001	505.58	0
					42	553.164 umol/L	1.001	505.58	1

ZY 1234 348

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
003	469	F	01z	F40	URIC ACID	HIGH	16	S	98	493.684	umol/L	505.58	0
							18	S	163	487.736	umol/L	505.58	0
							19	U	154	535.32	umol/L	505.58	1
							20	S	212	517.476	umol/L	505.58	1
							22	S	268	499.632	umol/L	505.58	0
							24	S	320	594.8	umol/L	505.58	1
							26	S	364	529.372	umol/L	505.58	1
							27	S	418	541.268	umol/L	505.58	1
							28	S	484	517.476	umol/L	505.58	1
003	470	M	01z	A16	EOSINOPHILS	HIGH	1	S	-2	4.24107	%	10	0
							2	S	0	3.50195	%	10	0
							3	S	6	3.43035	%	10	0
							4	S	13	4.86409	%	10	0
							5	S	20	3.76344	%	10	0
							6	S	27	6.41026	%	10	0
							7	S	34	12.0092	%	10	1
							8	S	41	18.2146	%	10	1
							16	S	98	2.51889	%	10	0
							18	S	153	3.03514	%	10	0
							20	S	209	2.22805	%	10	0
							24	S	321	1.21951	%	10	0
							26	S	364	1.10837	%	10	0
003	688	F	01z	C11	UA-RBC	INC2	1	S	-2	0	NO UNITS	3	0
							2	S	0	0	NO UNITS	3	0
							3	S	7	2	NO UNITS	3	0
							4	S	14	0	NO UNITS	3	0
							5	S	20	0	NO UNITS	3	0
							6	S	28	2	NO UNITS	3	0
							7	S	33	0	NO UNITS	3	0
							8	S	42	4	NO UNITS	3	1
003	695	M	01z	E03	ALT/SGPT	HIGH	1	S	-8	28	U/L	165	0
							2	U	-6	26	U/L	165	0
							2	S	0	29	U/L	165	0
							3	S	7	157	U/L	165	0
							4	S	14	215	U/L	165	1
							5	S	21	312	U/L	165	1
							6	S	28	145	U/L	165	0
							7	S	35	101	U/L	165	0
							8	S	43	118	U/L	165	0
							16	S	98	44	U/L	165	0
							18	S	154	39	U/L	165	0
							20	S	212	16	U/L	165	0
							22	S	266	22	U/L	165	0
							24	S	322	34	U/L	165	0

ZY 1234 349

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

003	695	M	01z	E03	ALT/SGPT	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
						HIGH	26	S	364	19	U/L	.	.	165 0
							27	S	420	24	U/L	.	.	165 0
						HIGH	1	S	43	8.97436	%	.	.	10 0
							10	S	49	10.9228	%	.	.	10 1
							11	S	57	8.69565	%	.	.	10 0
							12	S	63	8.02603	%	.	.	10 0
							13	S	70	8.11966	%	.	.	10 0
							14	S	77	6.29921	%	.	.	10 0
							15	S	84	11.2108	%	.	.	10 1
							16	S	98	10.5263	%	.	.	10 1
							18	S	154	11.1554	%	.	.	10 1
							22	S	266	5.12295	%	.	.	10 0
							24	S	322	5.81162	%	.	.	10 0
							26	S	367	16.9892	%	.	.	10 1
							27	S	421	8.74525	%	.	.	10 0
						HIGH	1	S	43	43	U/L	.	.	165 0
							10	S	49	176	U/L	.	.	165 1
							11	S	57	216	U/L	.	.	165 1
							12	S	63	117	U/L	.	.	165 0
							13	S	70	132	U/L	.	.	165 0
							14	S	77	108	U/L	.	.	165 0
							15	S	84	48	U/L	.	.	165 0
							16	S	98	54	U/L	.	.	165 0
							18	S	154	27	U/L	.	.	165 0
							20	S	210	37	U/L	.	.	165 0
							22	S	266	29	U/L	.	.	165 0
							24	S	322	40	U/L	.	.	165 0
							26	S	367	46	U/L	.	.	165 0
							27	S	421	38	U/L	.	.	165 0
						CREATINE PHOSPHOKINASE	1	S	-5	243	U/L	.	.	594 0
							2	S	0	113	U/L	.	.	594 0
							3	S	9	132	U/L	.	.	594 0
							4	S	16	150	U/L	.	.	594 0
							5	S	23	135	U/L	.	.	594 0
							6	S	30	136	U/L	.	.	594 0
							7	S	38	86	U/L	.	.	594 0
							8	S	44	126	U/L	.	.	594 0
							9	S	72	100	U/L	.	.	594 0
							16	S	100	117	U/L	.	.	594 0
							18	S	149	114	U/L	.	.	594 0
							20	S	205	132	U/L	.	.	594 0
							21	S	233	1280	U/L	.	.	594 1
						HIGH	1	S	-2	4.67112	%	.	.	10 0

[Handwritten signature]

ELI LILLY AND COMPANY
 FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
 ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
003	891	F	OLZ	A16	EOSINOPHILS	HIGH	2	S	0	4.44655 % WBC		10
							3	S	7	5.30099 % WBC		10
							4	S	14	5.06024 % WBC		10
							5	S	21	5.25727 % WBC		10
							6	S	28	8.07175 % WBC		10
							7	S	33	15.75 % WBC		10
							8	S	42	12.874 % WBC		10
							16	S	102	5.64103 % WBC		10
							18	S	161	1.88679 % WBC		10
							20	S	220	2.65589 % WBC		10
							22	S	284	2.29167 % WBC		10
							26	S	382	1.92744 % WBC		10
003	1116	M	OLZ	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	35	225 U/L		594
							10	S	42	225 U/L		594
							12	U	49	204 U/L		594
							12	S	55	104 U/L		594
							13	S	63	102 U/L		594
							14	S	73	2325 U/L		594
							15	S	77	1623 U/L		594
							16	S	89	145 U/L		594
							18	U	137	115 U/L		594
							18	S	150	191 U/L		594
							19	S	178	187 U/L		594
003	1386	F	OLZ	A16	EOSINOPHILS	HIGH	1	S	-2	9.22619 % WBC		10
							2	S	0	4.87805 % WBC		10
							3	S	7	10.6547 % WBC		10
							4	S	15	14.8235 % WBC		10
							5	S	21	7.09571 % WBC		10
							6	S	28	6.42361 % WBC		10
							7	S	36	7.36196 % WBC		10
							8	S	43	7.37834 % WBC		10
							18	S	155	3.9548 % WBC		10
							19	S	196	4.73934 % WBC		10
003	1426	F	OLZ	C11	UA-RBC	INC2	1	S	-2	4 NO UNITS		3
							2	S	0	0 NO UNITS		3
							3	S	9	0 NO UNITS		3
							4	S	14	0 NO UNITS		3
							5	S	21	0 NO UNITS		3
							6	S	28	0 NO UNITS		3
							7	S	35	3 NO UNITS		3
							8	S	42	0 NO UNITS		3
							16	S	77	4 NO UNITS		3
003	1429	M	OLZ	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-6	341 U/L		594

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
003	1429	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	2	S	0	313	U/L		594
							3	S	9	271	U/L		594
							4	S	16	244	U/L		594
							6	S	32	734	U/L		594
							10	S	45	376	U/L		594
							11	S	52	1226	U/L		594
003	1507	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	42	373	U/L		594
							10	S	51	247	U/L		594
							11	S	58	368	U/L		594
							12	S	65	385	U/L		594
							13	S	72	393	U/L		594
							14	S	79	460	U/L		594
							15	S	86	412	U/L		594
							16	S	100	391	U/L		594
							18	S	167	728	U/L		594
006	815	F	01z	E17	GGT(GGPT/SGGT/YGGT)	HIGH	1	S	-6	97	U/L		135
							2	S	0	70	U/L		135
							3	S	7	69	U/L		135
							4	S	14	95	U/L		135
							5	S	21	101	U/L		135
							6	S	28	261	U/L		135
							7	S	35	282	U/L		135
							8	S	42	221	U/L		135
							10	S	51	76	U/L		135
							11	S	58	63	U/L		135
							12	S	65	51	U/L		135
							13	S	72	42	U/L		135
							14	S	79	37	U/L		135
							15	S	86	31	U/L		135
							16	S	100	74	U/L		135
							18	S	156	42	U/L		135
							20	S	214	52	U/L		135
							22	S	276	37	U/L		135
006	815	F	01z	F31	GLUCOSE, NON-FASTING	HIGH	1	S	-6	4.77386	mmol/L	2.4975	13.875
							2	S	0	3.8857	mmol/L	2.4975	13.875
							3	S	7	8.04895	mmol/L	2.4975	13.875
							4	S	14	15.3763	mmol/L	2.4975	13.875
							5	S	21	10.0473	mmol/L	2.4975	13.875
							6	S	28	13.5444	mmol/L	2.4975	13.875
							7	S	35	15.2097	mmol/L	2.4975	13.875
							8	S	42	30.1974	mmol/L	2.4975	13.875
							10	S	51	12.5453	mmol/L	2.4975	13.875
							11	S	58	9.38119	mmol/L	2.4975	13.875
							12	S	65	9.65874	mmol/L	2.4975	13.875



ZY 1234 352

ELI LILLY AND COMPANY
F10-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
028	677	M	OLZ	E03	ALT/SGPT	HIGH	24	S	321	16	U/L	.	165	0
028	678	M	OLZ	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	42	137	U/L	.	594	0
							10	S	47	255	U/L	.	594	0
							11	S	53	175	U/L	.	594	0
							12	S	62	198	U/L	.	594	0
							13	S	67	202	U/L	.	594	0
							14	S	74	158	U/L	.	594	0
							15	S	82	8150	U/L	.	594	1
028	961	M	OLZ	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-7	471	U/L	.	594	0
							2	S	0	488	U/L	.	594	0
							3	S	5	8920	U/L	.	594	1
							4	S	12	970	U/L	.	594	1
							5	S	20	407	U/L	.	594	0
							6	S	25	249	U/L	.	594	0
							7	S	32	443	U/L	.	594	0
							8	S	41	262	U/L	.	594	0
							16	S	98	400	U/L	.	594	0
							18	S	153	9610	U/L	.	594	1
							20	S	209	196	U/L	.	594	0
029	169	F	Ha1	C11	UA-RBC	INC2	1	S	-9	0	NO UNITS	.	3	0
							2	S	0	0	NO UNITS	.	3	0
							3	S	7	4	NO UNITS	.	3	1
							4	S	13	4	NO UNITS	.	3	1
							6	U	24	0	NO UNITS	.	3	0
							6	S	28	0	NO UNITS	.	3	0
029	172	M	OLZ	E12	CREATINE PHOSPHOKINASE	HIGH	2	U	-3	310	U/L	.	594	0
							2	S	0	305	U/L	.	594	0
							3	S	7	254	U/L	.	594	0
							4	S	14	255	U/L	.	594	0
							5	S	21	522	U/L	.	594	0
							6	S	28	342	U/L	.	594	0
							7	S	33	542	U/L	.	594	0
							8	S	40	289	U/L	.	594	0
							9	S	68	327	U/L	.	594	0
							16	S	103	537	U/L	.	594	0
							18	S	153	1620	U/L	.	594	1
							19	U	168	3700	U/L	.	594	1
							19	U	181	435	U/L	.	594	0
							20	S	209	246	U/L	.	594	0
							22	S	273	1286	U/L	.	594	1
029	173	M	OLZ	E03	ALT/SGPT	HIGH	1	S	33	38	U/L	.	165	0
							10	S	40	54	U/L	.	165	0

ZY 1234 353

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
029	M	01z	E03	ALT/SGPT	HIGH	11	S	47	39	U/L	.	165	0
						12	S	54	101	U/L	.	165	0
						13	S	61	69	U/L	.	165	0
						14	S	68	103	U/L	.	165	0
						15	S	75	221	U/L	.	165	1
						16	S	103	396	U/L	.	165	1
						17	S	110	206	U/L	.	165	1

029	F	01z	A01	HEMATOCRIT	LOW	2	U	-2	0.34	1	0.32	0.5	0
						2	S	0	0.35	1	0.32	0.5	0
						3	S	6	0.38	1	0.32	0.5	0
						5	S	20	0.36	1	0.32	0.5	0
						6	S	27	0.34	1	0.32	0.5	0
						7	S	34	0.34	1	0.32	0.5	0
						8	S	41	0.34	1	0.32	0.5	0
						9	S	47	0.31	1	0.32	0.5	1

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
029	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	2	U	-5	115	U/L	.	594	0
						2	S	0	153	U/L	.	594	0
						3	S	7	1200	U/L	.	594	1
						4	S	14	383	U/L	.	594	0
						5	S	21	131	U/L	.	594	0
						6	S	28	85	U/L	.	594	0
						7	S	35	94	U/L	.	594	0
						8	S	42	75	U/L	.	594	0
						10	S	51	105	U/L	.	594	0
						11	S	61	100	U/L	.	594	0
						13	S	70	132	U/L	.	594	0
						14	S	75	90	U/L	.	594	0
						15	S	91	91	U/L	.	594	0
						16	S	105	243	U/L	.	594	0
						18	S	159	115	U/L	.	594	0
						20	S	215	65	U/L	.	594	0
						22	S	271	1600	U/L	.	594	1
						23	U	275	1288	U/L	.	594	1
						24	S	310	71	U/L	.	594	0

029	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-2	171	U/L	.	594	0
						2	S	0	142	U/L	.	594	0
						3	S	10	851	U/L	.	594	1
						4	S	14	11980	U/L	.	594	1
						5	S	19	1308	U/L	.	594	1
029	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	2	U	-3	86	U/L	.	594	0
						2	S	0	94	U/L	.	594	0
						3	S	8	980	U/L	.	594	1
						5	S	20	158	U/L	.	594	0

ZY 1234 354

ELI LILLY AND COMPANY
F1D-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE DIRECTN VISIT UNVISIT RELDAYS RESULT UNIT LOLIM HILIM ABRNM

029	967	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	6	S	28	181 U/L	.	594	0
							7	S	34	169 U/L	.	594	0
							8	S	43	70 U/L	.	594	0
							9	S	48	112 U/L	.	594	0
							16	S	112	649 U/L	.	594	1

①

029	969	M	01z	A03	ERYTHROCYTE COUNT	HIGH	1	S	-5	5.8 TI/L	3	6	0
							2	S	0	5.8 TI/L	3	6	0
							3	S	7	5.7 TI/L	3	6	0
							4	S	14	5.7 TI/L	3	6	0
							5	S	21	5.8 TI/L	3	6	0
							6	S	28	5.7 TI/L	3	6	0
							7	S	35	5.7 TI/L	3	6	0
							10	S	43	6 TI/L	3	6	0
							11	S	50	5.4 TI/L	3	6	0
							12	S	59	6.1 TI/L	3	6	1
							13	S	66	6.1 TI/L	3	6	1
							14	S	73	6.1 TI/L	3	6	1
							15	S	80	5.9 TI/L	3	6	0
							16	S	93	6.1 TI/L	3	6	1
							18	S	161	6 TI/L	3	6	0

029	974	M	01z	E17	GGT(GEPT/SGGT/YGGT)	HIGH	1	S	-10	99 U/L	.	195	0
							2	S	0	155 U/L	.	195	0
							3	S	7	184 U/L	.	195	0
							4	S	17	139 U/L	.	195	0
							5	S	26	232 U/L	.	195	1
							6	S	32	248 U/L	.	195	1
							7	S	39	260 U/L	.	195	1
							10	S	49	204 U/L	.	195	1
							11	S	55	236 U/L	.	195	1
							12	S	62	149 U/L	.	195	0
							13	S	69	167 U/L	.	195	0
							14	S	76	178 U/L	.	195	0
							15	S	83	199 U/L	.	195	1
							16	S	95	214 U/L	.	195	1
							18	S	151	120 U/L	.	195	0
							20	S	221	122 U/L	.	195	0
							22	S	278	156 U/L	.	195	0

①

031	482	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-3	54 U/L	.	594	0
							2	S	0	84 U/L	.	594	0
							3	S	5	181 U/L	.	594	0
							4	S	14	158 U/L	.	594	0
							5	S	20	89 U/L	.	594	0
							6	S	28	73 U/L	.	594	0
							10	S	39	256 U/L	.	594	0

ZY 1234 355

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
031	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	11	S	45	162	U/L	.	594	0
						12	S	52	126	U/L	.	594	0
						13	S	59	244	U/L	.	594	0
						14	S	66	95	U/L	.	594	0
						15	S	74	126	U/L	.	594	1
						16	S	88	805	U/L	.	594	1
						17	U	94	5865	U/L	.	594	1
						17	U	97	6180	U/L	.	594	1
						17	U	103	258	U/L	.	594	0
						18	S	146	153	U/L	.	594	0
						20	S	200	206	U/L	.	594	0
						22	S	262	124	U/L	.	594	0
						24	S	326	145	U/L	.	594	0
031	M	01z	E03	ALT/SGPT	HIGH	1	S	-9	8	U/L	.	165	0
						3	S	1	63	U/L	.	165	0
						4	S	8	27	U/L	.	165	0
						5	S	15	63	U/L	.	165	0
						6	S	25	30	U/L	.	165	0
						8	S	40	76	U/L	.	165	0
						10	S	50	26	U/L	.	165	0
						12	S	64	93	U/L	.	165	0
						13	S	71	169	U/L	.	165	1
						14	S	82	176	U/L	.	165	1
						15	S	85	181	U/L	.	165	1
						16	S	102	75	U/L	.	165	0
						18	S	158	17	U/L	.	165	0
031	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-4	140	U/L	.	594	0
						2	S	0	334	U/L	.	594	0
						4	S	15	714	U/L	.	594	1
						5	S	23	876	U/L	.	594	1
						6	S	29	535	U/L	.	594	0
						7	S	38	284	U/L	.	594	0
032	F	01z	A10	LEUCOCYTE COUNT	HIGH	1	S	-2	9.63	GI/L	2.8	16	0
						2	S	0	9.09	GI/L	2.8	16	0
						4	S	14	7.48	GI/L	2.8	16	0
						5	S	21	9.04	GI/L	2.8	16	0
						7	S	35	13.96	GI/L	2.8	16	0
						10	S	45	10.93	GI/L	2.8	16	0
						11	S	52	8.99	GI/L	2.8	16	0
						12	S	59	10.97	GI/L	2.8	16	0
						13	S	66	10.97	GI/L	2.8	16	0
						14	S	73	12.04	GI/L	2.8	16	0
						16	S	84	17.1	GI/L	2.8	16	1

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

032	448	M	01z	F06	PHOSPHORUS	HIGH	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
							1	S	-2	1.42076 mmol/L	0.48435	1.77595	0
							4	S	14	1.51763 mmol/L	0.48435	1.77595	0
							5	S	20	1.25931 mmol/L	0.48435	1.77595	0
							6	S	28	1.25931 mmol/L	0.48435	1.77595	0
							7	S	34	1.84053 mmol/L	0.48435	1.77595	1
							10	S	44	1.25931 mmol/L	0.48435	1.77595	0
							11	S	49	1.51763 mmol/L	0.48435	1.77595	0
							13	S	63	1.19473 mmol/L	0.48435	1.77595	0
							14	S	69	1.51763 mmol/L	0.48435	1.77595	0
							15	S	77	1.38847 mmol/L	0.48435	1.77595	0
							16	S	90	1.2916 mmol/L	0.48435	1.77595	0
							18	S	146	1.2916 mmol/L	0.48435	1.77595	0
							20	S	202	1.48534 mmol/L	0.48435	1.77595	0
							22	S	265	1.45305 mmol/L	0.48435	1.77595	0
							24	S	308	1.51763 mmol/L	0.48435	1.77595	0
							26	S	376	1.67908 mmol/L	0.48435	1.77595	0
							27	S	428	1.90511 mmol/L	0.48435	1.77595	1
							1	S	31	3.5124 % NBC	.	10	0
							10	S	38	5.07614 % NBC	.	10	0
							11	S	46	5.21921 % NBC	.	10	0
							12	S	53	8.18859 % NBC	.	10	0
							13	S	60	11.6788 % NBC	.	10	1
							14	S	67	14.91 % NBC	.	10	1
							15	S	75	11.8421 % NBC	.	10	1
							16	S	91	5.04032 % NBC	.	10	0
							18	S	146	5.26316 % NBC	.	10	0
							1	S	-4	9.12282 mmol/L-Fe	5.8957	10.2399	0
							2	S	0	9.9296 mmol/L-Fe	5.8957	10.2399	0
							3	S	7	9.43312 mmol/L-Fe	5.8957	10.2399	0
							4	S	14	9.49518 mmol/L-Fe	5.8957	10.2399	0
							5	S	21	9.37106 mmol/L-Fe	5.8957	10.2399	0
							6	S	28	9.06076 mmol/L-Fe	5.8957	10.2399	0
							7	S	35	8.81252 mmol/L-Fe	5.8957	10.2399	0
							8	S	40	9.80548 mmol/L-Fe	5.8957	10.2399	0
							16	S	98	6.8136 mmol/L-Fe	5.8957	10.2399	0
							18	S	154	10.1158 mmol/L-Fe	5.8957	10.2399	0
							20	S	210	9.74342 mmol/L-Fe	5.8957	10.2399	0
							22	S	273	10.6743 mmol/L-Fe	5.8957	10.2399	1
							1	S	-2	0 NO UNITS	.	3	0
							2	S	0	0 NO UNITS	.	3	0
							3	S	7	0 NO UNITS	.	3	0
							4	S	13	0 NO UNITS	.	3	0
							5	S	20	0 NO UNITS	.	3	0
							6	S	27	0 NO UNITS	.	3	0

①

ZY 1234 357

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

DIRECTN VISIT UNVISIT RELDAYS RESULT UNIT LOLIM HILIM ABNRM

032	453	F	01z	C11	UA-RBC	INC2	7	S	34	0 NO UNITS	.	3	0
							8	S	43	0 NO UNITS	.	3	0
							16	S	98	0 NO UNITS	.	3	0
							18	S	161	4 NO UNITS	.	3	1
033	752	F	01z	C07	UA-GLUCOSE <td>INC2</td> <td>1</td> <td>S</td> <td>-2</td> <td>0 NO UNITS</td> <td>.</td> <td>3</td> <td>0</td>	INC2	1	S	-2	0 NO UNITS	.	3	0
							2	S	-1	0 NO UNITS	.	3	0
							3	S	8	0 NO UNITS	.	3	0
							4	S	14	0 NO UNITS	.	3	0
							5	S	21	0 NO UNITS	.	3	0
							6	S	28	0 NO UNITS	.	3	0
							7	S	35	0 NO UNITS	.	3	0
							8	S	42	0 NO UNITS	.	3	0
							9	S	70	0 NO UNITS	.	3	0
							16	S	98	0 NO UNITS	.	3	0
							18	S	154	0 NO UNITS	.	3	0
							20	S	211	0 NO UNITS	.	3	0
							22	S	268	0 NO UNITS	.	3	0
							24	S	324	0 NO UNITS	.	3	0
							26	S	366	3 NO UNITS	.	3	1
033	752	F	01z	E17	GGT(GGPT/SGGT/YGGT) <td>HIGH</td> <td>1</td> <td>S</td> <td>-2</td> <td>70 U/L</td> <td>.</td> <td>135</td> <td>0</td>	HIGH	1	S	-2	70 U/L	.	135	0
							2	S	-1	77 U/L	.	135	0
							3	S	8	60 U/L	.	135	0
							4	S	14	50 U/L	.	135	0
							5	S	21	170 U/L	.	135	1
							6	S	28	259 U/L	.	135	1
							7	S	35	173 U/L	.	135	1
							8	S	42	85 U/L	.	135	0
							9	S	70	72 U/L	.	135	0
							16	S	98	110 U/L	.	135	0
							18	S	154	108 U/L	.	135	0
							20	S	211	147 U/L	.	135	1
							22	S	268	103 U/L	.	135	0
							24	S	324	115 U/L	.	135	0
							26	S	366	151 U/L	.	135	1
033	752	F	01z	F31	GLUCOSE, NON-FASTING <td>HIGH</td> <td>1</td> <td>S</td> <td>-2</td> <td>6.43916 mmol/L</td> <td>2.4975</td> <td>13.875</td> <td>0</td>	HIGH	1	S	-2	6.43916 mmol/L	2.4975	13.875	0
							2	S	-1	6.32814 mmol/L	2.4975	13.875	0
							3	S	8	6.60569 mmol/L	2.4975	13.875	0
							4	S	14	8.04895 mmol/L	2.4975	13.875	0
							5	S	21	7.60487 mmol/L	2.4975	13.875	0
							6	S	28	7.04977 mmol/L	2.4975	13.875	0
							7	S	35	6.99426 mmol/L	2.4975	13.875	0
							8	S	42	6.21712 mmol/L	2.4975	13.875	0
							9	S	70	4.55182 mmol/L	2.4975	13.875	0
							16	S	98	6.66612 mmol/L	2.4975	13.875	0

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
033	F	01z	F31	GLUCOSE, NON-FASTING	HIGH	18	S	154	5.551	mmol/L	2.4975	13.875	0
						20	S	211	8.77058	mmol/L	2.4975	13.875	0
						22	S	268	13.2114	mmol/L	2.4975	13.875	0
						24	S	324	11.4906	mmol/L	2.4975	13.875	0
						26	S	366	15.4318	mmol/L	2.4975	13.875	1
034	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-9	146	U/L	.	594	0
						2	S	0	140	U/L	.	594	0
						4	S	12	110	U/L	.	594	0
						5	S	22	1114	U/L	.	594	1
035	M	01z	A16	EOSINOPHILS	HIGH	1	S	38	6.23377	% WBC	.	10	0
						10	S	42	7.98526	% WBC	.	10	0
						11	S	52	10.303	% WBC	.	10	1
						12	S	59	10.665	% WBC	.	10	1
						13	S	66	11.3682	% WBC	.	10	1
						14	S	73	13.5109	% WBC	.	10	1
						15	S	80	12.2426	% WBC	.	10	1
						16	S	94	14.4564	% WBC	.	10	1
						18	S	150	15.1715	% WBC	.	10	1
						20	S	206	14.4769	% WBC	.	10	1
						21	S	234	10.562	% WBC	.	10	1
						22	S	261	15.4171	% WBC	.	10	1
						23	S	290	12.8099	% WBC	.	10	1
						24	S	318	12.9178	% WBC	.	10	1
						26	S	360	14.9567	% WBC	.	10	1
						27	S	416	9.89011	% WBC	.	10	0
						28	S	474	14.8066	% WBC	.	10	1
						29	U	528	11.284	% WBC	.	10	1
035	M	01z	A10	LEUCOCYTE COUNT	HIGH	1	S	-2	7.32	GI/L	2.8	16	0
						2	S	0	8.17	GI/L	2.8	16	0
						3	S	7	6.53	GI/L	2.8	16	0
						4	S	14	8.88	GI/L	2.8	16	0
						5	S	21	6.86	GI/L	2.8	16	0
						6	S	28	8.2	GI/L	2.8	16	0
						7	S	35	18.77	GI/L	2.8	16	1
035	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-2	172	U/L	.	594	0
						2	S	0	135	U/L	.	594	0
						3	S	7	206	U/L	.	594	0
						4	S	14	326	U/L	.	594	0
						5	S	21	426	U/L	.	594	0
						6	S	28	189	U/L	.	594	0
						7	S	35	659	U/L	.	594	1
035	M	01z	C01	UA-SPECIFIC GRAVITY	HIGH	1	S	-9	1.023	NO UNITS	1.001	1.035	0

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

035	716	M	01z	C01	UA-SPECIFIC GRAVITY	DIRECTN VISIT UNVISIT REVDAYS	RESULT UNIT	LOLIM	HILIM ABNRM
					HIGH	0	1.018 NO UNITS	1.001	1.035 0
						7	1.023 NO UNITS	1.001	1.035 0
						14	1.012 NO UNITS	1.001	1.035 0
						21	1.016 NO UNITS	1.001	1.035 0
						28	1.017 NO UNITS	1.001	1.035 0
						35	1.018 NO UNITS	1.001	1.035 0
						42	1.017 NO UNITS	1.001	1.035 0
						98	1.032 NO UNITS	1.001	1.035 0
						238	1.023 NO UNITS	1.001	1.035 0
						323	1.015 NO UNITS	1.001	1.035 0
						364	1.036 NO UNITS	1.001	1.035 1
					INC2	-9	0 NO UNITS	.	3 0
						0	1 NO UNITS	.	3 0
						7	2 NO UNITS	.	3 0
						14	0 NO UNITS	.	3 0
						21	1 NO UNITS	.	3 0
						28	0 NO UNITS	.	3 0
						35	0 NO UNITS	.	3 0
						42	0 NO UNITS	.	3 0
						98	3 NO UNITS	.	3 1
						238	3 NO UNITS	.	3 1
						323	3 NO UNITS	.	3 1
						364	3 NO UNITS	.	3 1
					HIGH	-9	5.60651 mmol/L	2.4975	13.875 0
						0	11.4906 mmol/L	2.4975	13.875 0
						7	7.7714 mmol/L	2.4975	13.875 0
						14	7.7714 mmol/L	2.4975	13.875 0
						21	8.93711 mmol/L	2.4975	13.875 0
						28	7.2163 mmol/L	2.4975	13.875 0
						35	7.54936 mmol/L	2.4975	13.875 0
						42	9.21466 mmol/L	2.4975	13.875 0
						98	11.6016 mmol/L	2.4975	13.875 0
						238	16.3755 mmol/L	2.4975	13.875 1
						323	15.6538 mmol/L	2.4975	13.875 1
						364	15.3208 mmol/L	2.4975	13.875 1
					LOW	-5	0.43 1	0.37	0.55 0
						0	0.43 1	0.37	0.55 0
						7	0.47 1	0.37	0.55 0
						14	0.46 1	0.37	0.55 0
						21	0.4 1	0.37	0.55 0
						28	0.44 1	0.37	0.55 0
						35	0.42 1	0.37	0.55 0
						42	0.4 1	0.37	0.55 0
						70	0.36 1	0.37	0.55 1

ZY 1234 360

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
036	211	M	Ha1	F02	CREATININE	HIGH	1	S	-4	167.96	umol/L	176.8	0
							2	S	0	159.12	umol/L	176.8	0
							3	S	13	185.64	umol/L	176.8	1
036	212	F	Olz	A01	HEMATOCRIT	LOW	1	S	-4	0.34	1	0.32	0
							2	S	0	0.35	1	0.32	0
							3	S	7	0.34	1	0.32	0
							4	S	15	0.32	1	0.32	0
							5	S	22	0.35	1	0.32	0
							6	S	29	0.32	1	0.32	0
							7	S	34	0.35	1	0.32	0
							8	S	41	0.3	1	0.32	0
							10	S	50	0.31	1	0.32	0
							11	S	57	0.31	1	0.32	0
							12	S	64	0.3	1	0.32	0
							13	S	71	0.3	1	0.32	0
							14	S	78	0.3	1	0.32	0
							15	S	85	0.3	1	0.32	0
							16	S	97	0.3	1	0.32	0
							18	S	155	0.32	1	0.32	0
							19	S	167	0.3	1	0.32	0
036	323	F	Olz	E03	ALT/SGPT	HIGH	1	S	-7	22	U/L	165	0
							2	U	-4	20	U/L	165	0
							2	S	0	21	U/L	165	0
							3	S	8	43	U/L	165	0
							4	S	17	229	U/L	165	1
							5	U	24	234	U/L	165	1
							5	S	24	226	U/L	165	1
							6	S	31	123	U/L	165	0
							7	S	41	64	U/L	165	0
							8	S	49	28	U/L	165	0
							9	S	76	14	U/L	165	0
							16	S	100	28	U/L	165	0
							18	S	141	16	U/L	165	0
							20	S	206	20	U/L	165	0
							22	S	260	21	U/L	165	0
							24	S	322	17	U/L	165	0
							26	S	366	31	U/L	165	0
							27	S	422	27	U/L	165	0
							28	S	478	21	U/L	165	0
038	224	M	Olz	C07	UA-GLUCOSE	INC2	1	S	-4	0	NO UNITS	3	0
							2	S	0	0	NO UNITS	3	0
							3	S	7	0	NO UNITS	3	0
							4	S	14	0	NO UNITS	3	0
							5	S	21	3	NO UNITS	3	1

ZY 1234 361

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

038	224	M	01z	C07	UA-GLUCOSE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
					INC2		6	S	28	1 NO UNITS			3
							7	S	36	0 NO UNITS			3
							8	S	42	3 NO UNITS			3
							16	S	102	0 NO UNITS			3
							18	S	150	1 NO UNITS			3
							20	S	213	3 NO UNITS			3
							22	S	269	3 NO UNITS			3
							24	S	323	1 NO UNITS			3
							26	S	367	0 NO UNITS			3
							27	S	423	0 NO UNITS			3
							28	S	478	1 NO UNITS			3
							29	S	534	3 NO UNITS			3
038	224	M	01z	F31	GLUCOSE, NON-FASTING	HIGH	1	S	-4	4.38529 mmol/L	2.4975	13.875	0
							2	S	0	4.4408 mmol/L	2.4975	13.875	0
							3	S	7	6.55018 mmol/L	2.4975	13.875	0
							4	S	14	6.6612 mmol/L	2.4975	13.875	0
							5	S	21	13.711 mmol/L	2.4975	13.875	0
							6	S	28	13.4889 mmol/L	2.4975	13.875	0
							7	S	36	7.66038 mmol/L	2.4975	13.875	0
							8	S	42	15.7648 mmol/L	2.4975	13.875	1
							16	S	102	5.551 mmol/L	2.4975	13.875	0
							18	S	150	11.6016 mmol/L	2.4975	13.875	0
							20	S	213	10.6579 mmol/L	2.4975	13.875	0
							22	S	269	15.3208 mmol/L	2.4975	13.875	1
							24	S	323	6.77222 mmol/L	2.4975	13.875	0
							26	S	367	6.16161 mmol/L	2.4975	13.875	0
							27	S	423	9.27017 mmol/L	2.4975	13.875	0
							28	S	478	10.1028 mmol/L	2.4975	13.875	0
							29	S	534	16.1534 mmol/L	2.4975	13.875	1
038	412	M	01z	A16	EOSINOPHILS	HIGH	1	S	-4	0.74212 % WBC			10
							2	S	0	3.25733 % WBC			10
							3	S	7	1.65663 % WBC			10
							4	S	14	0.64851 % WBC			10
							5	S	21	2.17391 % WBC			10
							6	S	28	4.46927 % WBC			10
							7	S	35	13.0829 % WBC			10
							8	S	42	18.1704 % WBC			10
							10	S	51	3.7092 % WBC			10
							11	S	56	6.34146 % WBC			10
							12	S	63	9.00735 % WBC			10
							13	S	70	4.7619 % WBC			10
							14	S	77	2.08333 % WBC			10
							15	S	86	2.10526 % WBC			10
							16	S	131	4.56349 % WBC			10
							18	S	156	1.47541 % WBC			10

ZY 1234 362

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

DIRECTN VISIT UNVISIT RELDAYS RESULT UNIT LOLIM HILIM ABRNM

038	412	M	01z	A16	EOSINOPHILS	HIGH	20	S	212	2.42131	% WBC	10	0
	22		S				22	S	273	1.47059	% WBC	10	0
	24		S				24	S	330	0.75075	% WBC	10	0
	26		S				26	S	370	1.1236	% WBC	10	0
	27		S				27	S	427	4.49735	% WBC	10	0
	28		S				28	S	483	3.62473	% WBC	10	0

038	681	M	01z	C11	UA-RBC	INC2	1	S	-3	0	NO UNITS	3	0
	2		S				2	S	0		0 NO UNITS	3	0
	3		S				3	S	5		0 NO UNITS	3	0
	4		S				4	S	11		0 NO UNITS	3	0
	5		S				5	S	19		0 NO UNITS	3	0
	6		S				6	S	25		0 NO UNITS	3	0
	7		S				7	S	32		0 NO UNITS	3	0
	8		S				8	S	41		4 NO UNITS	3	1

038	684	M	01z	A03	ERYTHROCYTE COUNT	HIGH	1	S	31	5.8	TI/L	3	6
	10		S				10	S	39	5.6	TI/L <td>3</td> <td>6</td>	3	6
	11		S				11	S	46	5.5	TI/L <td>3</td> <td>6</td>	3	6
	12		S				12	S	53	5.5	TI/L <td>3</td> <td>6</td>	3	6
	13		S				13	S	60	5.8	TI/L <td>3</td> <td>6</td>	3	6
	14		S				14	S	67	5.5	TI/L <td>3</td> <td>6</td>	3	6
	15		S				15	S	74	5.8	TI/L <td>3</td> <td>6</td>	3	6
	16		S				16	S	88	5.6	TI/L <td>3</td> <td>6</td>	3	6
	18		S				18	S	144	5.4	TI/L <td>3</td> <td>6</td>	3	6
	20		S				20	S	201	6.2	TI/L <td>3</td> <td>6</td>	3	6
	22		S				22	S	256	6.2	TI/L <td>3</td> <td>6</td>	3	6
	24		S				24	S	315	6.2	TI/L <td>3</td> <td>6</td>	3	6
	26		S				26	S	356	6.1	TI/L <td>3</td> <td>6</td>	3	6

039	389	M	01z	C11	UA-RBC	INC2	1	S	-6	0	NO UNITS	3	0
	2		S				2	S	0		1 NO UNITS	3	0
	3		S				3	S	8		0 NO UNITS	3	0
	4		S				4	S	12		2 NO UNITS	3	0
	5		S				5	S	21		0 NO UNITS	3	0
	6		S				6	S	28		0 NO UNITS	3	0
	7		S				7	S	35		0 NO UNITS	3	0
	8		S				8	S	42		0 NO UNITS	3	0
	10		S				10	S	57		0 NO UNITS	3	0
	11		S				11	S	64		0 NO UNITS	3	0
	12		S				12	S	70		0 NO UNITS	3	0
	13		S				13	S	77		0 NO UNITS	3	0
	14		S				14	S	83		0 NO UNITS	3	0
	15		S				15	S	96		0 NO UNITS	3	0
	16		S				16	S	113		4 NO UNITS	3	1
	17		S				17	S	140		4 NO UNITS	3	1
	18		S				18	S	168		0 NO UNITS	3	0

ZY 1234 363

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
039	389	M	01z	C11	UA-RBC	INC2	20	S	222	0 NO UNITS	.	.	3 0
							22	S	279	0 NO UNITS	.	.	3 0
							24	S	336	0 NO UNITS	.	.	3 0
039	392	M	01z	E03	ALT/SGPT	HIGH	1	S	-3	23 U/L	.	.	165 0
							2	S	0	19 U/L	.	.	165 0
							3	S	7	66 U/L	.	.	165 0
							5	S	21	246 U/L	.	.	165 1
							6	S	28	285 U/L	.	.	165 1
							7	S	35	137 U/L	.	.	165 0
							8	S	12	92 U/L	.	.	165 0
							16	S	98	34 U/L	.	.	165 0
							18	S	154	20 U/L	.	.	165 0
							20	S	210	22 U/L	.	.	165 0
							22	S	266	44 U/L	.	.	165 0
040	239	F	01z	C11	UA-RBC	INC2	1	S	.	0 NO UNITS	.	.	3 0
							2	S	.	0 NO UNITS	.	.	3 0
							3	S	.	0 NO UNITS	.	.	3 0
							4	S	.	0 NO UNITS	.	.	3 0
							5	S	.	0 NO UNITS	.	.	3 0
							6	S	.	0 NO UNITS	.	.	3 0
							7	S	.	0 NO UNITS	.	.	3 0
							8	S	.	4 NO UNITS	.	.	3 1
							10	S	.	0 NO UNITS	.	.	3 0
							11	S	.	0 NO UNITS	.	.	3 0
							12	S	.	0 NO UNITS	.	.	3 0
							13	S	.	0 NO UNITS	.	.	3 0
							14	S	.	0 NO UNITS	.	.	3 0
							15	S	.	0 NO UNITS	.	.	3 0
							16	S	.	0 NO UNITS	.	.	3 0
							18	S	.	0 NO UNITS	.	.	3 0
							20	S	.	0 NO UNITS	.	.	3 0
							22	S	.	0 NO UNITS	.	.	3 0
							24	S	.	4 NO UNITS	.	.	3 1
040	240	F	Ha1	F31	GLUCOSE, NON-FASTING	HIGH	1	S	-2	9.15915 mmol/L	2.4975	13.875	0
							2	S	0	13.6 mmol/L	2.4975	13.875	0
							3	S	7	9.88078 mmol/L	2.4975	13.875	0
							4	S	14	13.4889 mmol/L	2.4975	13.875	0
							5	S	21	6.32814 mmol/L	2.4975	13.875	0
							6	S	28	16.431 mmol/L	2.4975	13.875	1
							7	S	35	8.3265 mmol/L	2.4975	13.875	0
							8	S	42	15.7093 mmol/L	2.4975	13.875	1
040	851	M	Ha1	A10	LEUCOCYTE COUNT	HIGH	1	S	-6	8.27 GI/L	2.8	16	0
							2	S	0	9.51 GI/L	2.8	16	0

RMP.FIDSTSS1.SASPCN(LABNTJX) 85266

ZY 1234 364

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM		
040	851	M	Ha1	A10	LEUCOCYTE	COUNT	HIGH	3	S	7	10.43	GI/L	2.8	16	0
								4	S	14	8.01	GI/L	2.8	16	0
								5	S	21	8.8	GI/L	2.8	16	0
								6	S	28	10.35	GI/L	2.8	16	0
								7	S	35	12.31	GI/L	2.8	16	0
								8	S	42	18.11	GI/L	2.8	16	1
041	242	M	Ha1	A01	HEMATOCRIT	LOW		1	S	-2	0.41	I	0.37	0.55	0
								2	S	0	0.4	I	0.37	0.55	0
								3	S	6	0.4	I	0.37	0.55	0
								4	S	13	0.36	I	0.37	0.55	1
								5	S	20	0.37	I	0.37	0.55	0
								6	S	27	0.42	I	0.37	0.55	0
								7	S	34	0.39	I	0.37	0.55	0
								8	S	41	0.39	I	0.37	0.55	0
								16	S	96	0.36	I	0.37	0.55	1
								18	S	157	0.38	I	0.37	0.55	0
								20	S	209	0.37	I	0.37	0.55	0
								22	S	272	0.38	I	0.37	0.55	0
								24	S	321	0.41	I	0.37	0.55	0
								26	S	363	0.36	I	0.37	0.55	1
								27	S	419	0.35	I	0.37	0.55	1
								28	S	475	0.38	I	0.37	0.55	0
								29	S	531	0.39	I	0.37	0.55	0
041	245	F	Olz	C11	UA-RBC	INC2		1	S	-2	4	NO UNITS	.	3	1
								2	S	0	2	NO UNITS	.	3	0
								3	S	7	0	NO UNITS	.	3	0
								4	S	14	0	NO UNITS	.	3	0
								5	S	21	0	NO UNITS	.	3	0
								6	S	28	0	NO UNITS	.	3	0
								7	S	35	4	NO UNITS	.	3	1
								8	S	42	0	NO UNITS	.	3	0
								10	S	55	0	NO UNITS	.	3	0
								11	S	62	0	NO UNITS	.	3	0
								12	S	70	1	NO UNITS	.	3	0
								13	S	77	0	NO UNITS	.	3	0
								14	S	84	0	NO UNITS	.	3	0
								15	S	91	0	NO UNITS	.	3	0
								16	S	105	0	NO UNITS	.	3	0
								19	U	161	0	NO UNITS	.	3	0
								19	S	164	4	NO UNITS	.	3	1
041	397	M	Olz	E01	AST/SGOT	HIGH		1	S	-2	17	U/L	.	150	0
								2	S	0	15	U/L	.	150	0
								3	S	8	22	U/L	.	150	0
								4	S	14	19	U/L	.	150	0

ZY 1234 365

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	AST/SGOT	HIGH	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
041	397	M	OLZ	E01	AST/SGOT	HIGH		5	S	21	21	U/L		150	0
								6	S	28	20	U/L		150	0
								7	S	35	19	U/L		150	0
								8	S	42	18	U/L		150	0
								16	S	98	21	U/L		150	0
								18	S	154	18	U/L		150	0
								20	S	210	249	U/L		150	1
041	397	M	OLZ	E12	CREATINE PHOSPHOKINASE	HIGH		1	S	-2	47	U/L		594	0
								2	S	0	51	U/L		594	0
								3	S	8	60	U/L		594	0
								4	S	14	53	U/L		594	0
								5	S	21	90	U/L		594	0
								6	S	28	70	U/L		594	0
								7	S	35	79	U/L		594	0
								8	S	42	70	U/L		594	0
								16	S	98	68	U/L		594	0
								18	S	154	78	U/L		594	0
								20	S	210	24880	U/L		594	1
041	401	M	OLZ	E03	ALT/SGPT	HIGH		1	S	35	47	U/L		165	0
								10	S	42	40	U/L		165	0
								11	S	49	59	U/L		165	0
								12	S	56	110	U/L		165	0
								13	S	63	179	U/L		165	1
								14	S	70	416	U/L		165	1
								15	U	73	347	U/L		165	1
								15	U	75	368	U/L		165	1
								15	S	77	325	U/L		165	1
								16	U	80	274	U/L		165	1
								16	U	82	239	U/L		165	1
								16	U	84	295	U/L		165	1
								16	U	88	182	U/L		165	1
								16	S	91	156	U/L		165	0
								17	U	95	119	U/L		165	0
								17	U	98	118	U/L		165	0
								17	U	105	114	U/L		165	0
								17	U	112	77	U/L		165	0
								17	S	119	56	U/L		165	0
								18	U	136	46	U/L		165	0
								18	S	147	56	U/L		165	0
								20	S	201	26	U/L		165	0
								22	S	258	30	U/L		165	0
								24	S	314	27	U/L		165	0
041	1025	M	OLZ	F31	GLUCOSE, NON-FASTING	HIGH		1	S	-2	13.6555	mmol/L	2.4975	13.875	0
								2	S	0	12.2122	mmol/L	2.4975	13.875	0

ZY 1234 366

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
041	1025	M	01z	F31	GLUCOSE, NON-FASTING	HIGH	3	S	7	19.3175	mmol/L	2.4975	13.875
							4	S	14	19.9281	mmol/L	2.4975	13.875
							5	S	21	18.5959	mmol/L	2.4975	13.875
							6	S	26	21.7044	mmol/L	2.4975	13.875
							10	S	34	19.151	mmol/L	2.4975	13.875
							11	S	41	22.5371	mmol/L	2.4975	13.875
							12	S	48	22.8701	mmol/L	2.4975	13.875
							13	S	55	12.2677	mmol/L	2.4975	13.875
							14	S	62	22.4816	mmol/L	2.4975	13.875
							15	S	69	15.3208	mmol/L	2.4975	13.875
							16	S	83	19.9836	mmol/L	2.4975	13.875
							18	S	137	16.0979	mmol/L	2.4975	13.875
							20	S	195	23.9803	mmol/L	2.4975	13.875
042	247	M	Ha1	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-4	63	U/L	.	594
							2	S	0	65	U/L	.	594
							3	S	7	1248	U/L	.	594
							4	S	14	64	U/L	.	594
							5	S	22	49	U/L	.	594
							6	S	28	3145	U/L	.	594
							7	S	35	2160	U/L	.	594
							8	S	42	82	U/L	.	594
042	248	M	01z	F31	GLUCOSE, NON-FASTING	HIGH	1	S	-7	9.65874	mmol/L	2.4975	13.875
							2	S	0	12.1567	mmol/L	2.4975	13.875
							3	S	7	21.4269	mmol/L	2.4975	13.875
							4	S	15	24.7575	mmol/L	2.4975	13.875
							5	S	21	24.2579	mmol/L	2.4975	13.875
							6	S	28	18.1518	mmol/L	2.4975	13.875
							7	S	35	19.7616	mmol/L	2.4975	13.875
							8	S	42	12.9338	mmol/L	2.4975	13.875
							16	S	98	18.7069	mmol/L	2.4975	13.875
							18	S	154	21.4269	mmol/L	2.4975	13.875
							20	S	210	22.204	mmol/L	2.4975	13.875
							22	S	273	16.4865	mmol/L	2.4975	13.875
							24	S	322	20.8718	mmol/L	2.4975	13.875
							26	S	399	22.1485	mmol/L	2.4975	13.875
							27	S	455	15.2653	mmol/L	2.4975	13.875
							28	S	512	21.2603	mmol/L	2.4975	13.875
042	1465	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	34	80	U/L	.	594
							10	S	45	96	U/L	.	594
							11	S	52	118	U/L	.	594
							12	S	59	234	U/L	.	594
							13	S	66	616	U/L	.	594
							14	S	76	1112	U/L	.	594
							15	S	80	437	U/L	.	594

(J)

ZY 1234 367

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
042	1465	M	OLZ	E12	CREATINE PHOSPHOKINASE	HIGH	16	S	93	443	U/L	.	594	0
							18	S	149	173	U/L	.	594	0
043	1095	M	OLZ	A10	LEUCOCYTE COUNT	HIGH	1	S	-6	12	GI/L	2.8	16	0
							2	S	0	14.81	GI/L	2.8	16	0
							3	S	7	13.83	GI/L	2.8	16	0
							4	S	15	9.73	GI/L	2.8	16	0
							5	S	24	10.86	GI/L	2.8	16	0
							6	S	29	12.2	GI/L	2.8	16	0
							7	S	43	10.74	GI/L	2.8	16	0
							8	S	71	11.84	GI/L	2.8	16	0
							16	S	99	9.07	GI/L	2.8	16	0
							18	S	155	10.33	GI/L	2.8	16	0
							19	S	183	19.37	GI/L	2.8	16	1
044	1446	F	OLZ	C07	UA-GLUCOSE	INC2	1	S	-7	0	NO UNITS	.	3	0
							2	S	0	0	NO UNITS	.	3	0
							3	S	7	0	NO UNITS	.	3	0
							4	S	14	0	NO UNITS	.	3	0
							5	S	21	0	NO UNITS	.	3	0
							6	S	28	0	NO UNITS	.	3	0
							7	S	36	0	NO UNITS	.	3	0
							9	U	42	0	NO UNITS	.	3	0
							9	S	71	0	NO UNITS	.	3	0
							16	S	98	0	NO UNITS	.	3	0
							18	S	154	0	NO UNITS	.	3	0
							20	S	217	3	NO UNITS	.	3	1
044	1448	M	Ha1	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-7	77	U/L	.	594	0
							2	S	0	120	U/L	.	594	0
							3	S	7	818	U/L	.	594	1
044	1572	M	OLZ	C07	UA-GLUCOSE	INC2	1	S	-2	0	NO UNITS	.	3	0
							2	S	0	1	NO UNITS	.	3	0
							3	S	7	0	NO UNITS	.	3	0
							4	S	14	1	NO UNITS	.	3	0
							5	S	21	3	NO UNITS	.	3	1
							6	S	29	3	NO UNITS	.	3	1
							7	S	35	3	NO UNITS	.	3	1
							8	S	42	3	NO UNITS	.	3	1
							9	S	70	3	NO UNITS	.	3	1
							16	S	98	3	NO UNITS	.	3	1
							18	S	159	3	NO UNITS	.	3	1
044	1572	M	OLZ	F31	GLUCOSE, NON-FASTING	HIGH	1	S	-2	4.88488	mmol/L	2.4975	13.875	0
							2	S	0	7.38283	mmol/L	2.4975	13.875	0
							3	S	7	6.6612	mmol/L	2.4975	13.875	0

ZY 1234 368

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM	
044	1572	M	Olz	F31	GLUCOSE, NON-FASTING	HIGH	4	S	14	13.6555	mmol/L	2.4975	13.875	0
							6	S	29	22.5926	mmol/L	2.4975	13.875	1
							7	S	35	14.8767	mmol/L	2.4975	13.875	1
							8	S	42	17.0971	mmol/L	2.4975	13.875	1
							9	S	70	16.764	mmol/L	2.4975	13.875	1
							16	S	98	22.3705	mmol/L	2.4975	13.875	1
							18	S	159	17.4857	mmol/L	2.4975	13.875	1
045	267	F	Ha1	C01	UA-SPECIFIC GRAVITY	HIGH	1	S	-7	1.025	NO UNITS	1.001	1.035	0
							2	S	0	1.029	NO UNITS	1.001	1.035	0
							3	S	7	1.019	NO UNITS	1.001	1.035	0
							4	S	14	1.031	NO UNITS	1.001	1.035	0
							5	S	21	1.032	NO UNITS	1.001	1.035	0
							6	S	28	1.02	NO UNITS	1.001	1.035	0
							7	S	35	1.013	NO UNITS	1.001	1.035	0
							8	S	42	1.024	NO UNITS	1.001	1.035	0
							9	S	70	1.012	NO UNITS	1.001	1.035	0
							16	S	98	1.015	NO UNITS	1.001	1.035	0
							18	S	154	1.024	NO UNITS	1.001	1.035	0
							20	S	210	1.024	NO UNITS	1.001	1.035	0
							22	S	266	1.018	NO UNITS	1.001	1.035	0
							24	S	322	1.032	NO UNITS	1.001	1.035	0
							25	U	336	1.028	NO UNITS	1.001	1.035	0
							25	S	350	1.032	NO UNITS	1.001	1.035	0
							26	S	364	1.04	NO UNITS	1.001	1.035	1
045	267	F	Ha1	C07	UA-GLUCOSE	INC2	1	S	-7	3	NO UNITS	.	3	1
							2	S	0	1	NO UNITS	.	3	0
							3	S	7	3	NO UNITS	.	3	1
							4	S	14	3	NO UNITS	.	3	1
							5	S	21	3	NO UNITS	.	3	1
							6	S	28	2	NO UNITS	.	3	0
							7	S	35	0	NO UNITS	.	3	0
							8	S	42	2	NO UNITS	.	3	0
							9	S	70	0	NO UNITS	.	3	0
							16	S	98	0	NO UNITS	.	3	0
							18	S	154	0	NO UNITS	.	3	0
							20	S	210	0	NO UNITS	.	3	0
							22	S	266	0	NO UNITS	.	3	0
							24	S	322	3	NO UNITS	.	3	1
							25	U	336	3	NO UNITS	.	3	1
							25	S	350	3	NO UNITS	.	3	1
							26	S	364	3	NO UNITS	.	3	1
045	787	M	Olz	A10	LEUCOCYTE COUNT	HIGH	2	S	0	14.36	GI/L	2.8	16	0
							3	U	4	18.76	GI/L	2.8	16	1
							3	S	8	20.69	GI/L	2.8	16	1

RMP.FIDSISS1.SASPGM(LABNTJX) 85266

ZY 1234 369

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
045	787	M	01z	A10	LEUCOCYTE	COUNT	HIGH	4	S	15	14.67	GI/L	16
								5	S	22	13.62	GI/L	16
								6	S	29	13.03	GI/L	16
								7	S	36	10.29	GI/L	16
								8	S	43	15.09	GI/L	16
								10	S	60	11.59	GI/L	16
								11	S	67	10.56	GI/L	16
								12	S	74	12.33	GI/L	16
045	794	M	01z	E03	ALT/SGPT	HIGH	-1	1	S	-1	17	U/L	165
								2	S	0	18	U/L	165
								3	S	7	40	U/L	165
								4	S	14	55	U/L	165
								5	S	21	63	U/L	165
								6	S	28	241	U/L	165
								7	S	35	187	U/L	165
								8	S	42	97	U/L	165
								16	S	98	24	U/L	165
								18	S	154	81	U/L	165
								20	S	210	75	U/L	165
								22	S	265	56	U/L	165
								24	S	323	64	U/L	165
045	1279	M	01z	E12	CREATINE	PHOSPHOKINASE	HIGH	1	S	-1	119	U/L	594
								2	S	0	107	U/L	594
								3	S	3	736	U/L	594
045	1281	F	01z	C11	UA-RBC	INC2	-2	1	S	-2	0	NO UNITS	3
								2	S	0	0	NO UNITS	3
								3	S	6	0	NO UNITS	3
								4	S	13	0	NO UNITS	3
								5	S	23	0	NO UNITS	3
								6	S	28	0	NO UNITS	3
								7	S	35	0	NO UNITS	3
								8	S	41	3	NO UNITS	3
								16	S	99	4	NO UNITS	3
								17	S	133	0	NO UNITS	3
								18	S	159	0	NO UNITS	3
								20	S	209	0	NO UNITS	3
045	1408	M	01z	E12	CREATINE	PHOSPHOKINASE	HIGH	1	S	-5	126	U/L	594
								2	S	0	73	U/L	594
								3	S	7	4010	U/L	594
								4	U	9	5640	U/L	594
								4	U	12	947	U/L	594
								5	S	23	98	U/L	594
								6	S	28	110	U/L	594

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
045 1408	M	OLZ	E12	CREATINE PHOSPHOKINASE	HIGH	7	S	35	150	U/L	.	594	0
						8	S	42	111	U/L	.	594	0
						16	S	99	133	U/L	.	594	0
						18	S	153	178	U/L	.	594	0
						20	S	209	122	U/L	.	594	0
045 1409	F	OLZ	A10	LEUCOCYTE COUNT	HIGH	1	S	41	13.38	GI/L	2.8	16	0
						10	S	48	17.41	GI/L	2.8	16	1
						11	S	55	18.13	GI/L	2.8	16	1
						12	S	63	16.51	GI/L	2.8	16	1
						13	S	70	14.53	GI/L	2.8	16	0
						14	S	77	14.11	GI/L	2.8	16	0
						15	S	84	14.1	GI/L	2.8	16	0
						16	S	100	15.04	GI/L	2.8	16	0
						18	S	152	14.73	GI/L	2.8	16	0
						20	S	211	16.62	GI/L	2.8	16	1
045 1414	M	OLZ	A01	HEMATOCRIT	LOW	1	S	-2	0.39	1	0.37	0.55	0
						2	S	0	0.39	1	0.37	0.55	0
						3	S	6	0.39	1	0.37	0.55	0
						4	S	13	0.36	1	0.37	0.55	1
						5	S	20	0.36	1	0.37	0.55	1
						6	S	27	0.38	1	0.37	0.55	0
						7	S	34	0.36	1	0.37	0.55	1
						8	S	41	0.36	1	0.37	0.55	1
						16	S	95	0.42	1	0.37	0.55	0
						17	S	112	0.42	1	0.37	0.55	0
045 1414	M	OLZ	A16	EOSINOPHILS	HIGH	1	S	-2	5.86207	% MBC	.	10	0
						2	S	0	2.99213	% MBC	.	10	0
						3	S	6	11.1857	% MBC	.	10	1
						4	S	13	6.93431	% MBC	.	10	0
						5	S	20	12.3123	% MBC	.	10	1
						6	S	27	1.85185	% MBC	.	10	0
						7	S	34	15.5007	% MBC	.	10	1
						8	S	41	19.7464	% MBC	.	10	1
						16	S	95	9.60699	% MBC	.	10	0
						17	S	112	14.2061	% MBC	.	10	1
047 279	M	OLZ	C07	UA-GLUCOSE	INC2	1	S	-2	1	NO UNITS	.	3	0
						2	S	0	0	NO UNITS	.	3	0
						3	S	7	0	NO UNITS	.	3	0
						4	S	14	1	NO UNITS	.	3	0
						5	S	21	3	NO UNITS	.	3	1
						6	S	28	3	NO UNITS	.	3	1
						7	S	35	3	NO UNITS	.	3	1
						8	S	42	1	NO UNITS	.	3	0

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	INC2	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
047	279	M	01z	C07 UA-GLUCOSE	INC2		16	S	98	3	NO UNITS	.	.	3 1
							18	S	153	3	NO UNITS	.	.	3 1
							20	S	208	3	NO UNITS	.	.	3 1
							22	S	264	1	NO UNITS	.	.	3 0
							24	S	320	3	NO UNITS	.	.	3 1
							26	S	364	2	NO UNITS	.	.	3 0
							27	S	419	3	NO UNITS	.	.	3 1
							28	S	447	3	NO UNITS	.	.	3 1
047	282	M	Ha1	F40 URIC ACID	HIGH		1	S	-4	523.424	umol/L	.	624.54	0
							2	S	0	547.216	umol/L	.	624.54	0
							3	S	7	588.852	umol/L	.	624.54	0
							4	S	14	701.864	umol/L	.	624.54	1
							5	S	21	660.228	umol/L	.	624.54	1
							6	S	28	684.02	umol/L	.	624.54	1
							7	S	35	719.708	umol/L	.	624.54	1
							8	S	42	695.916	umol/L	.	624.54	1
							16	S	98	767.292	umol/L	.	624.54	1
048	283	M	Ha1	A10 LEUCOCYTE COUNT	HIGH		1	S	-2	10.69	GI/L	2.8	16	0
							2	S	0	10.23	GI/L	2.8	16	0
							3	S	7	13.43	GI/L	2.8	16	0
							4	S	14	13.45	GI/L	2.8	16	0
							5	S	21	10.35	GI/L	2.8	16	0
							6	S	28	16.14	GI/L	2.8	16	1
048	286	M	01z	A01 HEMATOCRIT	LOW		1	S	-14	0.37	1	0.37	0.55	0
							2	U	-11	0.38	1	0.37	0.55	0
							2	S	0	0.4	1	0.37	0.55	0
							3	S	7	0.37	1	0.37	0.55	0
							4	S	16	0.41	1	0.37	0.55	0
							5	S	23	0.38	1	0.37	0.55	0
							6	S	30	0.38	1	0.37	0.55	0
							7	S	37	0.36	1	0.37	0.55	1
							8	S	45	0.38	1	0.37	0.55	0
							9	S	58	0.35	1	0.37	0.55	1
048	352	M	Ha1	A16 EOSINOPHILS	HIGH		1	S	-3	3.84088	% NBC	.	10	0
							2	S	0	5.66036	% NBC	.	10	0
							3	S	6	4.43114	% NBC	.	10	0
							4	S	13	4.64824	% NBC	.	10	0
							5	S	19	3.47534	% NBC	.	10	0
							6	S	27	0.90386	% NBC	.	10	0
							7	S	33	1.79754	% NBC	.	10	0
							8	S	40	10.3982	% NBC	.	10	1
048	353	M	01z	E03 ALT/SGPT	HIGH		1	S	-4	64	U/L	.	165	0

ZY 1234 372

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

048	353	M	01z	E03	ALT/SOPT	DIRECTN VISIT UNVISIT RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
						0	111 U/L	.	165	0
						7	88 U/L	.	165	0
						14	103 U/L	.	165	0
						26	218 U/L	.	165	1
						31	224 U/L	.	165	1
						45	132 U/L	.	165	0
049	290	F	01z	C11	UA-RBC	-2	0 NO UNITS	.	3	0
						0	0 NO UNITS	.	3	0
						5	0 NO UNITS	.	3	0
						12	0 NO UNITS	.	3	0
						19	1 NO UNITS	.	3	0
						26	0 NO UNITS	.	3	0
						33	0 NO UNITS	.	3	0
						40	0 NO UNITS	.	3	0
						68	0 NO UNITS	.	3	0
						96	0 NO UNITS	.	3	0
						152	0 NO UNITS	.	3	0
						208	0 NO UNITS	.	3	0
						264	2 NO UNITS	.	3	0
						320	0 NO UNITS	.	3	0
						377	4 NO UNITS	.	3	1
						495	3 NO UNITS	.	3	1
049	291	F	01z	C07	UA-GLUCOSE	41	0 NO UNITS	.	3	0
						47	0 NO UNITS	.	3	0
						54	0 NO UNITS	.	3	0
						61	1 NO UNITS	.	3	0
						68	0 NO UNITS	.	3	0
						75	0 NO UNITS	.	3	0
						82	0 NO UNITS	.	3	0
						96	0 NO UNITS	.	3	0
						152	3 NO UNITS	.	3	1
						208	3 NO UNITS	.	3	1
						264	0 NO UNITS	.	3	0
						320	0 NO UNITS	.	3	0
						376	0 NO UNITS	.	3	0
						488	3 NO UNITS	.	3	1
049	291	F	01z	F31	GLUCOSE, NON-FASTING	41	4.66284 mmol/L	2.4975	13.875	0
						47	4.4408 mmol/L	2.4975	13.875	0
						54	7.7714 mmol/L	2.4975	13.875	0
						61	5.49549 mmol/L	2.4975	13.875	0
						68	10.2138 mmol/L	2.4975	13.875	0
						75	6.21712 mmol/L	2.4975	13.875	0
						82	6.77222 mmol/L	2.4975	13.875	0
						96	7.10528 mmol/L	2.4975	13.875	0

ZY 1234 373

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
049	F	01z	F31	GLUCOSE, NON-FASTING	HIGH	18	S	152	23.4252	mmol/L	2.4975	13.875	1
						20	S	208	28.3101	mmol/L	2.4975	13.875	1
						22	S	264	8.49303	mmol/L	2.4975	13.875	0
						24	S	320	4.49651	mmol/L	2.4975	13.875	0
						26	S	376	8.49303	mmol/L	2.4975	13.875	0
						28	S	488	35.1933	mmol/L	2.4975	13.875	1
049	F	01z	C07	UA-GLUCOSE	INC2	1	S	-2	2	NO UNITS	.	3	0
						2	S	0	0	NO UNITS	.	3	0
						3	S	5	0	NO UNITS	.	3	0
						5	S	19	0	NO UNITS	.	3	0
						6	S	26	0	NO UNITS	.	3	0
						7	S	33	1	NO UNITS	.	3	0
						8	S	40	0	NO UNITS	.	3	0
						10	S	47	1	NO UNITS	.	3	0
						11	S	54	0	NO UNITS	.	3	0
						12	S	61	0	NO UNITS	.	3	0
						13	S	68	1	NO UNITS	.	3	0
						14	S	76	0	NO UNITS	.	3	0
						15	S	82	0	NO UNITS	.	3	0
						16	S	96	0	NO UNITS	.	3	0
						18	S	152	0	NO UNITS	.	3	0
						20	S	208	0	NO UNITS	.	3	0
						22	S	264	3	NO UNITS	.	3	1
						24	S	320	2	NO UNITS	.	3	0
						26	U	362	3	NO UNITS	.	3	1
049	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-2	235	U/L	.	594	0
						2	S	0	469	U/L	.	594	0
						3	S	5	3785	U/L	.	594	1
049	M	Ha1	E03	ALT/SGPT	HIGH	1	S	-3	139	U/L	.	165	0
						2	S	0	148	U/L	.	165	0
						3	S	8	156	U/L	.	165	0
						4	S	15	128	U/L	.	165	0
						5	S	22	211	U/L	.	165	1
						6	S	29	168	U/L	.	165	1
049	M	01z	A02	HEMOGLOBIN	HIGH	1	S	31	10.5502	mm1/L-Fe	7.1369	11.4811	0
						10	S	56	10.7984	mm1/L-Fe	7.1369	11.4811	0
						11	S	43	10.1778	mm1/L-Fe	7.1369	11.4811	0
						12	S	50	10.1778	mm1/L-Fe	7.1369	11.4811	0
						13	S	57	11.0467	mm1/L-Fe	7.1369	11.4811	0
						14	S	63	11.1087	mm1/L-Fe	7.1369	11.4811	0
						15	S	71	11.357	mm1/L-Fe	7.1369	11.4811	0
						16	S	85	10.9226	mm1/L-Fe	7.1369	11.4811	0
						18	S	141	11.1708	mm1/L-Fe	7.1369	11.4811	0

ZY 1234 374

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

051	314	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
051	314	M	01z	E12	GGT(GGPT/SGGT/YGGT)	HIGH	1	S	-3	42 U/L	.	195	0
							2	S	-1	39 U/L	.	195	0
							3	S	6	41 U/L	.	195	0
							4	S	13	76 U/L	.	195	0
							5	S	20	43 U/L	.	195	0
							6	S	28	40 U/L	.	195	0
							7	S	34	34 U/L	.	195	0
							8	S	41	32 U/L	.	195	0
							9	S	69	27 U/L	.	195	0
							16	S	104	29 U/L	.	195	0
							17	S	132	27 U/L	.	195	0
							18	S	257	269 U/L	.	195	1
							19	U	153	21 U/L	.	195	0
							20	S	223	572 U/L	.	195	1
052	514	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-7	254 U/L	.	594	0
							2	S	0	230 U/L	.	594	0
							3	S	12	256 U/L	.	594	0
							4	S	14	226 U/L	.	594	0
							5	S	21	196 U/L	.	594	0
							6	S	28	10060 U/L	.	594	1
052	517	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-7	154 U/L	.	594	0
							2	S	0	397 U/L	.	594	0
							3	S	7	205 U/L	.	594	0
							4	S	14	541 U/L	.	594	0
							5	S	21	383 U/L	.	594	0
							6	S	28	320 U/L	.	594	0
							7	S	35	365 U/L	.	594	0
							8	S	42	351 U/L	.	594	0
							10	S	49	342 U/L	.	594	0
							11	S	56	303 U/L	.	594	0
							12	S	63	1660 U/L	.	594	1
							13	U	68	639 U/L	.	594	1
							13	S	70	634 U/L	.	594	1
							14	S	77	470 U/L	.	594	0
053	520	M	01z	A01	HEMATOCRIT	LOW	1	S	-2	0.43 1	0.37	0.55	0

ZY 1234 375

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

053	520	M	01z	A01	HEMATOCRIT	DIRECTN VISIT UNVISIT RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
						S	0.39 l	0.37	0.55	0
						S	0.37 l	0.37	0.55	0
						S	0.38 l	0.37	0.55	0
						S	0.36 l	0.37	0.55	1
						S	0.34 l	0.37	0.55	1
						S	0.4 l	0.37	0.55	0
						S	0.37 l	0.37	0.55	0
						S	0.41 l	0.37	0.55	0
						S	0.36 l	0.37	0.55	1
						S	0.4 l	0.37	0.55	0
						S	0.4 l	0.37	0.55	0
						S	0.44 l	0.37	0.55	0
						S	0.42 l	0.37	0.55	0
						S	0.42 l	0.37	0.55	0
						S	0.42 l	0.37	0.55	0
053	527	M	01z	E17	GGT(GGPT/SGGT/YGGT)	S	78 U/L	.	195	0
						S	83 U/L	.	195	0
						S	234 U/L	.	195	1
						S	340 U/L	.	195	1
						U	232 U/L	.	195	1
						S	189 U/L	.	195	0
						S	134 U/L	.	195	0
						S	233 U/L	.	195	1
						S	237 U/L	.	195	1
						C	238 U/L	.	195	1
						S	277 U/L	.	195	1
						S	62 U/L	.	195	0
						S	138 U/L	.	195	0
054	535	M	01z	A02	HEMOGLOBIN	S	10.7984 mmL/L-Fe	7.1369	11.4811	0
						S	10.2399 mmL/L-Fe	7.1369	11.4811	0
						S	10.4881 mmL/L-Fe	7.1369	11.4811	0
						S	10.0537 mmL/L-Fe	7.1369	11.4811	0
						S	10.0537 mmL/L-Fe	7.1369	11.4811	0
						S	10.4881 mmL/L-Fe	7.1369	11.4811	0
						S	10.364 mmL/L-Fe	7.1369	11.4811	0
						S	10.2399 mmL/L-Fe	7.1369	11.4811	0
						U	10.6123 mmL/L-Fe	7.1369	11.4811	0
						S	10.364 mmL/L-Fe	7.1369	11.4811	0
						S	10.302 mmL/L-Fe	7.1369	11.4811	0
						S	10.302 mmL/L-Fe	7.1369	11.4811	0
						S	10.6743 mmL/L-Fe	7.1369	11.4811	0
						S	10.302 mmL/L-Fe	7.1369	11.4811	0
						S	10.7984 mmL/L-Fe	7.1369	11.4811	0
						S	10.9226 mmL/L-Fe	7.1369	11.4811	0
						S	11.4811 mmL/L-Fe	7.1369	11.4811	1

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HELIM	ABNRM
054	M	Olz	F02	CREATININE	HIGH	1	S	33	106.08	umol/L	.	176.8	0
						10	S	40	114.92	umol/L	.	176.8	0
						11	S	50	132.6	umol/L	.	176.8	0
						12	S	55	123.76	umol/L	.	176.8	0
						13	S	63	132.6	umol/L	.	176.8	0
						14	S	69	132.6	umol/L	.	176.8	0
						15	S	76	141.44	umol/L	.	176.8	0
						16	S	92	176.8	umol/L	.	176.8	1
055	M	Olz	A02	HEMOGLOBIN	LOW	1	S	-4	7.4472	mmol/L-Fe	7.1369	11.4811	0
						2	S	0	7.50926	mmol/L-Fe	7.1369	11.4811	0
						3	S	9	7.50926	mmol/L-Fe	7.1369	11.4811	0
						4	S	16	7.4472	mmol/L-Fe	7.1369	11.4811	0
						5	S	23	7.63338	mmol/L-Fe	7.1369	11.4811	0
						6	S	30	7.26102	mmol/L-Fe	7.1369	11.4811	0
						10	S	43	7.26102	mmol/L-Fe	7.1369	11.4811	0
						11	S	51	7.63338	mmol/L-Fe	7.1369	11.4811	0
						12	S	59	6.76454	mmol/L-Fe	7.1369	11.4811	1
						13	S	64	7.07484	mmol/L-Fe	7.1369	11.4811	1
						14	S	71	7.32308	mmol/L-Fe	7.1369	11.4811	0
						15	S	77	7.01278	mmol/L-Fe	7.1369	11.4811	1
						16	S	94	6.95072	mmol/L-Fe	7.1369	11.4811	1
						18	S	155	8.75046	mmol/L-Fe	7.1369	11.4811	0
						20	S	209	8.25398	mmol/L-Fe	7.1369	11.4811	0
055	M	Olz	C07	UA-GLUCOSE	INC2	1	S	-4	0	NO UNITS	.	3	0
						2	S	0	0	NO UNITS	.	3	0
						3	S	9	3	NO UNITS	.	3	1
						4	S	16	3	NO UNITS	.	3	1
						5	S	23	3	NO UNITS	.	3	1
						6	S	30	3	NO UNITS	.	3	1
						10	S	43	3	NO UNITS	.	3	1
						11	S	51	3	NO UNITS	.	3	1
						12	S	59	0	NO UNITS	.	3	0
						13	S	64	3	NO UNITS	.	3	1
						14	S	71	3	NO UNITS	.	3	1
						15	S	77	3	NO UNITS	.	3	1
						16	S	94	3	NO UNITS	.	3	1
						18	S	155	2	NO UNITS	.	3	0
						19	S	183	3	NO UNITS	.	3	1
						20	S	209	2	NO UNITS	.	3	0
055	M	Olz	F31	GLUCOSE, NON-FASTING	HIGH	1	S	-4	5.60651	mmol/L	2.4975	13.875	0
						2	S	0	9.52568	mmol/L	2.4975	13.875	0
						3	S	9	10.7689	mmol/L	2.4975	13.875	0
						5	S	23	17.3746	mmol/L	2.4975	13.875	1
						6	S	30	13.933	mmol/L	2.4975	13.875	1

RMP.FIDSISSL.SASPCN(LABNTJX) 85266

ZY 1234 377

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

055	542	M	01z	F31	C07	01z	F	1266	F	01z	C07	UA-GLUCOSE	INC2	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
														10	S	43	25.8677 mmol/L	2.4975	13.875	1
														11	S	51	8.93711 mmol/L	2.4975	13.875	0
														12	S	59	4.55182 mmol/L	2.4975	13.875	0
														13	S	64	6.32814 mmol/L	2.4975	13.875	0
														14	S	71	27.4775 mmol/L	2.4975	13.875	1
														15	S	77	12.6008 mmol/L	2.4975	13.875	0
														16	S	94	5.21794 mmol/L	2.4975	13.875	0
														18	S	155	11.4906 mmol/L	2.4975	13.875	0
														20	S	209	7.93793 mmol/L	2.4975	13.875	0
														1	S	-2	0 NO UNITS	.	.	3
														3	S	7	0 NO UNITS	.	.	3
														4	S	15	0 NO UNITS	.	.	3
														5	S	21	0 NO UNITS	.	.	3
														6	S	28	0 NO UNITS	.	.	3
														7	S	35	2 NO UNITS	.	.	3
														8	S	42	0 NO UNITS	.	.	3
														16	S	98	3 NO UNITS	.	.	3
														18	S	154	3 NO UNITS	.	.	3
														20	S	217	3 NO UNITS	.	.	3
														22	S	273	3 NO UNITS	.	.	3
														1	S	-2	7.60487 mmol/L	2.4975	13.875	0
														2	S	0	12.3232 mmol/L	2.4975	13.875	0
														3	S	7	13.2114 mmol/L	2.4975	13.875	0
														4	S	15	7.2163 mmol/L	2.4975	13.875	0
														5	S	21	10.8245 mmol/L	2.4975	13.875	0
														6	S	28	10.0473 mmol/L	2.4975	13.875	0
														7	S	35	13.711 mmol/L	2.4975	13.875	0
														8	S	42	9.93629 mmol/L	2.4975	13.875	0
														9	S	79	15.5983 mmol/L	2.4975	13.875	1
														16	S	98	16.875 mmol/L	2.4975	13.875	1
														18	S	154	26.2562 mmol/L	2.4975	13.875	1
														20	S	217	19.0399 mmol/L	2.4975	13.875	1
														22	S	273	21.8709 mmol/L	2.4975	13.875	1
														1	S	35	64 U/L	.	.	165
														10	S	42	52 U/L	.	.	165
														11	S	49	60 U/L	.	.	165
														12	S	56	44 U/L	.	.	165
														13	S	64	62 U/L	.	.	165
														14	S	71	59 U/L	.	.	165
														15	S	78	88 U/L	.	.	165
														16	S	98	79 U/L	.	.	165
														18	S	148	72 U/L	.	.	165
														20	S	207	172 U/L	.	.	165
														22	S	265	195 U/L	.	.	165

Handwritten initials and a large 'V' mark.

ZY 1234 378

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
056	1267	F	Olz	E03	ALT/SGPT	HIGH	23	S	273	115	U/L	.	165	0
056	1270	M	Olz	A10	LEUCOCYTE COUNT	HIGH	1	S	-2	14.69	GI/L	2.8	16	0
							2	S	0	12.39	GI/L	2.8	16	0
							3	S	6	12.32	GI/L	2.8	16	0
							4	S	13	12.82	GI/L	2.8	16	0
							5	S	20	10.53	GI/L	2.8	16	0
							6	S	28	13.98	GI/L	2.8	16	0
							7	S	35	17.29	GI/L	2.8	16	1
							8	S	42	15.94	GI/L	2.8	16	0
							16	S	98	12.69	GI/L	2.8	16	0
							18	S	154	16.39	GI/L	2.8	16	1
							20	S	213	17.42	GI/L	2.8	16	1
057	569	F	Ha1	A01	HEMATOCRIT	HIGH	1	S	-7	0.46	1	0.32	0.5	0
							3	S	7	0.49	1	0.32	0.5	0
							4	S	15	0.49	1	0.32	0.5	0
							5	S	21	0.5	1	0.32	0.5	0
							6	S	28	0.53	1	0.32	0.5	1
							7	S	35	0.54	1	0.32	0.5	1
057	569	F	Ha1	A02	HEMOGLOBIN	HIGH	1	S	-7	8.87458	mmL/L-Fe	5.8957	10.2399	0
							3	S	7	9.43312	mmL/L-Fe	5.8957	10.2399	0
							4	S	15	9.6193	mmL/L-Fe	5.8957	10.2399	0
							5	S	21	9.43312	mmL/L-Fe	5.8957	10.2399	0
							6	S	28	9.99166	mmL/L-Fe	5.8957	10.2399	0
							7	S	35	10.302	mmL/L-Fe	5.8957	10.2399	1
057	569	F	Olz	A01	HEMATOCRIT	HIGH	1	S	37	0.5	1	0.32	0.5	0
							10	S	43	0.57	1	0.32	0.5	1
057	569	F	Olz	A02	HEMOGLOBIN	HIGH	1	S	37	9.55724	mmL/L-Fe	5.8957	10.2399	0
							10	S	43	10.9226	mmL/L-Fe	5.8957	10.2399	1
057	1060	M	Ha1	A10	LEUCOCYTE COUNT	HIGH	1	S	-7	9.06	GI/L	2.8	16	0
							2	S	0	11.29	GI/L	2.8	16	0
							3	S	7	8.48	GI/L	2.8	16	0
							4	S	13	18.85	GI/L	2.8	16	1
057	1061	F	Olz	C07	UA-GLUCOSE	INC2	1	S	-7	3	NO UNITS	.	3	1
							2	S	0	0	NO UNITS	.	3	0
							3	S	7	0	NO UNITS	.	3	0
							4	S	13	3	NO UNITS	.	3	1
							5	S	21	3	NO UNITS	.	3	1
							6	S	28	0	NO UNITS	.	3	0
							7	S	35	3	NO UNITS	.	3	1
							8	S	42	3	NO UNITS	.	3	1

ZY 1234 379

ELI LILLY AND COMPANY
FLD-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
057	1061	F	01z	C07	UA-GLUCOSE	INC2	9	U	49	3 NO UNITS	.	.	3 1
							9	U	56	2 NO UNITS	.	.	3 0
							16	S	70	3 NO UNITS	.	.	3 1
							20	S	98	3 NO UNITS	.	.	3 1
							22	S	210	3 NO UNITS	.	.	3 1
							24	S	272	3 NO UNITS	.	.	3 1
									322	3 NO UNITS	.	.	3 1
057	1061	F	01z	F31	GLUCOSE, NON-FASTING	HIGH	1	S	-7	12.8228 mmol/L	2.4975	13.875	0
							2	S	0	9.60323 mmol/L	2.4975	13.875	0
							3	S	7	9.27017 mmol/L	2.4975	13.875	0
							4	S	13	16.2089 mmol/L	2.4975	13.875	1
							5	S	21	20.7607 mmol/L	2.4975	13.875	1
							6	S	28	11.213 mmol/L	2.4975	13.875	0
							7	S	35	16.9306 mmol/L	2.4975	13.875	1
							8	S	42	18.3738 mmol/L	2.4975	13.875	1
							9	U	49	10.88 mmol/L	2.4975	13.875	0
							9	U	56	11.102 mmol/L	2.4975	13.875	0
							9	S	70	15.0987 mmol/L	2.4975	13.875	1
							16	S	98	10.4359 mmol/L	2.4975	13.875	0
							18	S	154	12.0457 mmol/L	2.4975	13.875	0
							20	S	210	18.2628 mmol/L	2.4975	13.875	1
							22	S	272	19.2065 mmol/L	2.4975	13.875	1
							24	S	322	15.6538 mmol/L	2.4975	13.875	1
057	1503	M	Ha1	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-4	131 U/L	.	.	594 0
							2	S	0	46 U/L	.	.	594 0
							3	S	8	666 U/L	.	.	594 1
							4	S	15	753 U/L	.	.	594 1
							5	S	22	90 U/L	.	.	594 0
							6	S	28	73 U/L	.	.	594 0
							7	S	37	71 U/L	.	.	594 0
							8	S	42	66 U/L	.	.	594 0
058	598	F	01z	C07	UA-GLUCOSE	INC2	1	S	43	0 NO UNITS	.	.	3 0
							10	S	48	0 NO UNITS	.	.	3 0
							11	S	55	1 NO UNITS	.	.	3 0
							12	S	62	2 NO UNITS	.	.	3 0
							13	S	69	0 NO UNITS	.	.	3 0
							14	S	76	0 NO UNITS	.	.	3 0
							15	S	83	3 NO UNITS	.	.	3 1
							16	S	97	3 NO UNITS	.	.	3 1
							18	S	153	3 NO UNITS	.	.	3 1
							20	S	210	1 NO UNITS	.	.	3 0
							22	S	265	0 NO UNITS	.	.	3 0
							24	S	321	0 NO UNITS	.	.	3 0
							26	S	363	0 NO UNITS	.	.	3 0

ZY 1234 380

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
059 1121	F	Olz	C11	UA-RBC	INC2	2	S	0	0	NO UNITS	.	.	3 0
						3	S	6	1	NO UNITS	.	.	3 0
						4	S	13	4	NO UNITS	.	.	3 1
						5	U	20	4	NO UNITS	.	.	3 1
						6	S	28	2	NO UNITS	.	.	3 0
						7	S	35	0	NO UNITS	.	.	3 0
						8	S	41	4	NO UNITS	.	.	3 1
						16	S	97	0	NO UNITS	.	.	3 0
						18	S	153	0	NO UNITS	.	.	3 0
						20	S	209	0	NO UNITS	.	.	3 0
						22	S	265	0	NO UNITS	.	.	3 0
						24	S	321	0	NO UNITS	.	.	3 0
059 1122	M	Olz	A01	HEMATOCRIT	LOW	1	S	-8	0.39	I	0.37	0.55	0
						2	S	0	0.38	I	0.37	0.55	0
						3	S	9	0.33	I	0.37	0.55	1
						4	S	14	0.36	I	0.37	0.55	1
						5	S	21	0.37	I	0.37	0.55	0
						6	S	29	0.35	I	0.37	0.55	1
						7	S	36	0.36	I	0.37	0.55	1
						8	S	43	0.37	I	0.37	0.55	0
						9	S	71	0.35	I	0.37	0.55	1
						16	S	99	0.4	I	0.37	0.55	0
						17	U	112	0.42	I	0.37	0.55	0
						18	S	162	0.41	I	0.37	0.55	0
						19	S	190	0.4	I	0.37	0.55	0
						20	S	218	0.41	I	0.37	0.55	0
						21	S	239	0.42	I	0.37	0.55	0
						22	S	272	0.44	I	0.37	0.55	0
						24	S	330	0.42	I	0.37	0.55	0
						25	S	358	0.41	I	0.37	0.55	0
059 1122	M	Olz	A02	HEMOGLOBIN	LOW	1	S	-8	7.69544	mmL/L-Fe	7.1369	11.4811	0
						2	S	0	7.69544	mmL/L-Fe	7.1369	11.4811	0
						3	S	9	6.88866	mmL/L-Fe	7.1369	11.4811	1
						4	S	14	7.38514	mmL/L-Fe	7.1369	11.4811	0
						5	S	21	7.26102	mmL/L-Fe	7.1369	11.4811	0
						6	S	29	7.01278	mmL/L-Fe	7.1369	11.4811	1
						7	S	36	7.1369	mmL/L-Fe	7.1369	11.4811	0
						8	S	43	6.70248	mmL/L-Fe	7.1369	11.4811	1
						9	S	71	7.01278	mmL/L-Fe	7.1369	11.4811	1
						16	S	99	8.19192	mmL/L-Fe	7.1369	11.4811	0
						17	U	112	8.6884	mmL/L-Fe	7.1369	11.4811	0
						18	S	162	8.87458	mmL/L-Fe	7.1369	11.4811	0
						19	S	190	8.81252	mmL/L-Fe	7.1369	11.4811	0
						20	S	218	8.93664	mmL/L-Fe	7.1369	11.4811	0
						21	S	239	8.87458	mmL/L-Fe	7.1369	11.4811	0

ZY 1234 381

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM	
059	1122	M	Olz	A02	HEMOGLOBIN	LOW	22	S	272	9.309	mmL/L-Fe	7.1369	11.4811	0
							24	S	330	8.6884	mmL/L-Fe	7.1369	11.4811	0
							25	S	358	8.62634	mmL/L-Fe	7.1369	11.4811	0
059	1243	M	Olz	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-5	72	U/L	.	594	0
							2	S	0	95	U/L	.	594	0
							3	S	7	6040	U/L	.	594	1
							4	U	9	1636	U/L	.	594	1
							4	S	14	190	U/L	.	594	0
							5	S	21	111	U/L	.	594	0
							6	S	28	96	U/L	.	594	0
							7	S	35	97	U/L	.	594	0
							8	S	44	128	U/L	.	594	0
							9	S	70	90	U/L	.	594	0
060	644	M	Ha1	A03	ERYTHROCYTE COUNT	HIGH	1	S	-3	4.9	TI/L	3	6	0
							2	S	-1	5.2	TI/L	3	6	0
							3	S	6	5.7	TI/L	3	6	0
							4	S	13	6	TI/L	3	6	0
							5	S	20	6.3	TI/L	3	6	1
							6	S	27	5.8	TI/L	3	6	0
							7	S	34	5.8	TI/L	3	6	0
							8	S	41	6.4	TI/L	3	6	1
							9	S	54	6.1	TI/L	3	6	1
060	650	M	Ha1	A01	HEMATOCRIT	HIGH	1	S	-3	0.53	1	0.37	0.55	0
							2	S	0	0.5	1	0.37	0.55	0
							3	S	6	0.49	1	0.37	0.55	0
							4	S	14	0.53	1	0.37	0.55	0
							5	S	20	0.52	1	0.37	0.55	0
							6	S	27	0.55	1	0.37	0.55	1
							7	S	34	0.6	1	0.37	0.55	1
							8	S	41	0.54	1	0.37	0.55	0
							16	U	73	0.51	1	0.37	0.55	0
							16	S	96	0.54	1	0.37	0.55	0
							18	S	152	0.56	1	0.37	0.55	1
							20	S	208	0.52	1	0.37	0.55	0
							22	S	264	0.51	1	0.37	0.55	0
061	1084	M	Ha1	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-6	556	U/L	.	594	0
							2	S	0	508	U/L	.	594	0
							3	S	6	621	U/L	.	594	1
062	1078	F	Olz	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-3	248	U/L	.	507	0
							2	S	0	300	U/L	.	507	0
							3	S	7	272	U/L	.	507	0
							4	S	14	201	U/L	.	507	0

ZY 1234 382

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

062 1078	F	Olz	E12	CREATINE PHOSPHOKINASE	DIRECTN VISIT UNVISIT RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
				HIGH	5	243 U/L	.	507	0
					6	249 U/L	.	507	0
					7	185 U/L	.	507	0
					8	214 U/L	.	507	0
					16	189 U/L	.	507	0
					18	229 U/L	.	507	0
					20	147 U/L	.	507	0
					22	610 U/L	.	507	1
062 1079	F	Hal	A01	HEMATOCRIT	1	0.35 1	0.32	0.5	0
				LOW	2	0.33 1	0.32	0.5	0
					3	0.29 1	0.32	0.5	1
					4	0.3 1	0.32	0.5	1
					5	0.31 1	0.32	0.5	1
					6	0.32 1	0.32	0.5	0
					7	0.34 1	0.32	0.5	0
062 1079	F	Hal	A02	HEMOGLOBIN	1	6.70248 mmL/L-Fe	5.8957	10.2399	0
				LOW	2	6.26806 mmL/L-Fe	5.8957	10.2399	0
					3	5.70952 mmL/L-Fe	5.8957	10.2399	1
					4	5.5854 mmL/L-Fe	5.8957	10.2399	1
					5	5.95776 mmL/L-Fe	5.8957	10.2399	0
					6	6.08188 mmL/L-Fe	5.8957	10.2399	0
					7	6.39218 mmL/L-Fe	5.8957	10.2399	0
062 1080	F	Olz	E17	GGT(GGPT/SGGT/YGGT)	1	65 U/L	.	135	0
				HIGH	2	71 U/L	.	135	0
					3	75 U/L	.	135	0
					4	90 U/L	.	135	0
					5	92 U/L	.	135	0
					6	127 U/L	.	135	0
					7	126 U/L	.	135	0
					8	135 U/L	.	135	0
					16	139 U/L	.	135	1
					18	169 U/L	.	135	1
					18	134 U/L	.	135	1
					18	147 U/L	.	135	1
					18	227 U/L	.	135	1
					19	201 U/L	.	135	1
					19	229 U/L	.	135	1
					19	287 U/L	.	135	1
066 1183	F	Olz	C15	UA-MBC	1	1 NO UNITS	.	3	0
				INC2	2	1 NO UNITS	.	3	0
					3	0 NO UNITS	.	3	0
					4	0 NO UNITS	.	3	0
					5	0 NO UNITS	.	3	0

ZY 1234 383

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

DIRECTN VISIT UNVISIT REIDAYS RESULT UNIT LOLIM HILIM ABNRM

066 1183	F	01z	C15	UA-MBC	INC2	6	S	26	0 NO UNITS	.	3	0
7	S	33	4 NO UNITS	.	3	1						
10	S	42	4 NO UNITS	.	3	1						
11	S	49	0 NO UNITS	.	3	0						
12	S	54	1 NO UNITS	.	3	0						
13	S	63	1 NO UNITS	.	3	0						
14	S	68	1 NO UNITS	.	3	0						
15	S	75	2 NO UNITS	.	3	0						
16	S	89	4 NO UNITS	.	3	1						
18	S	147	0 NO UNITS	.	3	0						
20	S	203	0 NO UNITS	.	3	0						
22	S	259	0 NO UNITS	.	3	0						

066 1188	M	01z	E03	ALT/SGPT	HIGH	1	S	-2	16 U/L	.	165	0
2	S	0	16 U/L	.	165	0						
3	S	7	22 U/L	.	165	0						
4	S	14	17 U/L	.	165	0						
5	S	21	16 U/L	.	165	0						
6	S	29	27 U/L	.	165	0						
10	S	41	43 U/L	.	165	0						
11	S	50	291 U/L	.	165	1						
12	S	57	411 U/L	.	165	1						
13	S	62	303 U/L	.	165	1						
14	S	70	178 U/L	.	165	1						
15	S	76	133 U/L	.	165	0						
16	S	91	44 U/L	.	165	0						
17	S	105	42 U/L	.	165	0						

066 1188	M	01z	E17	GGT (GGPT/SGPT/ΥGGT)	HIGH	1	S	-2	13 U/L	.	195	0
2	S	0	15 U/L	.	195	0						
3	S	7	21 U/L	.	195	0						
4	S	14	20 U/L	.	195	0						
5	S	21	20 U/L	.	195	0						
6	S	29	25 U/L	.	195	0						
10	S	41	32 U/L	.	195	0						
11	S	50	257 U/L	.	195	1						
12	S	57	219 U/L	.	195	1						
13	S	62	166 U/L	.	195	0						
14	S	70	184 U/L	.	195	0						
15	S	76	159 U/L	.	195	0						
16	S	91	60 U/L	.	195	0						
17	S	105	39 U/L	.	195	0						

068 1304	M	01z	C15	UA-MBC	INC2	1	S	-2	0 NO UNITS	.	3	0
2	S	0	0 NO UNITS	.	3	0						
3	S	7	0 NO UNITS	.	3	0						
4	S	14	0 NO UNITS	.	3	0						

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

068 1304	M	01z	C15	UA-WBC	DIRECTN VISIT UNVISIT RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
					5	INC2			3
					6				0
					7				3
					10				0
					11				3
					13				0
					14				3
					15				0
					16				3
					17				0
					110				3
									1
068 1304	M	01z	E12	CREATINE PHOSPHOKINASE	1	HIGH			594
					2				0
					3				594
					4				0
					5				594
					6				0
					7				594
					10				0
					11				594
					13				0
					14				594
					15				0
					16				594
					17				0
					110				594
									1
068 1307	M	01z	E03	ALT/SGPT	1	HIGH			165
					2				0
					3				165
					4				1
					5				165
					6				1
									165
									1
068 1608	M	01z	A01	HEMATOCRIT	1	LOW			0.55
					2				0
					3				0.55
					4				0
					5				0.55
					6				0
					7				0.55
					10				0
					11				0.55
					12				0
					13				0.55
					14				1
					15				0.55
					72				0
					79				0.55

ZY 1234 385

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

068 1608	M	01z	F07	SODIUM	DIRECTN VISIT UNVISIT RELDAYS	RESULT UNIT	LOLIM	HILIM ABNRM
					S	133 mmol/L	129	160 0
					S	136 mmol/L	129	160 0
					S	139 mmol/L	129	160 0
					S	136 mmol/L	129	160 0
					S	132 mmol/L	129	160 0
					S	132 mmol/L	129	160 0
					S	138 mmol/L	129	160 0
					S	135 mmol/L	129	160 0
					S	126 mmol/L	129	160 1
					S	114 mmol/L	129	160 1
					S	119 mmol/L	129	160 1
					S	131 mmol/L	129	160 0
					S	144 mmol/L	129	160 0
					S	142 mmol/L	129	160 0
					S	143 mmol/L	129	160 0
					S	139 mmol/L	129	160 0
					S	143 mmol/L	129	160 0
					S	142 mmol/L	129	160 0
					S	141 mmol/L	129	160 0
					S	140 mmol/L	129	160 0
					S	142 mmol/L	129	160 0
					S	140 mmol/L	129	160 0
					S	128 mmol/L	129	160 1
					S	72 U/L	.	165 0
					S	70 U/L	.	165 0
					S	107 U/L	.	165 0
					S	92 U/L	.	165 0
					S	289 U/L	.	165 1
					S	265 U/L	.	165 1
					S	151 U/L	.	165 0
					S	59 U/L	.	165 0
					S	70 U/L	.	165 0
					S	56 U/L	.	165 0
					S	85 U/L	.	165 0
					S	74 U/L	.	165 0
					S	91 U/L	.	165 0
					S	42 U/L	.	165 0
					S	32 U/L	.	165 0
					S	27 U/L	.	165 0
					S	374 U/L	.	594 0
					S	294 U/L	.	594 0
					S	307 U/L	.	594 0
					S	270 U/L	.	594 0
					S	320 U/L	.	594 0

0

0

068 1612 M 01z E12 : CREATINE PHOSPHOKINASE HIGH

ZY 1234 386

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
068	M	OLz	E12	CREATINE PHOSPHOKINASE	HIGH	6	S	28	510	U/L	.	594	0
						7	S	35	609	U/L	.	594	1
						8	S	40	338	U/L	.	594	0
						10	S	49	331	U/L	.	594	0
						11	S	56	343	U/L	.	594	0
						12	S	63	255	U/L	.	594	0
						13	S	70	350	U/L	.	594	0
						14	S	77	289	U/L	.	594	0
						15	S	88	279	U/L	.	594	0
						16	S	97	285	U/L	.	594	0
						18	S	160	266	U/L	.	594	0
						20	S	188	1564	U/L	.	594	1
070	M	OLz	F31	GLUCOSE, NON-FASTING	HIGH	1	S	-7	11.8791	mmol/L	2.4975	13.875	0
						2	S	0	13.7665	mmol/L	2.4975	13.875	0
						3	S	6	25.4791	mmol/L	2.4975	13.875	1
						4	S	11	9.71425	mmol/L	2.4975	13.875	0
						5	S	20	26.7558	mmol/L	2.4975	13.875	1
						6	S	27	14.9877	mmol/L	2.4975	13.875	1
						7	S	34	17.7077	mmol/L	2.4975	13.875	1
						8	S	43	23.4252	mmol/L	2.4975	13.875	1
						9	S	72	17.9297	mmol/L	2.4975	13.875	1
						16	S	105	5.71753	mmol/L	2.4975	13.875	0
070	M	OLz	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-11	213	U/L	.	594	0
						2	U	-6	240	U/L	.	594	0
						2	S	0	390	U/L	.	594	0
						3	S	8	254	U/L	.	594	0
						4	S	15	285	U/L	.	594	0
						5	S	22	160	U/L	.	594	0
						6	S	29	219	U/L	.	594	0
						10	S	38	384	U/L	.	594	0
						12	S	58	855	U/L	.	594	1
070	M	OLz	A01	HEMATOCRIT	LOW	1	S	-4	0.39	1	0.37	0.55	0
						2	S	-2	0.37	1	0.37	0.55	0
						3	S	6	0.4	1	0.37	0.55	0
						4	S	12	0.36	1	0.37	0.55	1
						5	S	19	0.34	1	0.37	0.55	1
						6	S	27	0.35	1	0.37	0.55	1
						7	S	34	0.37	1	0.37	0.55	0
						8	S	41	0.38	1	0.37	0.55	0
						9	S	68	0.36	1	0.37	0.55	1
						16	S	96	0.39	1	0.37	0.55	0
						18	S	173	0.41	1	0.37	0.55	0
070	M	OLz	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-4	471	U/L	.	594	0

ZY 1234 387

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
070	M	Olz	E12	CREATINE PHOSPHOKINASE	HIGH	2	S	-2	336	U/L	.	594	0
						3	S	6	290	U/L	.	594	0
						4	S	12	544	U/L	.	594	0
						5	S	19	732	U/L	.	594	1
						6	S	27	1884	U/L	.	594	1
						7	S	34	755	U/L	.	594	1
						8	S	41	556	U/L	.	594	0
						9	S	68	370	U/L	.	594	0
						16	S	96	981	U/L	.	594	1
						18	S	173	609	U/L	.	594	1
074	M	Olz	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-3	123	U/L	.	594	0
						2	S	0	112	U/L	.	594	0
						3	S	7	74	U/L	.	594	0
						4	S	14	98	U/L	.	594	0
						5	S	21	108	U/L	.	594	0
						6	S	28	96	U/L	.	594	0
						7	S	35	91	U/L	.	594	0
						8	S	42	563	U/L	.	594	0
						16	S	91	368	U/L	.	594	0
						18	S	154	167	U/L	.	594	0
						20	S	210	136	U/L	.	594	0
						21	S	238	282	U/L	.	594	0
						22	S	259	939	U/L	.	594	1
074	M	Olz	F40	URIC ACID	HIGH	1	S	-3	517.476	umol/L	.	624.54	0
						2	S	0	404.464	umol/L	.	624.54	0
						3	S	7	463.944	umol/L	.	624.54	0
						4	S	14	428.256	umol/L	.	624.54	0
						5	S	21	469.892	umol/L	.	624.54	0
						6	S	28	475.84	umol/L	.	624.54	0
						7	S	35	475.84	umol/L	.	624.54	0
						8	S	42	511.528	umol/L	.	624.54	0
						16	S	91	529.372	umol/L	.	624.54	0
						18	S	154	571.008	umol/L	.	624.54	0
						20	S	210	576.956	umol/L	.	624.54	0
						21	S	238	600.748	umol/L	.	624.54	0
						22	S	259	648.332	umol/L	.	624.54	1
074	M	Hal	A02	HEMOGLOBIN	HIGH	1	S	-2	11.2329	mmL/L-Fe	7.1369	11.4811	0
						2	S	0	10.9226	mmL/L-Fe	7.1369	11.4811	0
						3	S	7	11.9776	mmL/L-Fe	7.1369	11.4811	1
						4	S	14	11.6673	mmL/L-Fe	7.1369	11.4811	1
						5	S	21	10.9846	mmL/L-Fe	7.1369	11.4811	0
						6	S	28	11.6673	mmL/L-Fe	7.1369	11.4811	1
						7	S	35	11.2329	mmL/L-Fe	7.1369	11.4811	0
						8	S	42	11.7914	mmL/L-Fe	7.1369	11.4811	1

ZY 1234 388

ELI LILLY AND COMPANY
F10-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INVT PATIENT GENDER THERAPY ANALYTCD ANALYTE

OLZ	M	OLZ	A01	HEMATOCRIT	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
074	1535	M	OLZ	HEMATOCRIT	1	S	-6	0.39 1	0.37	0.55	0
					2	S	0	0.42 1	0.37	0.55	0
					3	S	7	0.45 1	0.37	0.55	0
					4	S	14	0.44 1	0.37	0.55	0
					5	S	21	0.4 1	0.37	0.55	0
					6	S	27	0.45 1	0.37	0.55	0
					7	S	35	0.39 1	0.37	0.55	0
					8	S	42	0.45 1	0.37	0.55	0
					10	S	55	0.39 1	0.37	0.55	0
					11	U	58	0.36 1	0.37	0.55	1
					11	S	62	0.36 1	0.37	0.55	1
					12	S	69	0.38 1	0.37	0.55	0
					13	S	76	0.4 1	0.37	0.55	0
					14	S	83	0.41 1	0.37	0.55	0
					15	S	90	0.38 1	0.37	0.55	0
					16	S	104	0.4 1	0.37	0.55	0
					18	S	139	0.43 1	0.37	0.55	0

074 1535 M OLZ E12 CREATINE PHOSPHOKINASE HIGH

1	S	-6	97 U/L	.	594	0
2	S	0	108 U/L	.	594	0
3	S	7	102 U/L	.	594	0
4	S	14	113 U/L	.	594	0
5	S	21	149 U/L	.	594	0
6	S	27	187 U/L	.	594	0
7	S	35	102 U/L	.	594	0
8	S	42	112 U/L	.	594	0
10	S	55	2126 U/L	.	594	1
11	U	58	13720 U/L	.	594	1
11	S	62	757 U/L	.	594	1
12	S	69	151 U/L	.	594	0
13	S	76	115 U/L	.	594	0
14	S	83	79 U/L	.	594	0
15	S	90	121 U/L	.	594	0
16	S	104	102 U/L	.	594	0
18	S	139	64 U/L	.	594	0

102 2013 M Ha1 E12 CREATINE PHOSPHOKINASE HIGH

1	S	-2	474 U/L	.	594	0
2	S	0	533 U/L	.	594	0
3	S	6	703 U/L	.	594	1

106 2037 F OLZ E17 GGT(GGPT/SGGT)/GGT HIGH

1	S	-8	114 U/L	.	135	0
2	S	0	129 U/L	.	135	0
3	S	7	124 U/L	.	135	0
4	S	14	192 U/L	.	135	1
5	S	21	179 U/L	.	135	1
6	S	28	137 U/L	.	135	1
7	S	35	105 U/L	.	135	0

ZY 1234 389

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	GGT(GGPT/SGGT/YGGT)	HIGH	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
106	2037	F	01z	E17	GGT(GGPT/SGGT/YGGT)	HIGH	8	S	S	43	102	U/L	.	135	0
							9	S	S	70	75	U/L	.	135	0
							16	S	S	98	85	U/L	.	135	0
							18	S	S	161	135	U/L	.	135	0
							20	S	S	215	74	U/L	.	135	0
							22	S	S	272	61	U/L	.	135	0
							23	S	S	307	44	U/L	.	135	0
							24	S	S	328	166	U/L	.	135	1
108	2052	M	01z	A03	ERYTHROCYTE COUNT	HIGH	1	S	S	-5	5.7	TL/L	3	6	0
							2	S	S	0	5.8	TL/L	3	6	0
							3	S	S	7	6	TL/L	3	6	0
							4	S	S	14	5.5	TL/L	3	6	0
							5	S	S	21	5.6	TL/L	3	6	0
							6	S	S	29	4.8	TL/L	3	6	0
							7	S	S	36	5.7	TL/L	3	6	0
							8	S	S	44	5.7	TL/L	3	6	0
							9	S	S	71	6.1	TL/L	3	6	1
							16	S	S	99	6.1	TL/L	3	6	1
							18	S	S	157	5.7	TL/L	3	6	0
							19	S	S	189	5.9	TL/L	3	6	0
							20	S	S	219	5.6	TL/L	3	6	0
110	2065	M	01z	C01	UA-SPECIFIC GRAVITY	HIGH	1	S	S	-5	1.029	NO UNITS	1.001	1.035	0
							2	S	S	-2	1.031	NO UNITS	1.001	1.035	0
							3	S	S	8	1.026	NO UNITS	1.001	1.035	0
							4	S	S	15	1.027	NO UNITS	1.001	1.035	0
							5	S	S	22	1.03	NO UNITS	1.001	1.035	0
							6	S	S	28	1.027	NO UNITS	1.001	1.035	0
							7	S	S	37	1.036	NO UNITS	1.001	1.035	1
200	2402	F	Ha1	C15	UA-MBC	INC2	1	S	S	-2	1	NO UNITS	.	3	0
							3	U	S	2	1	NO UNITS	.	3	0
							3	S	S	7	1	NO UNITS	.	3	0
							4	S	S	14	1	NO UNITS	.	3	0
							5	S	S	21	4	NO UNITS	.	3	1
							6	S	S	28	0	NO UNITS	.	3	0
							7	S	S	35	0	NO UNITS	.	3	0
							8	S	S	42	4	NO UNITS	.	3	1
200	2404	F	01z	A02	HEMOGLOBIN	HIGH	1	S	S	31	9.49518	mmL/L-Fe	5.8957	10.2399	0
							10	S	S	38	8.87458	mmL/L-Fe	5.8957	10.2399	0
							11	S	S	45	8.31604	mmL/L-Fe	5.8957	10.2399	0
							12	S	S	52	9.06076	mmL/L-Fe	5.8957	10.2399	0
							13	S	S	59	8.81252	mmL/L-Fe	5.8957	10.2399	0
							14	S	S	66	10.5502	mmL/L-Fe	5.8957	10.2399	1
							15	S	S	73	10.2399	mmL/L-Fe	5.8957	10.2399	1

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

DIRECTN VISIT UNVISIT RELDAYS RESULT UNIT LOLIM HILIM ABRNM

200 2404	F	01z	A02	A02	HEMOGLOBIN	HIGH	18	S	143	8.9987	mmL/L-Fe	5.8957	10.2399	0
21	U						21	U	228	9.309	mmL/L-Fe	5.8957	10.2399	0
22	S						22	S	256	9.06076	mmL/L-Fe	5.8957	10.2399	0
24	S						24	S	312	10.1158	mmL/L-Fe	5.8957	10.2399	0
26	S						26	S	356	9.309	mmL/L-Fe	5.8957	10.2399	0
27	S						27	S	410	9.49518	mmL/L-Fe	5.8957	10.2399	0
28	S						28	S	472	9.6193	mmL/L-Fe	5.8957	10.2399	0
200 2406	F	01z	A10	A10	LEUCOCYTE COUNT	HIGH	1	S	-2	11.18	GI/L	2.8	16	0
2	S						2	S	0	12.23	GI/L	2.8	16	0
3	S						3	S	7	10.7	GI/L	2.8	16	0
4	S						4	S	14	12.9	GI/L	2.8	16	0
5	S						5	S	21	11.98	GI/L	2.8	16	0
6	S						6	S	28	9.51	GI/L	2.8	16	0
7	S						7	S	35	14.11	GI/L	2.8	16	0
8	S						8	S	42	11.36	GI/L	2.8	16	0
16	S						16	S	70	21.72	GI/L	2.8	16	1
200 2464	M	01z	A01	A01	HEMATOCRIT	HIGH	2	S	0	0.51	1	0.37	0.55	0
3	S						3	S	7	0.51	1	0.37	0.55	0
4	S						4	S	14	0.46	1	0.37	0.55	0
5	S						5	S	21	0.5	1	0.37	0.55	0
6	S						6	S	28	0.49	1	0.37	0.55	0
7	S						7	S	35	0.5	1	0.37	0.55	0
8	S						8	S	42	0.5	1	0.37	0.55	0
16	U						16	U	70	0.5	1	0.37	0.55	0
16	S						16	S	97	0.55	1	0.37	0.55	1
18	S						18	S	165	0.53	1	0.37	0.55	0
20	S						20	S	210	0.52	1	0.37	0.55	0
22	S						22	S	266	0.53	1	0.37	0.55	0
24	S						24	S	322	0.55	1	0.37	0.55	1
26	S						26	S	364	0.55	1	0.37	0.55	1
200 2464	M	01z	A02	A02	HEMOGLOBIN	HIGH	2	S	0	11.0467	mmL/L-Fe	7.1369	11.4811	0
3	S						3	S	7	10.9846	mmL/L-Fe	7.1369	11.4811	0
4	S						4	S	14	10.2399	mmL/L-Fe	7.1369	11.4811	0
5	S						5	S	21	10.4881	mmL/L-Fe	7.1369	11.4811	0
6	S						6	S	28	10.4881	mmL/L-Fe	7.1369	11.4811	0
7	S						7	S	35	10.6123	mmL/L-Fe	7.1369	11.4811	0
8	S						8	S	42	10.8605	mmL/L-Fe	7.1369	11.4811	0
16	U						16	U	70	10.6743	mmL/L-Fe	7.1369	11.4811	0
16	S						16	S	97	11.419	mmL/L-Fe	7.1369	11.4811	0
18	S						18	S	165	10.6743	mmL/L-Fe	7.1369	11.4811	0
20	S						20	S	210	10.9226	mmL/L-Fe	7.1369	11.4811	0
22	S						22	S	266	10.7364	mmL/L-Fe	7.1369	11.4811	0
24	S						24	S	322	10.6123	mmL/L-Fe	7.1369	11.4811	0
26	S						26	S	364	11.5432	mmL/L-Fe	7.1369	11.4811	1

13:18 Wednesday, July 5, 1995 '96

ZY 1234 390

RMP.FIDSTSS1.SASPGM(LABNTJX)

85266

ZY 1234 391

ELI LILLY AND COMPANY
F1D-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

200	2465	F	Ha1	C11	UA-RBC	INC2	1	S	-3	0 NO UNITS	.	.	3	0
201	2408	F	Olz	C11	UA-RBC	INC2	2	S	0	0 NO UNITS	.	.	3	0
202	2417	M	Olz	C15	UA-MBC	INC2	3	S	7	0 NO UNITS	.	.	3	0
203	2421	F	Olz	C11	UA-RBC	INC2	4	S	15	4 NO UNITS	.	.	3	1
203	2424	M	Olz	E03	ALT/SGPT	HIGH	1	S	0	0 NO UNITS	.	.	3	0
204	2427	F	Olz	E17	GGT(SGGPT/SGGT/YGGT)	HIGH	2	S	-4	1 NO UNITS	.	.	3	0
							3	S	-1	0 NO UNITS	.	.	3	0
							4	S	7	0 NO UNITS	.	.	3	0
							5	S	14	0 NO UNITS	.	.	3	0
							6	S	21	0 NO UNITS	.	.	3	0
							7	S	28	0 NO UNITS	.	.	3	0
							1	S	35	4 NO UNITS	.	.	3	1
							2	S	-2	0 NO UNITS	.	.	3	0
							3	S	0	0 NO UNITS	.	.	3	0
							4	S	6	0 NO UNITS	.	.	3	0
							1	S	14	4 NO UNITS	.	.	3	1
							10	S	37	9 U/L	.	.	165	0
							11	S	44	12 U/L	.	.	165	0
							12	S	51	111 U/L	.	.	165	0
							13	S	58	275 U/L	.	.	165	1
							1	S	63	215 U/L	.	.	165	1
							2	S	-3	102 U/L	.	.	135	0
							3	S	0	97 U/L	.	.	135	0
							4	S	9	133 U/L	.	.	135	0
							5	S	17	135 U/L	.	.	135	0
							6	S	23	139 U/L	.	.	135	1
							7	S	30	116 U/L	.	.	135	0
							8	S	36	107 U/L	.	.	135	0
							16	S	43	97 U/L	.	.	135	0
							18	S	99	48 U/L	.	.	135	0
							20	S	157	56 U/L	.	.	135	0
							22	S	219	50 U/L	.	.	135	0
							24	S	261	61 U/L	.	.	135	0
							26	S	323	136 U/L	.	.	135	1
							27	S	365	68 U/L	.	.	135	0
							2	S	421	144 U/L	.	.	135	1
							2	S	0	0.38 1	.	0.32	0.5	0
							3	S	7	0.38 1	.	0.32	0.5	0
							4	S	14	0.36 1	.	0.32	0.5	0

204 2428 F Olz A01 HEMATOCRIT LOW

RMP.F1DIS1.SASPGM(LABNTJX) 85266

ZY 1234 392

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

DIRECTN VISIT UNVISIT RELDAYS RESULT UNIT LOLIM HILIM ABRNM

204	2428	F	01z	A01	HEMATOCRIT	LOW	5	S	21	0.39	1	0.32	0.5	0
							6	S	28	0.38	1	0.32	0.5	0
							7	S	36	0.37	1	0.32	0.5	0
							8	S	43	0.38	1	0.32	0.5	0
							16	S	99	0.36	1	0.32	0.5	0
							18	S	155	0.41	1	0.32	0.5	0
							19	U	168	0.4	1	0.32	0.5	0
							20	S	217	0.28	1	0.32	0.5	1
							21	U	227	0.3	1	0.32	0.5	1
							21	S	239	0.31	1	0.32	0.5	1
							22	S	269	0.35	1	0.32	0.5	0
							24	S	325	0.34	1	0.32	0.5	0
							26	S	367	0.4	1	0.32	0.5	0
							27	S	416	0.38	1	0.32	0.5	0

204	2428	F	01z	A02	HEMOGLOBIN	LOW	2	S	0	8.31604	mmL/L-Fe	5.8957	10.2399	0
							3	S	7	8.44016	mmL/L-Fe	5.8957	10.2399	0
							4	S	14	7.50926	mmL/L-Fe	5.8957	10.2399	0
							5	S	21	7.94368	mmL/L-Fe	5.8957	10.2399	0
							6	S	28	8.12986	mmL/L-Fe	5.8957	10.2399	0
							7	S	36	7.88162	mmL/L-Fe	5.8957	10.2399	0
							8	S	43	8.6884	mmL/L-Fe	5.8957	10.2399	0
							16	S	99	7.63338	mmL/L-Fe	5.8957	10.2399	0
							18	S	155	8.25398	mmL/L-Fe	5.8957	10.2399	0
							19	U	168	8.25398	mmL/L-Fe	5.8957	10.2399	0
							20	S	217	5.46128	mmL/L-Fe	5.8957	10.2399	1
							21	U	227	5.83364	mmL/L-Fe	5.8957	10.2399	1
							21	S	239	5.5854	mmL/L-Fe	5.8957	10.2399	1
							22	S	269	6.45424	mmL/L-Fe	5.8957	10.2399	0
							24	S	325	6.64042	mmL/L-Fe	5.8957	10.2399	0
							26	S	367	7.7575	mmL/L-Fe	5.8957	10.2399	0
							27	S	416	7.38514	mmL/L-Fe	5.8957	10.2399	0

205	2432	M	01z	E17	GGT(GGPT/SGGT/YGGT)	HIGH	1	S	-3	117	U/L	.	195	0
							2	S	0	115	U/L	.	195	0
							3	S	7	79	U/L	.	195	0
							4	S	14	53	U/L	.	195	0
							5	S	21	44	U/L	.	195	0
							6	S	28	54	U/L	.	195	0
							7	S	35	75	U/L	.	195	0
							8	S	42	69	U/L	.	195	0
							16	S	98	114	U/L	.	195	0
							18	S	154	98	U/L	.	195	0
							20	S	210	167	U/L	.	195	0
							22	S	268	296	U/L	.	195	1
							23	U	283	307	U/L	.	195	1
							24	S	329	496	U/L	.	195	1

ZY 1234 393

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
205 2432	M	Olz	E17	GGT(GGPT/SGGT/YGGT)	HIGH	25	U	357	370 U/L	.	195	1
						26	S	364	381 U/L	.	195	1
						27	S	422	290 U/L	.	195	1
						28	S	478	259 U/L	.	195	1
205 2434	F	Olz	F40	URIC ACID	HIGH	1	S	-3	387 umol/L	.	505.58	0
						2	S	0	401 umol/L	.	505.58	0
						3	S	7	397 umol/L	.	505.58	0
						4	S	14	412 umol/L	.	505.58	0
						5	S	21	432 umol/L	.	505.58	0
						6	S	28	403 umol/L	.	505.58	0
						7	S	35	420 umol/L	.	505.58	0
						8	S	43	403 umol/L	.	505.58	0
						16	S	98	448 umol/L	.	505.58	0
						17	S	126	425 umol/L	.	505.58	0
						18	S	154	437 umol/L	.	505.58	0
						20	S	210	465 umol/L	.	505.58	0
						22	S	266	409 umol/L	.	505.58	0
						25	U	326	621 umol/L	.	505.58	1
						26	S	368	568 umol/L	.	505.58	1
						27	S	424	617 umol/L	.	505.58	1
						28	S	480	619 umol/L	.	505.58	1
205 2436	F	Olz	A16	EOSINOPHILS	HIGH	1	S	-4	9.7148 % WBC	.	10	0
						2	S	0	8.60324 % WBC	.	10	0
						3	S	7	11.8952 % WBC	.	10	1
						4	S	14	14.6067 % WBC	.	10	1
						5	S	22	13.1001 % WBC	.	10	1
						6	S	28	14.5455 % WBC	.	10	1
						7	S	35	14.6341 % WBC	.	10	1
						8	S	42	18.0239 % WBC	.	10	1
						9	S	58	6.15551 % WBC	.	10	0
205 2452	F	Olz	A16	EOSINOPHILS	HIGH	1	S	30	3.18471 % WBC	.	10	0
						10	S	35	2.75974 % WBC	.	10	0
						12	S	51	6.39535 % WBC	.	10	0
						13	S	58	7.85441 % WBC	.	10	0
						14	S	65	9.73783 % WBC	.	10	0
						15	S	72	10.1322 % WBC	.	10	1
205 2452	F	Olz	F01	UREA NITROGEN	HIGH	1	S	30	5.8 mmol/L	.	10.71	0
						10	S	35	7.7 mmol/L	.	10.71	0
						12	S	51	11.8 mmol/L	.	10.71	1
						13	S	58	11.1 mmol/L	.	10.71	1
						14	S	65	8.9 mmol/L	.	10.71	0
						15	S	72	9.7 mmol/L	.	10.71	0

ZY 1234 394

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

206 2439	M	01z	C07	UA-GLUCOSE	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
				INC2	1	S	-4	0 NO UNITS	.	.	3 0
					2	S	0	0 NO UNITS	.	.	3 0
					3	S	7	0 NO UNITS	.	.	3 0
					4	S	14	0 NO UNITS	.	.	3 0
					6	U	21	0 NO UNITS	.	.	3 0
					6	S	29	0 NO UNITS	.	.	3 0
					7	S	35	0 NO UNITS	.	.	3 0
					8	S	42	0 NO UNITS	.	.	3 0
					16	S	105	0 NO UNITS	.	.	3 0
					18	S	164	1 NO UNITS	.	.	3 0
					20	S	233	0 NO UNITS	.	.	3 0
					22	S	287	1 NO UNITS	.	.	3 0
					24	S	346	1 NO UNITS	.	.	3 0
					26	S	364	1 NO UNITS	.	.	3 0
					27	S	513	2 NO UNITS	.	.	3 0
					28	S	569	3 NO UNITS	.	.	3 1

206 2439	M	01z	F31	GLUCOSE, NON-FASTING	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
				HIGH	1	S	-4	6.5 mmol/L	2.4975	13.875	0
					2	S	0	3.8 mmol/L	2.4975	13.875	0
					3	S	7	5.1 mmol/L	2.4975	13.875	0
					4	S	14	6.7 mmol/L	2.4975	13.875	0
					6	U	21	7.1 mmol/L	2.4975	13.875	0
					6	S	29	6.9 mmol/L	2.4975	13.875	0
					7	S	35	4.2 mmol/L	2.4975	13.875	0
					8	S	42	6.9 mmol/L	2.4975	13.875	0
					18	S	164	6.6 mmol/L	2.4975	13.875	0
					20	S	233	13.2 mmol/L	2.4975	13.875	0
					22	S	287	12.1 mmol/L	2.4975	13.875	0
					24	S	346	9.3 mmol/L	2.4975	13.875	0
					26	S	364	8.7 mmol/L	2.4975	13.875	0
					27	S	513	14.3 mmol/L	2.4975	13.875	1
					28	S	569	15.2 mmol/L	2.4975	13.875	1

206 2441	F	01z	A16	EOSINOPHILS	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
				HIGH	1	S	-4	5.96273 % WBC	.	.	10 0
					2	S	0	5.98592 % WBC	.	.	10 0
					3	S	7	8.63388 % WBC	.	.	10 0
					4	S	14	11.2607 % WBC	.	.	10 1
					5	S	21	11.8545 % WBC	.	.	10 1
					6	S	28	4.60449 % WBC	.	.	10 0
					7	S	36	3.95604 % WBC	.	.	10 0
					8	S	42	7.48065 % WBC	.	.	10 0
					16	S	101	2.93225 % WBC	.	.	10 0
					18	S	158	3.83721 % WBC	.	.	10 0
					20	S	232	4.55556 % WBC	.	.	10 0
					21	S	283	5.50964 % WBC	.	.	10 0

240 2552	M	01z	A10	LEUCOCYTE COUNT	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
				HIGH	1	S	32	6.53 GI/L	2.8	16	0

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
240	M	01z	A10	LEUCOCYTE COUNT	HIGH	10	S	39	7.34	GI/L	2.8		16
						11	S	46	6.11	GI/L	2.8		16
						12	S	53	6.45	GI/L	2.8		16
						13	S	61	6.96	GI/L	2.8		16
						14	S	68	7.74	GI/L	2.8		16
						15	S	75	6.54	GI/L	2.8		16
						16	S	85	6.97	GI/L	2.8		16
						18	S	151	6.69	GI/L	2.8		16
						19	S	166	17.74	GI/L	2.8		16
280	F	01z	A16	EOSINOPHILS	HIGH	1	S	-7	2.5641	% MBC	.		10
						4	S	14	3.0303	% MBC	.		10
						5	S	21	7.55467	% MBC	.		10
						6	S	28	12.6603	% MBC	.		10
						7	S	35	26.793	% MBC	.		10
						8	S	42	13.7441	% MBC	.		10
						9	S	77	5.59567	% MBC	.		10
						16	S	106	2.1097	% MBC	.		10
						18	S	150	2.09924	% MBC	.		10
						21	U	218	2.75229	% MBC	.		10
						22	S	262	3.125	% MBC	.		10
						26	S	360	2.88136	% MBC	.		10
300	F	01z	C11	UA-RBC	INC2	1	S	-2	0	NO UNITS	.		3
						2	S	0	0	NO UNITS	.		3
						3	S	7	0	NO UNITS	.		3
						5	S	21	0	NO UNITS	.		3
						6	S	28	0	NO UNITS	.		3
						7	S	35	0	NO UNITS	.		3
						8	S	43	0	NO UNITS	.		3
						16	S	96	0	NO UNITS	.		3
						18	S	151	0	NO UNITS	.		3
						20	S	207	0	NO UNITS	.		3
						22	S	265	0	NO UNITS	.		3
						24	S	316	4	NO UNITS	.		3
300	F	01z	C15	UA-RBC	INC2	1	S	-2	1	NO UNITS	.		3
						2	S	0	0	NO UNITS	.		3
						3	S	7	1	NO UNITS	.		3
						5	S	21	0	NO UNITS	.		3
						6	S	28	0	NO UNITS	.		3
						7	S	35	0	NO UNITS	.		3
						8	S	43	0	NO UNITS	.		3
						16	S	96	0	NO UNITS	.		3
						18	S	151	0	NO UNITS	.		3
						20	S	207	0	NO UNITS	.		3
						22	S	265	0	NO UNITS	.		3
						24	S	316	4	NO UNITS	.		3

ZY 1234 396

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV	PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
300	2994	F	01z	C15	UA-WBC	INC2	24	S	316	4	NO UNITS	.	.	3 1
300	3003	F	01z	C01	UA-SPECIFIC GRAVITY	HIGH	1	S	-2	1.035	NO UNITS	1.001	1.035	0
							2	S	0	1.035	NO UNITS	1.001	1.035	0
							3	S	9	1.035	NO UNITS	1.001	1.035	1
300	3003	F	01z	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-2	236	U/L	.	507	0
							2	S	0	170	U/L	.	507	0
							3	S	9	5490	U/L	.	507	1
302	2813	M	01z	A01	HEMATOCRIT	HIGH	1	S	-6	0.48	1	0.37	0.55	0
							2	S	0	0.48	1	0.37	0.55	0
							3	S	6	0.48	1	0.37	0.55	0
							4	S	13	0.44	1	0.37	0.55	0
							5	U	15	0.46	1	0.37	0.55	0
							5	S	20	0.45	1	0.37	0.55	0
							6	S	27	0.43	1	0.37	0.55	0
							7	S	35	0.44	1	0.37	0.55	0
							8	S	41	0.45	1	0.37	0.55	0
							16	S	97	0.46	1	0.37	0.55	0
							18	S	153	0.48	1	0.37	0.55	0
							20	S	208	0.54	1	0.37	0.55	0
							22	S	265	0.52	1	0.37	0.55	0
							24	S	322	0.52	1	0.37	0.55	0
							26	S	364	0.52	1	0.37	0.55	0
							27	S	419	0.54	1	0.37	0.55	0
							28	S	475	0.56	1	0.37	0.55	1
303	2820	F	01z	F40	URIC ACID	HIGH	1	S	-3	437	umol/L	.	505.58	0
							2	S	0	438	umol/L	.	505.58	0
							3	S	7	409	umol/L	.	505.58	0
							4	S	14	513	umol/L	.	505.58	1
							5	S	21	608	umol/L	.	505.58	1
							6	S	28	535	umol/L	.	505.58	1
							10	S	35	425	umol/L	.	505.58	0
							11	S	42	426	umol/L	.	505.58	0
304	2825	F	01z	E17	GGT(GGPT/SGGT/YGGT)	HIGH	1	S	-2	96	U/L	.	135	0
							3	S	7	148	U/L	.	135	1
							4	U	9	156	U/L	.	135	1
							4	S	14	137	U/L	.	135	1
							5	S	22	147	U/L	.	135	1
							6	S	28	138	U/L	.	135	1
							7	S	37	118	U/L	.	135	0
							8	S	58	78	U/L	.	135	0
							16	S	112	125	U/L	.	135	0

ZY 1234 397

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
305	2831	F	01z	C15	UA-WBC	INC2	27	U	369	0 NO UNITS	.	.	3 0
							27	S	427	2 NO UNITS	.	.	3 0
							28	U	467	3 NO UNITS	.	.	3 1
306	2838	M	01z	A10	LEUCOCYTE COUNT	HIGH	1	S	-3	12.75 GI/L	2.8	2.8	16 0
							3	U	3	19.74 GI/L	2.8	2.8	16 1
							3	S	10	26.91 GI/L	2.8	2.8	16 1
							4	S	14	17.29 GI/L	2.8	2.8	16 1
							5	S	23	19.31 GI/L	2.8	2.8	16 1
306	2839	F	Ha1	C11	UA-RBC	INC2	1	S	-5	0 NO UNITS	.	.	3 0
							2	S	0	0 NO UNITS	.	.	3 0
							3	S	7	0 NO UNITS	.	.	3 0
							4	S	14	0 NO UNITS	.	.	3 0
							5	S	21	0 NO UNITS	.	.	3 0
							6	S	28	0 NO UNITS	.	.	3 0
							7	S	36	0 NO UNITS	.	.	3 0
							8	S	42	4 NO UNITS	.	.	3 1
306	2841	M	01z	E03	ALT/SGPT	HIGH	1	S	-7	99 U/L	.	.	165 0
							2	S	0	110 U/L	.	.	165 0
							3	S	7	194 U/L	.	.	165 1
							4	S	13	179 U/L	.	.	165 1
							5	S	21	233 U/L	.	.	165 1
306	3074	F	01z	A16	EOSINOPHILS	HIGH	1	S	-5	2.98399 % ABC	.	.	10 0
							2	S	0	3.08483 % ABC	.	.	10 0
							3	S	7	4.73118 % ABC	.	.	10 0
							4	S	14	4.26716 % ABC	.	.	10 0
							5	S	21	6.04255 % ABC	.	.	10 0
							6	S	28	10.7219 % ABC	.	.	10 1
							7	S	35	12.2424 % ABC	.	.	10 1
							8	S	42	9.36687 % ABC	.	.	10 0
							9	U	49	5.18639 % ABC	.	.	10 0
							9	S	70	3.04991 % ABC	.	.	10 0
							16	S	99	4.41883 % ABC	.	.	10 0
							18	S	163	5.94369 % ABC	.	.	10 0
							20	S	231	3.46667 % ABC	.	.	10 0
307	2844	M	Ha1	F01	UREA NITROGEN	HIGH	1	S	-7	7.3 mmol/L	.	.	10.71 0
							2	S	0	4.1 mmol/L	.	.	10.71 0
							3	S	6	5.2 mmol/L	.	.	10.71 0
							4	S	13	6.1 mmol/L	.	.	10.71 0
							6	S	27	5.8 mmol/L	.	.	10.71 0
							7	S	34	8.2 mmol/L	.	.	10.71 0
							8	S	40	11.2 mmol/L	.	.	10.71 1

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

307 2847	F	Ha1	C15	UA-WBC	DIRECTN VISIT UNVISIT REVDAYS	RESULT UNIT	LOLIM	HILIM ABNRM
					-7	0 NO UNITS		3 0
					0	1 NO UNITS		3 0
					7	0 NO UNITS		3 0
					14	0 NO UNITS		3 0
					21	4 NO UNITS		3 1
					28	4 NO UNITS		3 1
					35	4 NO UNITS		3 1
307 2848	F	0Lz	F40	URIC ACID	-7	435 umol/L		505.58 0
					0	504 umol/L		505.58 0
					7	469 umol/L		505.58 0
					14	505 umol/L		505.58 0
					21	469 umol/L		505.58 0
					28	494 umol/L		505.58 0
					42	458 umol/L		505.58 0
					70	489 umol/L		505.58 0
					98	449 umol/L		505.58 0
					154	504 umol/L		505.58 0
					217	490 umol/L		505.58 0
					266	508 umol/L		505.58 1
					322	498 umol/L		505.58 0
					364	516 umol/L		505.58 1
					420	520 umol/L		505.58 1
					476	553 umol/L		505.58 1
307 3046	F	0Lz	E17	GGT(GGPT/SGGT/YGGT)	-2	69 U/L		135 0
					0	63 U/L		135 0
					5	64 U/L		135 0
					12	63 U/L		135 0
					19	63 U/L		135 0
					26	101 U/L		135 0
					33	105 U/L		135 0
					39	129 U/L		135 0
					47	160 U/L		135 1
					68	90 U/L		135 0
					96	71 U/L		135 0
					159	76 U/L		135 0
					208	111 U/L		135 0
					271	174 U/L		135 1
					285	132 U/L		135 0
					320	124 U/L		135 0
					334	115 U/L		135 0
					362	121 U/L		135 0
					418	160 U/L		135 1
307 3048	M	0Lz	A01	HEMATOCRIT	-2	0.41 I	0.37	0.55 0
					0	0.37 I	0.37	0.55 0

ZY 1234 399

ELI LILLY AND COMPANY
FLD-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

307 3048	M	01z	A01	HEMATOCRIT	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
				LOW	3	S	7	0.36 1	0.37	0.55	1
					4	S	14	0.37 1	0.37	0.55	0
					5	S	21	0.36 1	0.37	0.55	1
					6	S	28	0.34 1	0.37	0.55	1
					7	S	35	0.35 1	0.37	0.55	1
					8	S	42	0.37 1	0.37	0.55	0
					9	S	70	0.42 1	0.37	0.55	0
					16	S	98	0.41 1	0.37	0.55	0
					18	S	154	0.41 1	0.37	0.55	0
					20	S	210	0.42 1	0.37	0.55	0
					22	S	266	0.4 1	0.37	0.55	0
					24	S	322	0.43 1	0.37	0.55	0
308 2849	M	01z	A01	HEMATOCRIT							
				HIGH	1	S	-5	0.5 1	0.37	0.55	0
					2	S	0	0.49 1	0.37	0.55	0
					3	S	7	0.5 1	0.37	0.55	0
					4	S	14	0.47 1	0.37	0.55	0
					5	S	21	0.46 1	0.37	0.55	0
					6	S	28	0.47 1	0.37	0.55	0
					7	S	35	0.48 1	0.37	0.55	0
					9	S	63	0.5 1	0.37	0.55	0
					16	S	91	0.47 1	0.37	0.55	0
					18	S	147	0.45 1	0.37	0.55	0
					20	S	210	0.49 1	0.37	0.55	0
					22	S	266	0.51 1	0.37	0.55	0
					24	S	322	0.48 1	0.37	0.55	0
					26	S	399	0.51 1	0.37	0.55	0
					28	U	455	0.55 1	0.37	0.55	1
308 2852	M	01z	C07	UA-GLUCOSE							
				INC2	1	S	-4	0 NO UNITS	.	3	0
					2	S	0	1 NO UNITS	.	3	0
					3	S	7	3 NO UNITS	.	3	1
					4	S	14	3 NO UNITS	.	3	1
					5	S	21	0 NO UNITS	.	3	0
					6	S	28	0 NO UNITS	.	3	0
					7	S	35	1 NO UNITS	.	3	0
					8	S	42	0 NO UNITS	.	3	0
					9	S	52	0 NO UNITS	.	3	0
					16	S	133	0 NO UNITS	.	3	0
					17	S	161	0 NO UNITS	.	3	0
					18	S	189	0 NO UNITS	.	3	0
					19	S	217	0 NO UNITS	.	3	0
					23	U	252	0 NO UNITS	.	3	0
					24	S	315	0 NO UNITS	.	3	0
					25	S	343	0 NO UNITS	.	3	0
					26	U	378	3 NO UNITS	.	3	1

ZY 1234 400

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

312 2877	F	OLZ	A20	PLATELET COUNT	DIRECTN VISIT UNVISIT RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
1	S			HIGH	-3	329 GI/L	75	700	0
2	S				0	311 GI/L	75	700	0
3	S				7	381 GI/L	75	700	0
4	S				14	386 GI/L	75	700	0
5	S				21	392 GI/L	75	700	0
6	S				28	265 GI/L	75	700	0
10	S				37	300 GI/L	75	700	0
11	S				44	307 GI/L	75	700	0
12	S				51	297 GI/L	75	700	0
13	S				58	325 GI/L	75	700	0
14	S				65	317 GI/L	75	700	0
15	S				72	303 GI/L	75	700	0
16	S				86	282 GI/L	75	700	0
18	S				137	328 GI/L	75	700	0
20	S				191	327 GI/L	75	700	0
22	S				247	352 GI/L	75	700	0
24	S				303	315 GI/L	75	700	0
26	S				343	735 GI/L	75	700	1
312 3193	M	OLZ	C11	UA-RBC	INC2	0 NO UNITS	.	3	0
2	S				-2	0 NO UNITS	.	3	0
3	S				0	0 NO UNITS	.	3	0
4	S				7	0 NO UNITS	.	3	0
5	S				13	0 NO UNITS	.	3	0
6	S				21	0 NO UNITS	.	3	0
10	S				28	1 NO UNITS	.	3	0
11	S				37	0 NO UNITS	.	3	0
12	S				44	0 NO UNITS	.	3	0
12	S				51	4 NO UNITS	.	3	1
312 3193	M	OLZ	C15	UA-RBC	INC2	0 NO UNITS	.	3	0
2	S				-2	0 NO UNITS	.	3	0
3	S				0	0 NO UNITS	.	3	0
4	S				7	0 NO UNITS	.	3	0
5	S				13	0 NO UNITS	.	3	0
6	S				21	0 NO UNITS	.	3	0
10	S				28	1 NO UNITS	.	3	0
11	S				37	0 NO UNITS	.	3	0
12	S				44	0 NO UNITS	.	3	0
12	S				51	4 NO UNITS	.	3	1
312 3194	F	OLZ	C15	UA-RBC	INC2	0 NO UNITS	.	3	0
1	S				-3	0 NO UNITS	.	3	0
3	S				7	0 NO UNITS	.	3	0
4	S				14	0 NO UNITS	.	3	0
5	S				21	2 NO UNITS	.	3	0
6	S				28	3 NO UNITS	.	3	1
7	S				35	4 NO UNITS	.	3	1
8	S				39	4 NO UNITS	.	3	1
16	S				101	0 NO UNITS	.	3	0

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

312	3194	F	01z	C15	UA-MBC	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
						INC2	18	S	0 NO UNITS	.	.	3 0
							20	S	0 NO UNITS	.	.	3 0
							22	U	0 NO UNITS	.	.	3 0
315	2893	F	Ha1	A02	HEMOGLOBIN	HIGH	1	S	9.43312 mmL/L-Fe	5.8957	10.2399	0
							2	S	9.6193 mmL/L-Fe	5.8957	10.2399	0
							3	S	8.87458 mmL/L-Fe	5.8957	10.2399	0
							4	S	9.49518 mmL/L-Fe	5.8957	10.2399	0
							5	S	9.68136 mmL/L-Fe	5.8957	10.2399	0
							6	S	8.9987 mmL/L-Fe	5.8957	10.2399	0
							7	S	8.87458 mmL/L-Fe	5.8957	10.2399	0
							8	S	9.12282 mmL/L-Fe	5.8957	10.2399	0
							9	S	9.74342 mmL/L-Fe	5.8957	10.2399	0
							16	S	9.9296 mmL/L-Fe	5.8957	10.2399	0
							18	U	9.80548 mmL/L-Fe	5.8957	10.2399	0
							18	U	9.6193 mmL/L-Fe	5.8957	10.2399	0
							18	S	10.4881 mmL/L-Fe	5.8957	10.2399	1
315	2894	F	Ha1	E03	ALT/SGPT	HIGH	1	S	11 U/L	.	.	165 0
							2	S	12 U/L	.	.	165 0
							3	S	533 U/L	.	.	165 1
							4	S	345 U/L	.	.	165 1
315	3146	M	01z	A01	HEMATOCRIT	LOW	1	S	0.39 1	0.37	0.55	0
							2	S	0.39 1	0.37	0.55	0
							3	S	0.44 1	0.37	0.55	0
							4	S	0.37 1	0.37	0.55	0
							6	S	0.35 1	0.37	0.55	1
							7	S	0.38 1	0.37	0.55	0
							8	S	0.36 1	0.37	0.55	1
315	3146	M	01z	C11	UA-RBC	INC2	1	S	1 NO UNITS	.	.	3 0
							2	S	0 NO UNITS	.	.	3 0
							3	S	0 NO UNITS	.	.	3 0
							4	S	0 NO UNITS	.	.	3 0
							5	S	0 NO UNITS	.	.	3 0
							6	S	0 NO UNITS	.	.	3 0
							7	S	4 NO UNITS	.	.	3 1
							8	S	4 NO UNITS	.	.	3 1
315	3146	M	01z	C15	UA-MBC	INC2	1	S	4 NO UNITS	.	.	3 1
							2	S	0 NO UNITS	.	.	3 0
							3	S	2 NO UNITS	.	.	3 0
							4	S	0 NO UNITS	.	.	3 0
							5	S	0 NO UNITS	.	.	3 0
							6	S	2 NO UNITS	.	.	3 0
							7	S	1 NO UNITS	.	.	3 0

ZY 1234 402

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILLIM	ABNRM
315 3146	M	OLZ	C15	UA-MBC	INC2	8	S	42	4	NO UNITS	.	.	3 1
315 3146	M	OLZ	C21	UA-PROTEIN	INC2	1	S	-3	0	NO UNITS	.	.	3 0
						2	S	0	0	NO UNITS	.	.	3 0
						3	S	7	0	NO UNITS	.	.	3 0
						4	S	14	0	NO UNITS	.	.	3 0
						5	S	21	0	NO UNITS	.	.	3 0
						6	S	26	0	NO UNITS	.	.	3 0
						7	S	35	3	NO UNITS	.	.	3 1
						8	S	42	3	NO UNITS	.	.	3 1
315 3146	M	OLZ	F01	UREA NITROGEN	HIGH	1	S	-3	5.9	mmol/L	.	10.71	0
						2	S	0	7.1	mmol/L	.	10.71	0
						3	S	7	8.4	mmol/L	.	10.71	0
						4	S	14	9.8	mmol/L	.	10.71	0
						5	S	21	8.1	mmol/L	.	10.71	0
						6	S	26	11.7	mmol/L	.	10.71	1
						7	S	35	10.3	mmol/L	.	10.71	0
						8	S	42	23.9	mmol/L	.	10.71	1
315 3146	M	OLZ	F06	PHOSPHORUS	HIGH	1	S	-3	1.01	mmol/L	0.48435	1.77595	0
						2	S	0	0.93	mmol/L	0.48435	1.77595	0
						3	S	7	0.97	mmol/L	0.48435	1.77595	0
						4	S	14	1.15	mmol/L	0.48435	1.77595	0
						5	S	21	1.09	mmol/L	0.48435	1.77595	0
						6	S	26	1.3	mmol/L	0.48435	1.77595	0
						7	S	35	1.06	mmol/L	0.48435	1.77595	0
						8	S	42	1.82	mmol/L	0.48435	1.77595	1
315 3147	F	Ha1	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-2	52	U/L	.	.	507 0
						2	S	0	60	U/L	.	.	507 0
						3	S	6	52	U/L	.	.	507 0
						4	S	13	48	U/L	.	.	507 0
						5	S	20	1820	U/L	.	.	507 1
316 2899	M	OLZ	E03	ALT/SGPT	HIGH	1	S	-7	15	U/L	.	.	165 0
						2	S	0	16	U/L	.	.	165 0
						3	S	8	37	U/L	.	.	165 0
						4	S	14	59	U/L	.	.	165 0
						5	S	21	31	U/L	.	.	165 0
						6	S	28	16	U/L	.	.	165 0
						7	S	35	15	U/L	.	.	165 0
						8	S	42	13	U/L	.	.	165 0
						16	S	103	21	U/L	.	.	165 0
						18	S	146	198	U/L	.	.	165 1
318 2913	M	OLZ	C07	UA-GLUCOSE	INC2	1	S	-2	0	NO UNITS	.	.	3 0

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

318 2913	M	01z	C07	UA-GLUCOSE	DIRECTN VISIT UNVISIT REVDAYS	RESULT UNIT	LOLIM	HILIM ABNRM
				INC2	2 S	0 NO UNITS		3 0
					3 S	0 NO UNITS		3 0
					4 S	0 NO UNITS		3 0
					5 S	0 NO UNITS		3 0
					6 S	1 NO UNITS		3 0
					7 S	1 NO UNITS		3 0
					8 S	3 NO UNITS		3 1
					16 S	0 NO UNITS		3 0
					18 S	1 NO UNITS		3 0
					20 S	0 NO UNITS		3 0
					22 S	3 NO UNITS		3 1
					24 S	3 NO UNITS		3 1
					26 S	1 NO UNITS		3 0
318 2913	M	01z	F31	GLUCOSE, NON-FASTING	1 S	8.7 mmol/L	2.4975	13.875 0
					2 S	10 mmol/L	2.4975	13.875 0
					3 S	7.2 mmol/L	2.4975	13.875 0
					4 S	6.7 mmol/L	2.4975	13.875 0
					5 S	8.6 mmol/L	2.4975	13.875 0
					6 S	10.1 mmol/L	2.4975	13.875 0
					7 S	9.6 mmol/L	2.4975	13.875 0
					8 S	12.7 mmol/L	2.4975	13.875 0
					16 S	10.1 mmol/L	2.4975	13.875 0
					18 S	9.8 mmol/L	2.4975	13.875 0
					20 S	7.7 mmol/L	2.4975	13.875 0
					22 S	15.9 mmol/L	2.4975	13.875 1
					24 S	12.1 mmol/L	2.4975	13.875 0
					26 S	18.1 mmol/L	2.4975	13.875 1
319 2915	F	01z	C01	UA-SPECIFIC GRAVITY	1 S	1.035 NO UNITS	1.001	1.035 0
					2 S	1.02 NO UNITS	1.001	1.035 0
					3 S	1.027 NO UNITS	1.001	1.035 0
					4 S	1.023 NO UNITS	1.001	1.035 0
					5 S	1.012 NO UNITS	1.001	1.035 0
					6 S	1.016 NO UNITS	1.001	1.035 0
					7 S	1.017 NO UNITS	1.001	1.035 0
					8 S	1.013 NO UNITS	1.001	1.035 0
					17 U	1.027 NO UNITS	1.001	1.035 0
					17 S	1.03 NO UNITS	1.001	1.035 0
					20 S	1.036 NO UNITS	1.001	1.035 1
					22 S	1.035 NO UNITS	1.001	1.035 0
					24 S	1.026 NO UNITS	1.001	1.035 0
					27 S	1.036 NO UNITS	1.001	1.035 1
					28 S	1.036 NO UNITS	1.001	1.035 1
319 2915	F	01z	C07	UA-GLUCOSE	1 S	2 NO UNITS		3 0
					2 S	0 NO UNITS		3 0

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

DIRECTN VISIT UNVISIT REIDAYS RESULT UNIT LOLIM HILIM ABNRM

319 2915	F	01z	C07	UA-GLUCOSE	INC2	3	S	7	1 NO UNITS	.	.	3	0
4	S	14				4	S	14	0 NO UNITS	.	.	3	0
5	S	21				5	S	21	0 NO UNITS	.	.	3	0
6	S	28				6	S	28	0 NO UNITS	.	.	3	0
7	S	35				7	S	35	0 NO UNITS	.	.	3	0
8	S	42				8	S	42	0 NO UNITS	.	.	3	0
17	U	112				17	U	112	0 NO UNITS	.	.	3	0
17	S	141				17	S	141	1 NO UNITS	.	.	3	0
20	S	251				20	S	251	3 NO UNITS	.	.	3	1
22	S	309				22	S	309	3 NO UNITS	.	.	3	1
24	S	329				24	S	329	3 NO UNITS	.	.	3	1
27	S	460				27	S	460	3 NO UNITS	.	.	3	1
28	S	558				28	S	558	3 NO UNITS	.	.	3	1

319 2915	F	01z	F31	GLUCOSE, NON-FASTING	HIGH	2	U	-2	7.6 mmol/L	2.4975	13.875	0
2	S	0				2	S	0	8 mmol/L	2.4975	13.875	0
3	S	7				3	S	7	6.7 mmol/L	2.4975	13.875	0
4	S	14				4	S	14	5.5 mmol/L	2.4975	13.875	0
5	S	21				5	S	21	5.8 mmol/L	2.4975	13.875	0
6	S	28				6	S	28	5.5 mmol/L	2.4975	13.875	0
8	S	42				8	S	42	5.1 mmol/L	2.4975	13.875	0
17	U	112				17	U	112	8.5 mmol/L	2.4975	13.875	0
17	S	141				17	S	141	17.2 mmol/L	2.4975	13.875	1
20	S	251				20	S	251	15.4 mmol/L	2.4975	13.875	1
22	S	309				22	S	309	12.1 mmol/L	2.4975	13.875	0
24	S	329				24	S	329	21.2 mmol/L	2.4975	13.875	1
27	S	460				27	S	460	20.8 mmol/L	2.4975	13.875	1
28	S	558				28	S	558	14.6 mmol/L	2.4975	13.875	1

320 2922	F	01z	F31	GLUCOSE, NON-FASTING	LOM	1	S	-4	4.6 mmol/L	2.4975	13.875	0
2	S	-1				2	S	-1	4.8 mmol/L	2.4975	13.875	0
3	S	7				3	S	7	4.6 mmol/L	2.4975	13.875	0
4	S	14				4	S	14	4.8 mmol/L	2.4975	13.875	0
5	S	21				5	S	21	4.5 mmol/L	2.4975	13.875	0
6	S	28				6	S	28	4.7 mmol/L	2.4975	13.875	0
7	S	35				7	S	35	4.6 mmol/L	2.4975	13.875	0
8	S	42				8	S	42	5 mmol/L	2.4975	13.875	0
16	S	98				16	S	98	4.9 mmol/L	2.4975	13.875	0
18	S	153				18	S	153	4.1 mmol/L	2.4975	13.875	0
20	S	210				20	S	210	4.7 mmol/L	2.4975	13.875	0
22	U	238				22	U	238	4.8 mmol/L	2.4975	13.875	0
22	S	266				22	S	266	4.4 mmol/L	2.4975	13.875	0
23	S	296				23	S	296	1.7 mmol/L	2.4975	13.875	1

321 2930	M	01z	A16	EOSINOPHTLS	HIGH	1	S	-5	5.38302 % WBC	.	.	10	0
2	S	0				2	S	0	5.14541 % WBC	.	.	10	0
3	S	7				3	S	7	14.9789 % WBC	.	.	10	1

ZY 1234 405

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

321 2930	M	Olz	A16	EOSINOPHILS	DIRECTN VISIT UNVISIT RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
5	S				21	11.0283 % MBC		10	1
6	S				28	10.5495 % MBC		10	1
7	S				35	9.25553 % MBC		10	0
8	S				49	10.8929 % MBC		10	1
18	S				151	8.29493 % MBC		10	0
20	U				184	5.08083 % MBC		10	0
21	U				212	9.28144 % MBC		10	0
21	U				218	7.18563 % MBC		10	0
22	S				266	5.98007 % MBC		10	0
24	S				331	5.04587 % MBC		10	0
26	U				373	5.35714 % MBC		10	0
26	U				401	7.26496 % MBC		10	0
27	S				429	2.90135 % MBC		10	0
1	S				-2	0.47 1	0.32	0.5	0
2	S				0	0.39 1	0.32	0.5	0
3	S				7	0.4 1	0.32	0.5	0
4	S				14	0.45 1	0.32	0.5	0
5	S				21	0.51 1	0.32	0.5	1
6	S				28	0.51 1	0.32	0.5	1
7	S				35	0.51 1	0.32	0.5	1
8	S				42	0.54 1	0.32	0.5	1
18	S				154	0.47 1	0.32	0.5	0
1	S				-4	4 NO UNITS		3	1
2	S				0	0 NO UNITS		3	0
3	S				7	0 NO UNITS		3	0
4	S				14	0 NO UNITS		3	0
5	S				21	4 NO UNITS		3	1
6	S				28	0 NO UNITS		3	0
7	S				36	0 NO UNITS		3	0
8	S				42	0 NO UNITS		3	0
9	S				46	4 NO UNITS		3	1
1	S				-4	1 NO UNITS		3	0
2	S				0	1 NO UNITS		3	0
3	S				7	1 NO UNITS		3	0
4	S				14	1 NO UNITS		3	0
5	S				21	1 NO UNITS		3	0
6	S				28	4 NO UNITS		3	1
7	S				36	4 NO UNITS		3	1
8	S				42	0 NO UNITS		3	0
9	S				46	0 NO UNITS		3	0
1	S				-4	1 NO UNITS		3	0
2	S				0	1 NO UNITS		3	0
3	S				7	1 NO UNITS		3	0
4	S				14	1 NO UNITS		3	0
5	S				21	1 NO UNITS		3	0
6	S				28	4 NO UNITS		3	1
7	S				36	4 NO UNITS		3	1
8	S				42	0 NO UNITS		3	0
9	S				46	0 NO UNITS		3	0
1	S				-4	1 NO UNITS		3	0
2	S				0	0 NO UNITS		3	0
3	S				7	0 NO UNITS		3	0
4	S				14	1 NO UNITS		3	0
5	S				21	1 NO UNITS		3	0
6	S				28	4 NO UNITS		3	1
7	S				36	4 NO UNITS		3	1
8	S				42	0 NO UNITS		3	0
9	S				46	0 NO UNITS		3	0
1	S				-4	1 NO UNITS		3	0
2	S				0	0 NO UNITS		3	0
3	S				7	0 NO UNITS		3	0
4	S				14	1 NO UNITS		3	0
5	S				21	1 NO UNITS		3	0
6	S				28	4 NO UNITS		3	1
7	S				36	4 NO UNITS		3	1
8	S				42	0 NO UNITS		3	0
9	S				46	0 NO UNITS		3	0
1	S				-4	1 NO UNITS		3	0
2	S				0	0 NO UNITS		3	0
3	S				7	0 NO UNITS		3	0

EX.
LOST
AST/SGOT
on need
printouts

ZY 1234 406

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
321	3138	F	Ha1	C21	UA-PROTEIN	INC2	4	S	14	0 NO UNITS	.	3	0
							5	S	21	0 NO UNITS	.	3	0
							6	S	28	1 NO UNITS	.	3	0
							7	S	36	1 NO UNITS	.	3	0
							8	S	42	0 NO UNITS	.	3	0
							9	S	46	3 NO UNITS	.	3	1
321	3138	F	Ha1	E03	ALT/SGPT	HIGH	1	S	-4	35 U/L	.	165	0
							2	S	0	37 U/L	.	165	0
							3	S	7	74 U/L	.	165	0
							4	S	14	175 U/L	.	165	1
							5	S	21	70 U/L	.	165	0
							6	S	28	137 U/L	.	165	0
							7	S	36	331 U/L	.	165	1
							8	U	38	389 U/L	.	165	1
							8	S	42	527 U/L	.	165	1
							9	S	46	487 U/L	.	165	1
322	3011	M	Olz	C26	UA-CASTS, GRANULAR	INC2	1	S	-2	0 NO UNITS	.	3	0
							2	S	0	0 NO UNITS	.	3	0
							3	S	7	0 NO UNITS	.	3	0
							4	S	15	0 NO UNITS	.	3	0
							5	S	21	0 NO UNITS	.	3	0
							6	S	28	0 NO UNITS	.	3	0
							7	S	36	0 NO UNITS	.	3	0
							8	S	42	0 NO UNITS	.	3	0
							16	U	78	0 NO UNITS	.	3	0
							16	S	106	0 NO UNITS	.	3	0
							18	S	155	0 NO UNITS	.	3	0
							20	S	211	0 NO UNITS	.	3	0
							22	S	267	0 NO UNITS	.	3	0
							24	S	327	0 NO UNITS	.	3	0
							25	S	355	3 NO UNITS	.	3	1
322	3011	M	Olz	C58	UA-KETONES	INC2	1	S	-2	0 NO UNITS	.	3	0
							2	S	0	0 NO UNITS	.	3	0
							3	S	7	0 NO UNITS	.	3	0
							4	S	15	0 NO UNITS	.	3	0
							5	S	21	0 NO UNITS	.	3	0
							6	S	28	0 NO UNITS	.	3	0
							7	S	36	0 NO UNITS	.	3	0
							8	S	42	0 NO UNITS	.	3	0
							16	U	78	0 NO UNITS	.	3	0
							16	S	106	0 NO UNITS	.	3	0
							18	S	155	0 NO UNITS	.	3	0
							20	S	211	0 NO UNITS	.	3	0
							22	S	267	0 NO UNITS	.	3	0
							24	S	327	0 NO UNITS	.	3	0
							25	S	355	3 NO UNITS	.	3	1

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
322 3011	M	01z	C58 UA-KETONES	INC2	24	S	327	0 NO UNITS	.	.	3 0
					25	S	355	3 NO UNITS	.	.	3 1
322 3011	M	01z	F40 URIC ACID	HIGH	1	S	-2	358 umol/L	.	.	624.54 0
					2	S	0	350 umol/L	.	.	624.54 0
					3	S	7	334 umol/L	.	.	624.54 0
					4	S	15	344 umol/L	.	.	624.54 0
					5	S	21	327 umol/L	.	.	624.54 0
					6	S	28	320 umol/L	.	.	624.54 0
					7	S	36	412 umol/L	.	.	624.54 0
					8	S	42	354 umol/L	.	.	624.54 0
					16	U	78	341 umol/L	.	.	624.54 0
					16	S	106	357 umol/L	.	.	624.54 0
					18	S	155	404 umol/L	.	.	624.54 0
					20	S	211	381 umol/L	.	.	624.54 0
					22	S	267	361 umol/L	.	.	624.54 0
					24	S	327	424 umol/L	.	.	624.54 0
					25	S	355	932 umol/L	.	.	624.54 1
322 3011	M	01z	601 BILIRUBIN, TOTAL	HIGH	1	S	-2	12 umol/L	.	.	34.2 0
					2	S	0	7 umol/L	.	.	34.2 0
					3	S	7	8 umol/L	.	.	34.2 0
					4	S	15	14 umol/L	.	.	34.2 0
					5	S	21	10 umol/L	.	.	34.2 0
					6	S	28	14 umol/L	.	.	34.2 0
					7	S	36	10 umol/L	.	.	34.2 0
					8	S	42	12 umol/L	.	.	34.2 0
					16	U	78	10 umol/L	.	.	34.2 0
					16	S	106	11 umol/L	.	.	34.2 0
					18	S	155	17 umol/L	.	.	34.2 0
					20	S	211	16 umol/L	.	.	34.2 0
					22	S	267	14 umol/L	.	.	34.2 0
					24	S	327	12 umol/L	.	.	34.2 0
					25	S	355	36 umol/L	.	.	34.2 1
322 3283	M	01z	C01 UA-SPECIFIC GRAVITY	HIGH	1	S	-2	1.03 NO UNITS	1.001	1.035	0
					2	S	0	1.021 NO UNITS	1.001	1.035	0
					3	S	6	1.026 NO UNITS	1.001	1.035	0
					4	S	14	1.02 NO UNITS	1.001	1.035	0
					5	S	19	1.021 NO UNITS	1.001	1.035	0
					6	S	29	1.026 NO UNITS	1.001	1.035	0
					7	S	35	1.029 NO UNITS	1.001	1.035	0
					10	S	46	1.023 NO UNITS	1.001	1.035	0
					11	S	53	1.015 NO UNITS	1.001	1.035	0
					12	S	61	1.025 NO UNITS	1.001	1.035	0
					13	S	67	1.027 NO UNITS	1.001	1.035	0
					14	S	74	1.03 NO UNITS	1.001	1.035	0

(19)

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
322	3283	M	01z	C01	UA-SPECIFIC GRAVITY	HIGH	15	S	81	1.035	NO UNITS	1.001	0
							16	S	95	1.036	NO UNITS	1.001	1
325	2951	F	Ha1	C11	UA-RBC	INC2	1	S	-6	0	NO UNITS	.	3
							2	S	0	0	NO UNITS	.	0
							3	S	8	0	NO UNITS	.	3
							4	S	15	0	NO UNITS	.	0
							5	S	23	0	NO UNITS	.	3
							6	S	29	4	NO UNITS	.	3
325	2951	F	Ha1	C15	UA-MBC	INC2	1	S	-6	0	NO UNITS	.	3
							2	S	0	0	NO UNITS	.	0
							3	S	8	0	NO UNITS	.	3
							4	S	15	0	NO UNITS	.	0
							5	S	23	0	NO UNITS	.	3
							6	S	29	4	NO UNITS	.	3
325	2955	F	01z	A02	HEMOGLOBIN	HIGH	1	S	-3	8.9987	mm1/L-Fe	5.8957	0
							2	S	0	9.12282	mm1/L-Fe	5.8957	0
							3	S	7	9.06076	mm1/L-Fe	5.8957	0
							4	S	14	9.06076	mm1/L-Fe	5.8957	0
							5	S	21	8.93664	mm1/L-Fe	5.8957	0
							6	S	28	9.18488	mm1/L-Fe	5.8957	0
							7	S	35	8.81252	mm1/L-Fe	5.8957	0
							8	S	42	9.24694	mm1/L-Fe	5.8957	0
							9	S	49	8.9987	mm1/L-Fe	5.8957	0
							16	S	98	9.43312	mm1/L-Fe	5.8957	0
							17	S	103	10.302	mm1/L-Fe	5.8957	1
325	2955	F	01z	E03	ALT/SGPT	HIGH	1	S	-3	44	U/L	.	165
							2	S	0	35	U/L	.	165
							3	S	7	31	U/L	.	165
							4	S	14	49	U/L	.	165
							5	S	21	35	U/L	.	165
							6	S	28	30	U/L	.	165
							7	S	35	27	U/L	.	165
							8	S	42	25	U/L	.	165
							9	U	49	20	U/L	.	165
							16	S	98	376	U/L	.	165
							17	S	103	337	U/L	.	165
325	3026	F	01z	C11	UA-RBC	INC2	1	S	-4	1	NO UNITS	.	3
							2	S	0	1	NO UNITS	.	0
							3	S	7	0	NO UNITS	.	3
							4	U	9	0	NO UNITS	.	0
							4	S	14	0	NO UNITS	.	3
							5	S	21	0	NO UNITS	.	0

ZY 1234 410

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	'TSIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
325 3026	F	OLZ	C11	UA-RBC	INC2	6	S	25	0	NO UNITS	.	3	0
						7	S	35	0	NO UNITS	.	3	0
						8	S	59	1	NO UNITS	.	3	0
						9	S	71	0	NO UNITS	.	3	0
						16	S	98	1	NO UNITS	.	3	0
						18	S	154	0	NO UNITS	.	3	0
						20	S	207	0	NO UNITS	.	3	0
						22	S	263	0	NO UNITS	.	3	0
						24	S	318	0	NO UNITS	.	3	0
						26	S	361	4	NO UNITS	.	3	1
325 3029	M	OLZ	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-2	192	U/L	.	594	0
						2	S	0	108	U/L	.	594	0
						3	S	6	123	U/L	.	594	0
						4	S	9	1731	U/L	.	594	1
327 2965	M	OLZ	C01	UA-SPECIFIC GRAVITY	HIGH	1	S	29	1.013	NO UNITS	1.001	1.035	0
						10	S	35	1.005	NO UNITS	1.001	1.035	0
						11	S	42	1.022	NO UNITS	1.001	1.035	0
						12	S	49	1.006	NO UNITS	1.001	1.035	0
						13	S	54	1.021	NO UNITS	1.001	1.035	0
						14	S	62	1.018	NO UNITS	1.001	1.035	0
						15	S	68	1.019	NO UNITS	1.001	1.035	0
						16	S	82	1.015	NO UNITS	1.001	1.035	0
						18	S	139	1.011	NO UNITS	1.001	1.035	0
						20	S	195	1.015	NO UNITS	1.001	1.035	0
						22	S	251	1.02	NO UNITS	1.001	1.035	0
						24	S	314	1.026	NO UNITS	1.001	1.035	0
						26	S	363	1.02	NO UNITS	1.001	1.035	0
						27	S	419	1.023	NO UNITS	1.001	1.035	0
						28	S	475	1.036	NO UNITS	1.001	1.035	1
327 3106	M	OLZ	A03	ERYTHROCYTE COUNT	HIGH	1	S	-2	5.8	TI/L	3	6	0
						2	S	0	5.9	TI/L	3	6	0
						3	S	5	5.9	TI/L	3	6	0
						4	S	12	6	TI/L	3	6	0
						5	S	19	5.6	TI/L	3	6	0
						7	S	33	5.7	TI/L	3	6	0
						8	S	39	5.5	TI/L	3	6	0
						16	S	97	6.3	TI/L	3	6	1
						18	S	160	6.2	TI/L	3	6	1
328 3063	F	OLZ	C11	UA-RBC	INC2	1	S	-7	0	NO UNITS	.	3	0
						2	U	-2	0	NO UNITS	.	3	0
						3	S	1	0	NO UNITS	.	3	0
						4	S	6	0	NO UNITS	.	3	0
						4	S	13	0	NO UNITS	.	3	0

ZY 1234 411

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

INC2	5	6	10	11	12	13	14	15	16	18	20	22	24	25	26	27	1	2	3	4	5	6	7	8	10	1	2	3	1	10	11	12	13	14	15	16	18	20	22	24	1	2	3		
INC2	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
INC2	20	26	34	41	48	55	62	69	83	139	195	251	307	321	349	405	-2	0	7	14	21	28	35	43	54	-3	0	5	35	40	47	54	61	68	75	89	145	201	257	313	-5	0	7		
INC2	0 NO UNITS	0 NO UNITS	0 NO UNITS	0 NO UNITS	0 NO UNITS	0 NO UNITS	0 NO UNITS	0 NO UNITS	0 NO UNITS	0 NO UNITS	0 NO UNITS	0 NO UNITS	0 NO UNITS	0 NO UNITS	2 NO UNITS	4 NO UNITS	1.034 NO UNITS	1.031 NO UNITS	1.001 NO UNITS	1.03 NO UNITS	1.029 NO UNITS	1.034 NO UNITS	1.025 NO UNITS	1.021 NO UNITS	1.036 NO UNITS	156 U/L	189 U/L	966 U/L	349 U/L	311 U/L	663 U/L	997 U/L	817 U/L	501 U/L	401 U/L	413 U/L	601 U/L	323 U/L	398 U/L	1358 U/L	412 U/L	518 U/L	588 U/L		
INC2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
INC2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001	1.001		
INC2	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	HILIM	
INC2	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	ABNRM	

ZY 1234 412

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
332	3244	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	4	S	14	348 U/L	.	594	0
							5	S	22	483 U/L	.	594	0
							6	S	28	463 U/L	.	594	0
							7	S	35	503 U/L	.	594	0
							8	S	42	498 U/L	.	594	0
							16	S	101	225 U/L	.	594	0
							18	S	154	1019 U/L	.	594	1
							19	U	161	835 U/L	.	594	1
333	3287	M	01z	A10	LEUCOCYTE COUNT	LOW	1	S	-2	3.24 GI/L	2.8	16	0
							2	S	0	3.04 GI/L	2.8	16	0
							3	S	5	2.45 GI/L	2.8	16	1
							4	S	14	3.02 GI/L	2.8	16	0
							5	S	21	4.38 GI/L	2.8	16	0
							6	S	28	2.65 GI/L	2.8	16	1
							7	S	35	2.73 GI/L	2.8	16	1
							8	S	42	2.86 GI/L	2.8	16	0
							16	S	105	5.03 GI/L	2.8	16	0
							18	S	155	6.17 GI/L	2.8	16	0
							20	S	210	3.04 GI/L	2.8	16	0
							22	S	266	2.78 GI/L	2.8	16	1
334	3170	F	01z	C11	UA-RBC	INC2	1	S	-3	0 NO UNITS	.	3	0
							3	S	7	0 NO UNITS	.	3	0
							4	S	12	0 NO UNITS	.	3	0
							5	S	21	0 NO UNITS	.	3	0
							6	S	28	0 NO UNITS	.	3	0
							7	S	35	1 NO UNITS	.	3	0
							8	S	42	0 NO UNITS	.	3	0
							16	S	98	4 NO UNITS	.	3	1
334	3236	F	01z	E17	GGT(GGPT/SGGT/YGGT)	HIGH	1	S	-4	61 U/L	.	135	0
							2	S	0	72 U/L	.	135	0
							3	S	7	141 U/L	.	135	1
							4	U	10	215 U/L	.	135	1
							4	S	14	229 U/L	.	135	1
							5	S	21	256 U/L	.	135	1
							6	U	24	224 U/L	.	135	1
							6	S	28	196 U/L	.	135	1
							7	S	35	152 U/L	.	135	1
							8	S	42	117 U/L	.	135	0
							9	U	56	122 U/L	.	135	0
							16	U	87	38 U/L	.	135	0
							16	S	98	32 U/L	.	135	0
							17	S	126	95 U/L	.	135	0
							18	U	140	79 U/L	.	135	0
							18	S	154	90 U/L	.	135	0

ZY 1234 413

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	E17	E12	C11	UA-RBC	HIGH	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
334	F	01z	E17	GGT(GGPT/SGGT/YGGT)					HIGH	20	S	210	137 U/L	.	135	1
					22	U				22	U	238	125 U/L	.	135	0
					22	S				22	S	266	153 U/L	.	135	1
					23	U				24	S	296	109 U/L	.	135	0
					24	S				25	U	322	174 U/L	.	135	1
					25	U						330	102 U/L	.	135	0
334	F	01z	C11	UA-RBC				INC2		1	S	-2	0 NO UNITS	.	3	0
					2	S				2	S	0	0 NO UNITS	.	3	0
					3	S				3	S	7	0 NO UNITS	.	3	0
					4	S				4	S	14	0 NO UNITS	.	3	0
					5	S				5	S	21	0 NO UNITS	.	3	0
					6	S				6	S	28	0 NO UNITS	.	3	0
					7	S				7	S	35	0 NO UNITS	.	3	0
					8	S				8	S	42	0 NO UNITS	.	3	0
					16	S				16	S	98	0 NO UNITS	.	3	0
					17	S				17	S	110	4 NO UNITS	.	3	1
334	F	01z	C15	UA-RBC				INC2		1	S	-2	0 NO UNITS	.	3	0
					2	S				2	S	0	0 NO UNITS	.	3	0
					3	S				3	S	7	0 NO UNITS	.	3	0
					4	S				4	S	14	0 NO UNITS	.	3	0
					5	S				5	S	21	0 NO UNITS	.	3	0
					6	S				6	S	28	0 NO UNITS	.	3	0
					7	S				7	S	35	0 NO UNITS	.	3	0
					8	S				8	S	42	0 NO UNITS	.	3	0
					16	S				16	S	98	2 NO UNITS	.	3	0
					17	S				17	S	110	4 NO UNITS	.	3	1
336	F	01z	E12	CREATINE PHOSPHOKINASE				HIGH		1	S	-5	196 U/L	.	507	0
					2	S				2	S	0	136 U/L	.	507	0
					3	S				3	S	7	110 U/L	.	507	0
					4	S				4	S	14	181 U/L	.	507	0
					5	S				5	S	21	104 U/L	.	507	0
					6	S				6	S	28	98 U/L	.	507	0
					7	S				7	S	35	138 U/L	.	507	0
					8	S				8	S	42	98 U/L	.	507	0
					9	S				9	S	49	597 U/L	.	507	1
337	F	Ha1	C11	UA-RBC				INC2		1	S	-3	0 NO UNITS	.	3	0
					2	S				2	S	0	0 NO UNITS	.	3	0
					3	S				3	S	7	0 NO UNITS	.	3	0
					4	S				4	S	14	0 NO UNITS	.	3	0
					5	S				5	S	21	0 NO UNITS	.	3	0
					7	U				7	U	29	0 NO UNITS	.	3	0
					7	S				7	S	35	4 NO UNITS	.	3	1

ZY 1234 414

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	ALT/SGPT	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
401 4111	F	Olz	E03	ALT/SGPT	HIGH	1	S	S	-3	14 U/L	.	165	0
						2	S	S	0	10 U/L	.	165	0
						3	S	S	9	24 U/L	.	165	0
						5	U	U	17	64 U/L	.	165	0
						5	S	S	21	104 U/L	.	165	0
						6	S	S	28	216 U/L	.	165	1
						7	S	S	37	269 U/L	.	165	1
						8	S	S	42	233 U/L	.	165	1
						9	S	S	72	92 U/L	.	165	0
						16	S	S	98	28 U/L	.	165	0
401 4168	M	Olz	E03	ALT/SGPT	HIGH	1	S	S	-3	24 U/L	.	165	0
						2	S	S	0	97 U/L	.	165	0
						3	S	S	9	117 U/L	.	165	0
						4	S	S	14	108 U/L	.	165	0
						5	S	S	21	194 U/L	.	165	1
						6	S	S	29	205 U/L	.	165	1
						7	S	S	35	174 U/L	.	165	1
						8	S	S	43	213 U/L	.	165	1
401 4168	M	Olz	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	S	-3	231 U/L	.	594	0
						2	S	S	0	177 U/L	.	594	0
						3	S	S	9	365 U/L	.	594	0
						4	S	S	14	235 U/L	.	594	0
						5	S	S	21	327 U/L	.	594	0
						6	S	S	29	340 U/L	.	594	0
						7	S	S	35	341 U/L	.	594	0
						8	S	S	43	632 U/L	.	594	1
401 4175	M	Hal	A16	EOSINOPHILS	HIGH	1	S	S	-6	4.6875 % MBC	.	10	0
						2	S	S	0	1.79949 % MBC	.	10	0
						3	S	S	7	2.58216 % MBC	.	10	0
						4	S	S	14	3.9501 % MBC	.	10	0
						5	S	S	20	2.08333 % MBC	.	10	0
						6	S	S	27	2.59521 % MBC	.	10	0
						7	S	S	36	6.86869 % MBC	.	10	0
						8	S	S	42	15.2855 % MBC	.	10	1
						9	S	S	70	2.54453 % MBC	.	10	0
						16	S	S	99	10.5896 % MBC	.	10	1
						18	S	S	161	2.01613 % MBC	.	10	0
						20	S	S	217	9.30233 % MBC	.	10	0
						22	S	S	266	12.7451 % MBC	.	10	1
401 4214	M	Hal	A10	LEUCOCYTE COUNT	HIGH	1	S	S	-2	9.71 GI/L	2.8	16	0
						2	S	S	0	9.57 GI/L	2.8	16	0
						3	S	S	7	9 GI/L	2.8	16	0
						4	S	S	14	10.03 GI/L	2.8	16	0

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM		
401	4214	M	Ha1	A10	LEUCOCYTE COUNT	HIGH	5	S	21	10.85	GI/L	2.8	16	0
							6	S	27	13.42	GI/L	2.8	16	0
							7	S	35	10.75	GI/L	2.8	16	0
							8	S	42	14.82	GI/L	2.8	16	0
							9	S	49	16.67	GI/L	2.8	16	1
402	4116	F	Ha1	A01	HEMATOCRIT	HIGH	1	S	-5	0.43	I	0.32	0.5	0
							2	S	0	0.41	I	0.32	0.5	0
							3	S	7	0.44	I	0.32	0.5	0
							4	S	14	0.44	I	0.32	0.5	0
							5	S	21	0.45	I	0.32	0.5	0
							6	S	28	0.47	I	0.32	0.5	0
							7	S	35	0.46	I	0.32	0.5	0
							8	S	42	0.42	I	0.32	0.5	0
							16	S	98	0.47	I	0.32	0.5	0
							18	S	154	0.49	I	0.32	0.5	0
							19	S	162	0.52	I	0.32	0.5	1
404	4229	M	Ha1	C01	UA-SPECIFIC GRAVITY	HIGH	1	S	-4	1.011	NO UNITS	1.001	1.035	0
							2	S	0	1.029	NO UNITS	1.001	1.035	0
							3	S	4	1.036	NO UNITS	1.001	1.035	1
407	4145	M	O1z	A03	ERYTHROCYTE COUNT	HIGH	1	S	-2	5.9	TI/L	3	6	0
							2	S	0	5.8	TI/L	3	6	0
							3	S	7	5.7	TI/L	3	6	0
							4	S	14	6.1	TI/L	3	6	1
							5	S	20	6.1	TI/L	3	6	1
407	4146	F	O1z	A02	HEMOGLOBIN	HIGH	1	S	-4	10.1158	mmL/L-Fe	5.8957	10.2399	0
							2	S	0	9.9296	mmL/L-Fe	5.8957	10.2399	0
							3	S	7	9.68136	mmL/L-Fe	5.8957	10.2399	0
							4	S	14	9.74342	mmL/L-Fe	5.8957	10.2399	0
							5	S	21	9.99166	mmL/L-Fe	5.8957	10.2399	0
							6	S	29	10.1158	mmL/L-Fe	5.8957	10.2399	0
							7	S	36	9.68136	mmL/L-Fe	5.8957	10.2399	0
							8	S	44	9.309	mmL/L-Fe	5.8957	10.2399	0
							9	S	51	9.309	mmL/L-Fe	5.8957	10.2399	0
							16	S	63	10.2399	mmL/L-Fe	5.8957	10.2399	1
407	4146	F	O1z	C11	UA-RBC	INC2	1	S	-4	0	NO UNITS	.	3	0
							2	S	0	0	NO UNITS	.	3	0
							3	S	7	0	NO UNITS	.	3	0
							4	S	14	0	NO UNITS	.	3	0
							5	S	21	0	NO UNITS	.	3	0
							6	S	29	0	NO UNITS	.	3	0
							7	S	36	0	NO UNITS	.	3	0
							8	S	44	0	NO UNITS	.	3	0

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

407 4146 F Olz C11 UA-RBC

408 4194 M Olz F40 URIC ACID

502 4514 M Olz E12 CREATINE PHOSPHOKINASE HIGH

502 4516 M Olz A01 HEMATOCRIT HIGH

503 4520 M Olz C11 UA-RBC

13:18 Wednesday, July 5, 1995 122

ZY 1234 416

DIRECTN VISIT UNVISIT RELDAYS RESULT UNIT LOLIM HILIM ABNRM

INC2 9 S 51 0 NO UNITS
16 S 63 4 NO UNITS

HIGH 1 S -1 475 umol/L
2 S 0 451 umol/L
3 S 7 509 umol/L
4 S 14 488 umol/L
5 S 21 510 umol/L
6 S 28 636 umol/L
7 S 35 590 umol/L
9 S 70 644 umol/L
16 S 98 556 umol/L
18 S 154 704 umol/L
20 S 217 725 umol/L
22 S 231 623 umol/L

1 S -3 566 U/L
2 S 0 444 U/L
3 S 7 1208 U/L
4 S 14 1053 U/L
5 S 21 199 U/L
6 S 28 303 U/L
7 S 35 484 U/L
8 S 42 330 U/L
10 S 53 394 U/L

1 S -4 0.52 I
2 S 0 0.54 I
3 S 7 0.5 I
4 S 14 0.55 I
5 S 21 0.56 I
6 S 28 0.55 I
7 S 35 0.51 I
20 S 225 0.52 I

INC2 1 S -3 0 NO UNITS
2 S 0 0 NO UNITS
3 S 7 0 NO UNITS
4 S 14 1 NO UNITS
5 S 21 0 NO UNITS
6 S 28 0 NO UNITS
7 S 35 4 NO UNITS
10 S 47 4 NO UNITS
11 S 54 0 NO UNITS
12 S 61 0 NO UNITS
13 S 68 1 NO UNITS
14 S 75 1 NO UNITS

. 624.54 0
. 624.54 0
. 624.54 0
. 624.54 0
. 624.54 1
. 624.54 0
. 624.54 1
. 624.54 1
. 624.54 0
. 624.54 1
. 624.54 1
. 624.54 1
. 624.54 0

. 594 0
. 594 0
. 594 1
. 594 1
. 594 0
. 594 0
. 594 0
. 594 0
. 594 0

0.37 0.55 0
0.37 0.55 0
0.37 0.55 0
0.37 0.55 1
0.37 0.55 1
0.37 0.55 1
0.37 0.55 1
0.37 0.55 0
0.37 0.55 0

. 3 0
. 3 0
. 3 0
. 3 0
. 3 1
. 3 1
. 3 0
. 3 0
. 3 0
. 3 0
. 3 0
. 3 0
. 3 0

13:18 Wednesday, July 5, 1995 123

ZY 1234 417

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

503 4520	M	01z	C11	UA-RBC	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
					INC2	S	82	0 NO UNITS	.	3	0
						S	96	0 NO UNITS	.	3	0
						S	152	1 NO UNITS	.	3	0
						S	216	0 NO UNITS	.	3	0
						S	272	0 NO UNITS	.	3	0
						S	328	0 NO UNITS	.	3	0
						S	369	0 NO UNITS	.	3	0
503 4520	M	01z	E03	ALT/SGPT	HIGH	S	-3	59 U/L	.	165	0
						S	0	41 U/L	.	165	0
						S	7	72 U/L	.	165	0
						S	14	226 U/L	.	165	1
						S	21	222 U/L	.	165	1
						S	28	243 U/L	.	165	1
						S	35	111 U/L	.	165	0
						S	47	34 U/L	.	165	0
						S	54	30 U/L	.	165	0
						S	61	67 U/L	.	165	0
						S	68	52 U/L	.	165	0
						S	75	30 U/L	.	165	0
						S	82	53 U/L	.	165	0
						S	96	36 U/L	.	165	0
						S	152	36 U/L	.	165	0
						S	216	22 U/L	.	165	0
						S	272	36 U/L	.	165	0
						S	328	30 U/L	.	165	0
						S	369	38 U/L	.	165	0
503 4523	M	01z	E03	ALT/SGPT	HIGH	S	-4	35 U/L	.	165	0
						S	0	116 U/L	.	165	0
						S	7	183 U/L	.	165	1
						S	14	195 U/L	.	165	1
						S	21	77 U/L	.	165	0
						S	30	65 U/L	.	165	0
						S	37	82 U/L	.	165	0
						S	44	95 U/L	.	165	0
						S	70	27 U/L	.	165	0
						S	98	29 U/L	.	165	0
						S	154	14 U/L	.	165	0
						S	211	24 U/L	.	165	0
						S	266	26 U/L	.	165	0
						S	325	27 U/L	.	165	0
600 4882	M	01z	A01	HEMATOCRIT	HIGH	S	48	0.54 I	0.37	0.55	0
						S	55	0.52 I	0.37	0.55	0
						S	62	0.51 I	0.37	0.55	0
						S	69	0.49 I	0.37	0.55	0

RMP.FIDSTGSL.SASPGM(LABNTJX) 85266

ELI LILLY AND COMPANY
 FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
 ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

13:18 Wednesday, July 5, 1995 124

ZY 1234 418

600 4882	M	01z	A01	HENATOGRIT	HIGH	13	S	76	0.53 I	0.37	0.55 0
						14	S	83	0.51 I	0.37	0.55 0
						15	S	92	0.5 I	0.37	0.55 0
						16	S	106	0.52 I	0.37	0.55 0
						18	S	167	0.54 I	0.37	0.55 0
						20	S	219	0.55 I	0.37	0.55 1
						21	S	244	0.57 I	0.37	0.55 1
600 4933	M	01z	A10	LEUCOCYTE COUNT	HIGH	1	S	30	14.85 GI/L	2.8	16 0
						10	S	37	12.79 GI/L	2.8	16 0
						11	S	44	15.62 GI/L	2.8	16 0
						12	S	51	11.79 GI/L	2.8	16 0
						13	S	58	14.7 GI/L	2.8	16 0
						14	S	65	14.05 GI/L	2.8	16 0
						15	S	77	22.33 GI/L	2.8	16 1
602 4893	F	01z	C11	UA-RBC	INC2	1	S	-9	0 NO UNITS	.	3 0
						2	U	-5	0 NO UNITS	.	3 0
						2	S	0	0 NO UNITS	.	3 0
						3	S	6	0 NO UNITS	.	3 0
						4	S	12	0 NO UNITS	.	3 0
						5	S	20	0 NO UNITS	.	3 0
						6	S	27	4 NO UNITS	.	3 1
602 4896	M	01z	A03	ERYTHROCYTE COUNT	HIGH	1	S	-4	5.9 TI/L	3	6 0
						2	S	0	5.8 TI/L	3	6 0
						3	S	6	5.9 TI/L	3	6 0
						4	S	14	6.2 TI/L	3	6 1
						5	S	20	5.7 TI/L	3	6 0
						6	S	27	5.7 TI/L	3	6 0
						7	S	35	6 TI/L	3	6 0
						8	S	42	6 TI/L	3	6 0
						9	S	70	5.5 TI/L	3	6 0
						16	S	99	5.6 TI/L	3	6 0
						18	S	157	6.1 TI/L	3	6 1
						20	S	219	6 TI/L	3	6 0
						22	S	273	5.9 TI/L	3	6 0
						24	S	332	6 TI/L	3	6 0
						26	S	384	6.2 TI/L	3	6 1
						27	U	422	6.3 TI/L	3	6 1
602 4896	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-4	54 U/L	.	594 0
						2	S	0	97 U/L	.	594 0
						3	S	6	67 U/L	.	594 0
						4	S	14	138 U/L	.	594 0
						5	S	20	56 U/L	.	594 0
						6	S	27	60 U/L	.	594 0

ZY 1234 419

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
602 4896	M	OLZ	E12	CREATINE PHOSPHOKINASE	HIGH	7	S	35	109	U/L	.	594	0
						8	S	42	106	U/L	.	594	0
						9	S	70	247	U/L	.	594	0
						16	S	99	530	U/L	.	594	0
						18	S	157	968	U/L	.	594	1
						20	S	219	71	U/L	.	594	0
						22	S	273	94	U/L	.	594	0
						24	S	332	88	U/L	.	594	0
						26	S	384	120	U/L	.	594	0
						27	U	422	4670	U/L	.	594	1
602 4931	M	OLZ	E03	ALT/SGPT	HIGH	1	S	54	18	U/L	.	165	0
						10	S	62	54	U/L	.	165	0
						11	S	69	71	U/L	.	165	0
						12	S	76	182	U/L	.	165	1
						13	S	85	267	U/L	.	165	1
						14	S	91	166	U/L	.	165	1
						15	S	105	131	U/L	.	165	0
						16	S	113	143	U/L	.	165	0
						18	S	162	35	U/L	.	165	0
						20	S	216	14	U/L	.	165	0
						22	S	274	16	U/L	.	165	0
						24	S	327	40	U/L	.	165	0
						26	S	376	23	U/L	.	165	0
602 4960	M	OLZ	A20	PLATELET COUNT	LOW	1	S	-4	119	GI/L	75	700	0
						2	S	0	108	GI/L	75	700	0
						3	S	7	71	GI/L	75	700	1
						4	S	14	61	GI/L	75	700	1
						5	S	21	77	GI/L	75	700	0
						6	S	30	88	GI/L	75	700	0
						7	S	37	66	GI/L	75	700	1
602 4960	M	OLZ	C11	UA-RBC	INC2	1	S	-4	0	NO UNITS	.	3	0
						2	S	0	0	NO UNITS	.	3	0
						3	S	7	0	NO UNITS	.	3	0
						4	S	14	4	NO UNITS	.	3	1
						5	S	21	4	NO UNITS	.	3	1
						6	S	30	4	NO UNITS	.	3	1
						7	S	37	4	NO UNITS	.	3	1
						8	S	44	4	NO UNITS	.	3	1
602 4965	M	OLZ	A01	HEMATOCRIT	HIGH	1	S	-3	0.53	1	0.37	0.55	0
						2	S	0	0.53	1	0.37	0.55	0
						3	S	7	0.54	1	0.37	0.55	0
						4	S	14	0.52	1	0.37	0.55	0
						5	S	21	0.5	1	0.37	0.55	0

25

ZY 1234 420

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

602 4965	M	Olz	A01	HEMATOCRIT	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
				HIGH	6	S	28	0.52 I	0.37	0.55	0
					7	S	35	0.57 I	0.37	0.55	1
					8	S	42	0.55 I	0.37	0.55	1
					9	S	70	0.52 I	0.37	0.55	0
					16	S	105	0.5 I	0.37	0.55	0
					18	S	168	0.49 I	0.37	0.55	0
					20	S	221	0.51 I	0.37	0.55	0
605 4912	M	Olz	E03	ALT/SGPT	1	S	-3	33 U/L	.	165	0
				HIGH	2	S	0	29 U/L	.	165	0
					3	S	7	21 U/L	.	165	0
					4	S	14	86 U/L	.	165	0
					5	S	21	174 U/L	.	165	1
					6	S	28	187 U/L	.	165	1
					7	S	35	145 U/L	.	165	0
					8	S	42	175 U/L	.	165	1
					9	S	70	102 U/L	.	165	0
					16	S	98	50 U/L	.	165	0
					18	S	154	30 U/L	.	165	0
					20	S	204	29 U/L	.	165	0
					22	S	260	21 U/L	.	165	0
606 4920	M	Olz	A01	HEMATOCRIT	1	S	-5	0.52 I	0.37	0.55	0
				HIGH	2	S	0	0.5 I	0.37	0.55	0
					3	S	7	0.52 I	0.37	0.55	0
					4	S	14	0.56 I	0.37	0.55	1
					5	S	22	0.55 I	0.37	0.55	1
					6	S	28	0.56 I	0.37	0.55	1
					7	S	35	0.55 I	0.37	0.55	1
606 4921	M	Olz	A03	ERYTHROCYTE COUNT	1	S	-4	5.9 TI/L	3	6	0
				HIGH	2	S	0	5.9 TI/L	3	6	0
					3	S	8	5.7 TI/L	3	6	0
					4	S	14	5.8 TI/L	3	6	0
					5	S	22	5.9 TI/L	3	6	0
					6	S	28	5.8 TI/L	3	6	0
					7	S	35	5.7 TI/L	3	6	0
					8	S	43	5.9 TI/L	3	6	0
					9	S	71	5.7 TI/L	3	6	0
					16	S	99	5.8 TI/L	3	6	0
					18	S	155	6.2 TI/L	3	6	1
					19	S	163	6.3 TI/L	3	6	1
606 4922	M	Ha1	G01	BILIRUBIN, TOTAL	1	S	-3	12 umol/L	.	34.2	0
				HIGH	3	S	7	21 umol/L	.	34.2	0
					4	S	14	18 umol/L	.	34.2	0
					5	S	21	24 umol/L	.	34.2	0

ELI LILLY AND COMPANY
F1D-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
606	4922	M	Ha1	G01	BILIRUBIN, TOTAL	HIGH	6	S	27	28	umol/L	34.2	0
							7	S	34	27	umol/L	34.2	0
							8	S	41	28	umol/L	34.2	0
							9	S	68	22	umol/L	34.2	0
							16	S	96	29	umol/L	34.2	0
							18	S	152	39	umol/L	34.2	1
							20	S	208	39	umol/L	34.2	1
							22	S	265	24	umol/L	34.2	0
							26	S	362	27	umol/L	34.2	0
606	4941	F	Olz	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-3	70	U/L	507	0
							2	S	-1	97	U/L	507	0
							3	S	10	267	U/L	507	0
							4	S	17	173	U/L	507	0
							5	S	25	103	U/L	507	0
							6	S	32	73	U/L	507	0
							10	S	40	165	U/L	507	0
							11	S	47	60	U/L	507	0
							12	S	54	71	U/L	507	0
							13	S	61	65	U/L	507	0
							14	S	68	89	U/L	507	0
							15	S	75	105	U/L	507	0
							16	S	89	92	U/L	507	0
							18	S	144	59	U/L	507	0
							20	S	199	78	U/L	507	0
							22	S	250	70	U/L	507	0
							24	S	306	843	U/L	507	1
700	5261	M	Ha1	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-9	127	U/L	594	0
							2	S	0	476	U/L	594	0
							3	S	7	756	U/L	594	1
							4	S	14	1801	U/L	594	1
							5	S	20	823	U/L	594	1
							6	S	28	332	U/L	594	0
							7	S	35	297	U/L	594	0
							8	S	41	295	U/L	594	0
							9	S	68	202	U/L	594	0
							16	S	97	421	U/L	594	0
							18	S	152	136	U/L	594	0
							20	S	210	183	U/L	594	0
							22	S	264	196	U/L	594	0
							24	S	322	223	U/L	594	0
							26	S	368	229	U/L	594	0
722	5535	M	Ha1	A10	LEUCOCYTE COUNT	LOW	1	S	-3	6.36	GI/L	16	0
							2	S	0	7.37	GI/L	16	0
							3	S	7	7.18	GI/L	16	0

32

ZY 1234 422

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
722	M	Ha1	A10	LEUCOCYTE COUNT	LOW	4	S	14	7.14	GI/L	2.8		16 0
						5	S	21	6.18	GI/L	2.8		16 0
						6	S	27	2.56	GI/L	2.8		16 1
723	F	Ha1	C01	UA-SPECIFIC GRAVITY	HIGH	1	S	-2	1.01	NO UNITS	1.001		1.035 0
						2	S	0	1.012	NO UNITS	1.001		1.035 0
						3	S	7	1.025	NO UNITS	1.001		1.035 0
						4	S	15	1.023	NO UNITS	1.001		1.035 0
						5	S	22	1.026	NO UNITS	1.001		1.035 0
						6	S	29	1.02	NO UNITS	1.001		1.035 0
						7	S	36	1.026	NO UNITS	1.001		1.035 0
						8	S	42	1.017	NO UNITS	1.001		1.035 0
						16	S	93	1.023	NO UNITS	1.001		1.035 0
						18	S	156	1.012	NO UNITS	1.001		1.035 0
						19	S	184	1.036	NO UNITS	1.001		1.035 1
723	F	Olz	A16	EOSINOPHILS	HIGH	1	S	-2	1.61943	% MBC			10 0
						2	S	0	2.41636	% MBC			10 0
						3	S	7	2.63692	% MBC			10 0
						4	S	16	4.48718	% MBC			10 0
						5	S	21	0.93458	% MBC			10 0
						6	S	28	4.64345	% MBC			10 0
						7	S	35	12.7389	% MBC			10 1
						8	S	41	11.4563	% MBC			10 1
						16	S	103	3.89972	% MBC			10 0
						18	S	154	2.38474	% MBC			10 0
						19	S	182	0.58997	% MBC			10 0
723	M	Olz	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-2	128	U/L			594 0
						2	S	0	135	U/L			594 0
						3	S	6	646	U/L			594 1
723	F	Olz	C11	UA-RBC	INC2	1	S	-2	0	NO UNITS			3 0
						2	S	0	0	NO UNITS			3 0
						3	S	7	0	NO UNITS			3 0
						4	S	14	0	NO UNITS			3 0
						6	S	28	0	NO UNITS			3 0
						10	S	39	0	NO UNITS			3 0
						11	S	46	0	NO UNITS			3 0
						12	S	54	4	NO UNITS			3 1
752	F	Olz	F40	URIC ACID	HIGH	1	S	-3	449	umol/L			505.58 0
						2	S	0	422	umol/L			505.58 0
						3	S	7	412	umol/L			505.58 0
						4	S	14	429	umol/L			505.58 0
						5	S	21	447	umol/L			505.58 0
						6	S	28	507	umol/L			505.58 1

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

DIRECTN VISIT UNVISIT RELDAYS RESULT UNIT LOLIM HILIM ABRNM

752 6065	F	01z	C26	UA-CASTS, GRANULAR	INC2	1	S	-5	0 NO UNITS	.	3	0
2	S	0				2	S	0	0 NO UNITS	.	3	0
3	S	7				3	S	7	0 NO UNITS	.	3	0
4	S	14				4	S	14	0 NO UNITS	.	3	0
5	S	21				5	S	21	1 NO UNITS	.	3	0
6	S	29				6	S	29	0 NO UNITS	.	3	0
7	S	35				7	S	35	0 NO UNITS	.	3	0
8	S	42				8	S	42	0 NO UNITS	.	3	0
16	S	100				16	S	100	0 NO UNITS	.	3	0
18	S	156				18	S	156	0 NO UNITS	.	3	0
20	S	216				20	S	216	3 NO UNITS	.	3	1

752 6066	F	Ha1	C11	UA-RBC	INC2	1	S	-4	0 NO UNITS	.	3	0
2	S	0				2	S	0	0 NO UNITS	.	3	0
3	S	7				3	S	7	0 NO UNITS	.	3	0
4	S	14				4	S	14	0 NO UNITS	.	3	0
5	S	22				5	S	22	4 NO UNITS	.	3	1
6	S	28				6	S	28	0 NO UNITS	.	3	0
7	S	35				7	S	35	0 NO UNITS	.	3	0
8	S	42				8	S	42	0 NO UNITS	.	3	0
16	S	98				16	S	98	0 NO UNITS	.	3	0
18	S	155				18	S	155	0 NO UNITS	.	3	0
20	S	210				20	S	210	4 NO UNITS	.	3	1

800 6304	M	01z	A01	HEMATOCRIT	HIGH	1	S	-6	0.49 1	0.37	0.55	0
2	S	0				2	S	0	0.45 1	0.37	0.55	0
3	S	8				3	S	8	0.48 1	0.37	0.55	0
4	S	16				4	S	16	0.46 1	0.37	0.55	0
6	U	22				6	U	22	0.47 1	0.37	0.55	0
6	S	28				6	S	28	0.49 1	0.37	0.55	0
7	S	37				7	S	37	0.45 1	0.37	0.55	0
8	S	42				8	S	42	0.44 1	0.37	0.55	0
16	S	99				16	S	99	0.5 1	0.37	0.55	0
18	S	152				18	S	152	0.51 1	0.37	0.55	0
20	S	216				20	S	216	0.6 1	0.37	0.55	1

800 6304	M	01z	A02	HEMOGLOBIN	HIGH	1	S	-6	10.0537	7.1369	11.4811	0
2	S	0				2	S	0	9.49518	7.1369	11.4811	0
3	S	8				3	S	8	10.1158	7.1369	11.4811	0
4	S	16				4	S	16	9.86754	7.1369	11.4811	0
6	U	22				6	U	22	10.1158	7.1369	11.4811	0
6	S	28				6	S	28	10.4881	7.1369	11.4811	0
7	S	37				7	S	37	10.1158	7.1369	11.4811	0
8	S	42				8	S	42	9.99166	7.1369	11.4811	0
16	S	99				16	S	99	10.6743	7.1369	11.4811	0
18	S	152				18	S	152	10.9846	7.1369	11.4811	0
20	S	216				20	S	216	11.6673	7.1369	11.4811	1

ZY 1234 424

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

800	6304	M	Olz	A03	ERYTHROCYTE COUNT	DIRECTN VISIT UNVISIT RELDAYS	RESULT UNIT	LOLIM	HILIM ABRNM
					HIGH	1 S	5.2 U/L	3	6 0
						2 S	5 U/L	3	6 0
						3 S	5.2 U/L	3	6 0
						4 S	5.1 U/L	3	6 0
						6 U	5.2 U/L	3	6 0
						6 S	5.3 U/L	3	6 0
						7 S	5 U/L	3	6 0
						8 S	5.1 U/L	3	6 0
						16 S	5.6 U/L	3	6 0
						18 S	5.7 U/L	3	6 0
						20 S	6.2 U/L	3	6 1
801	6308	M	Ha1	A02	HEMOGLOBIN	1 S	11.1087 mm1/L-Fe	7.1369	11.4811
					HIGH	2 S	11.2949 mm1/L-Fe	7.1369	11.4811
						3 S	11.8535 mm1/L-Fe	7.1369	11.4811
						4 S	11.4811 mm1/L-Fe	7.1369	11.4811
						5 S	10.9226 mm1/L-Fe	7.1369	11.4811
						6 S	10.9846 mm1/L-Fe	7.1369	11.4811
						7 S	11.0467 mm1/L-Fe	7.1369	11.4811
						8 S	11.419 mm1/L-Fe	7.1369	11.4811
807	6346	F	Ha1	C11	UA-RBC	1 S	0 NO UNITS	.	3 0
					INC2	2 S	0 NO UNITS	.	3 0
						3 S	0 NO UNITS	.	3 0
						4 S	0 NO UNITS	.	3 0
						5 S	0 NO UNITS	.	3 0
						6 S	0 NO UNITS	.	3 0
						7 S	0 NO UNITS	.	3 0
						8 S	0 NO UNITS	.	3 0
						9 S	4 NO UNITS	.	3 1
807	6346	F	Ha1	C15	UA-MBC	1 S	0 NO UNITS	.	3 0
					INC2	2 S	0 NO UNITS	.	3 0
						3 S	0 NO UNITS	.	3 0
						4 S	0 NO UNITS	.	3 0
						5 S	0 NO UNITS	.	3 0
						6 S	0 NO UNITS	.	3 0
						7 S	0 NO UNITS	.	3 0
						8 S	0 NO UNITS	.	3 0
						9 S	4 NO UNITS	.	3 1
807	6347	M	Olz	E12	CREATINE PHOSPHOKINASE	1 S	72 U/L	.	594 0
					HIGH	2 S	98 U/L	.	594 0
						3 S	817 U/L	.	594 1
809	6355	M	Olz	C01	UA-SPECIFIC GRAVITY	1 S	1.028 NO UNITS	1.001	1.035 0
					HIGH	2 S	1.025 NO UNITS	1.001	1.035 0

ZY 1234 425

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
809 6355	M	Olz	C01	UA-SPECIFIC GRAVITY	HIGH	3	S	-3	1.026 NO UNITS	1.001	1.035	0
						5	S	4	1.024 NO UNITS	1.001	1.035	0
						6	S	11	1.024 NO UNITS	1.001	1.035	0
						7	S	18	1.019 NO UNITS	1.001	1.035	0
						8	S	25	1.024 NO UNITS	1.001	1.035	0
						9	U	32	1.022 NO UNITS	1.001	1.035	0
						9	S	63	1.014 NO UNITS	1.001	1.035	0
						16	S	99	1.021 NO UNITS	1.001	1.035	0
						18	S	158	1.011 NO UNITS	1.001	1.035	0
						20	S	213	1.027 NO UNITS	1.001	1.035	0
						22	S	247	1.036 NO UNITS	1.001	1.035	1
809 6433	M	Olz	A16	EOSINOPHILS	HIGH	1	S	-3	5.41796 % MBC	.	10	0
						2	S	-1	8.71935 % MBC	.	10	0
						3	S	9	9.54774 % MBC	.	10	0
						4	S	16	12.4126 % MBC	.	10	1
						5	S	23	12.4101 % MBC	.	10	1
						6	S	30	8.36278 % MBC	.	10	0
						7	S	37	9.51009 % MBC	.	10	0
						8	S	44	12.4161 % MBC	.	10	1
						16	S	90	4.1791 % MBC	.	10	0
						18	S	156	9.5339 % MBC	.	10	0
						20	S	223	9.35551 % MBC	.	10	0
						21	S	255	6.29183 % MBC	.	10	0
						22	S	286	5.40541 % MBC	.	10	0
809 6434	M	Olz	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-3	577 U/L	.	594	0
						3	S	4	2381 U/L	.	594	1
						4	S	9	848 U/L	.	594	1
						5	S	11	978 U/L	.	594	1
809 6435	M	Ha1	C15	UA-MBC	INC2	1	S	-3	0 NO UNITS	.	3	0
						2	S	0	0 NO UNITS	.	3	0
						3	S	5	1 NO UNITS	.	3	0
						4	S	11	4 NO UNITS	.	3	1
809 6437	M	Olz	E12	CREATINE PHOSPHOKINASE	HIGH	2	S	0	148 U/L	.	594	0
						3	S	5	164 U/L	.	594	0
						4	S	12	306 U/L	.	594	0
						5	S	18	497 U/L	.	594	0
						6	S	28	2031 U/L	.	594	1
809 6440	M	Olz	E03	ALT/SGPT	HIGH	1	S	-3	30 U/L	.	165	0
						2	S	0	20 U/L	.	165	0
						3	S	7	29 U/L	.	165	0
						4	S	14	96 U/L	.	165	0
						5	S	21	195 U/L	.	165	1

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

809 6440	M	Olz	E03	ALT/SGPT	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
					6	S	28	279 U/L	.	165	1
					7	S	33	133 U/L	.	165	0
					8	S	41	68 U/L	.	165	0
					16	S	102	22 U/L	.	165	0
					18	S	157	15 U/L	.	165	0
					20	S	213	26 U/L	.	165	0
					22	S	273	26 U/L	.	165	0
811 6368	F	Ha1	C15	UA-MBC	1	S	-7	4 NO UNITS	.	3	1
					2	S	0	0 NO UNITS	.	3	0
					3	S	7	0 NO UNITS	.	3	0
					4	S	14	4 NO UNITS	.	3	1
					5	S	21	4 NO UNITS	.	3	1
					6	S	28	4 NO UNITS	.	3	1
					7	S	35	1 NO UNITS	.	3	0
813 6381	M	Olz	E12	CREATINE PHOSPHOKINASE	1	S	-5	202 U/L	.	594	0
					2	S	0	199 U/L	.	594	0
					3	S	7	155 U/L	.	594	0
					4	S	14	173 U/L	.	594	0
					5	S	21	182 U/L	.	594	0
					7	S	34	127 U/L	.	594	0
					8	S	43	173 U/L	.	594	0
					9	S	70	175 U/L	.	594	0
					16	S	105	191 U/L	.	594	0
					18	S	154	164 U/L	.	594	0
					20	S	210	340 U/L	.	594	0
					22	S	266	181 U/L	.	594	0
					24	S	321	2496 U/L	.	594	1
813 6410	F	Olz	F02	CREATININE	1	S	-2	163 umol/L	.	176.8	0
					2	S	0	167 umol/L	.	176.8	0
					3	S	7	197 umol/L	.	176.8	1
					5	S	21	196 umol/L	.	176.8	1
					6	S	28	194 umol/L	.	176.8	1
					10	S	39	186 umol/L	.	176.8	1
					11	S	48	174 umol/L	.	176.8	0
					12	S	56	179 umol/L	.	176.8	1
					13	S	63	174 umol/L	.	176.8	0
					14	S	70	184 umol/L	.	176.8	1
					15	S	77	177 umol/L	.	176.8	1
					16	S	91	169 umol/L	.	176.8	0
					18	S	147	173 umol/L	.	176.8	0
					19	U	175	188 umol/L	.	176.8	1
					20	S	202	173 umol/L	.	176.8	0
					22	S	258	173 umol/L	.	176.8	0
					24	S	319	176 umol/L	.	176.8	0

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

813 6410	F	01z	F02	F40	CREATININE	DIRECTN VISIT UNVISIT RELDAYS	RESULT UNIT	LOLIM	HILIM ABNRM
813 6410	F	01z	F40		URIC ACID	26 S	HIGH		
						357	185 umol/L		176.8 1
						-2	407 umol/L		505.58 0
						0	463 umol/L		505.58 0
						7	535 umol/L		505.58 1
						21	500 umol/L		505.58 0
						28	478 umol/L		505.58 0
						39	498 umol/L		505.58 0
						48	464 umol/L		505.58 0
						56	469 umol/L		505.58 0
						63	443 umol/L		505.58 0
						70	466 umol/L		505.58 0
						77	424 umol/L		505.58 0
						91	433 umol/L		505.58 0
						147	530 umol/L		505.58 1
						175	537 umol/L		505.58 1
						202	502 umol/L		505.58 0
						258	590 umol/L		505.58 1
						319	510 umol/L		505.58 1
						357	550 umol/L		505.58 1
813 6414	F	01z	C07		UA-GLUCOSE	1 S	INC2		3 0
						-2	1 NO UNITS		3 0
						0	0 NO UNITS		3 0
						14	3 NO UNITS		3 1
						21	1 NO UNITS		3 0
						28	1 NO UNITS		3 0
						42	2 NO UNITS		3 0
						50	2 NO UNITS		3 0
						57	3 NO UNITS		3 1
						64	3 NO UNITS		3 1
						71	2 NO UNITS		3 0
						77	3 NO UNITS		3 1
						91	3 NO UNITS		3 1
						148	3 NO UNITS		3 1
						203	0 NO UNITS		3 0
						264	0 NO UNITS		3 0
813 6414	F	01z	F31		GLUCOSE, NON-FASTING	1 S	HIGH		2.4975 13.875 0
						-2	11.5 mmol/L		2.4975 13.875 0
						0	9.9 mmol/L		2.4975 13.875 0
						8	14.4 mmol/L		2.4975 13.875 1
						14	15.4 mmol/L		2.4975 13.875 1
						21	12 mmol/L		2.4975 13.875 0
						28	15.6 mmol/L		2.4975 13.875 1
						42	11.2 mmol/L		2.4975 13.875 0
						50	19.7 mmol/L		2.4975 13.875 1
						57	21.9 mmol/L		2.4975 13.875 1
						64	23.8 mmol/L		2.4975 13.875 1

RMP.FIDTSSL.SASPEN(LABNTJX) 85266

ZY 1234 428

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
813	F	01z	F31	GLUCOSE, NON-FASTING	HIGH	14	S	71	15.8	mmol/L	2.4975	13.875	1
						15	S	77	16.4	mmol/L	2.4975	13.875	1
						16	S	91	18.7	mmol/L	2.4975	13.875	1
						18	S	148	18.2	mmol/L	2.4975	13.875	1
						20	S	203	11.8	mmol/L	2.4975	13.875	0
						22	S	264	11.4	mmol/L	2.4975	13.875	0
814	M	01z	E03	ALT/SGPT	HIGH	2	U	-1	50	U/L	.	165	0
						3	S	7	80	U/L	.	165	0
						4	S	14	170	U/L	.	165	1
						5	S	21	118	U/L	.	165	0
						6	S	28	106	U/L	.	165	0
						10	S	42	86	U/L	.	165	0
						11	S	49	103	U/L	.	165	0
						12	S	56	157	U/L	.	165	0
						13	S	63	146	U/L	.	165	0
						14	S	70	123	U/L	.	165	0
						15	S	77	131	U/L	.	165	0
						16	U	84	126	U/L	.	165	0
						16	S	91	120	U/L	.	165	0
						17	U	105	106	U/L	.	165	0
						18	S	147	152	U/L	.	165	0
						20	S	203	199	U/L	.	165	1
						22	S	259	156	U/L	.	165	0
						23	U	280	145	U/L	.	165	0
						24	S	315	208	U/L	.	165	1
816	M	Ha1	A03	ERYTHROCYTE COUNT	HIGH	1	S	-5	5.6	TI/L	3	6	0
						2	S	0	5.8	TI/L	3	6	0
						3	S	7	6.1	TI/L	3	6	1
						4	S	14	6.2	TI/L	3	6	1
						5	S	22	5.9	TI/L	3	6	0
816	M	01z	E17	GGT(SGGT/SGGT/YGGT)	HIGH	1	S	36	82	U/L	.	195	0
						10	S	44	216	U/L	.	195	1
						11	S	50	328	U/L	.	195	1
						12	S	55	317	U/L	.	195	1
816	M	01z	A01	HEMATOCRIT	LOW	1	S	-2	0.39	1	0.37	0.55	0
						3	S	7	0.42	1	0.37	0.55	0
						5	S	21	0.38	1	0.37	0.55	0
						7	S	40	0.39	1	0.37	0.55	0
						10	S	50	0.36	1	0.37	0.55	1
816	M	01z	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-2	56	U/L	.	594	0
						3	S	7	78	U/L	.	594	0
						5	S	21	100	U/L	.	594	0

34

816

816

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

ZY 1234 429

13:16 Wednesday, July 5, 1995 135

816	6557	M	OLZ	Ha1	E12	A10	CREATINE PHOSPHOKINASE	HIGH	7	S	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
									10	S		40	71 U/L	.	.	594 0
										S		50	3910 U/L	.	.	594 1
									1	S		-3	4.92 GI/L	2.8		16 0
								LOW	2	S		0	4.1 GI/L	2.8		16 0
									3	S		6	3.27 GI/L	2.8		16 0
									4	S		14	2.68 GI/L	2.8		16 1
									1	S		-2	6 TI/L	3		6 0
								HIGH	2	S		0	5.8 TI/L	3		6 0
									3	S		7	5.6 TI/L	3		6 0
									4	S		14	5.7 TI/L	3		6 0
									10	S		36	5.7 TI/L	3		6 0
									11	S		43	5.6 TI/L	3		6 0
									12	S		50	5.4 TI/L	3		6 0
									13	S		56	5.7 TI/L	3		6 0
									14	S		63	5.8 TI/L	3		6 0
									15	S		70	5.6 TI/L	3		6 0
									16	U		77	5.7 TI/L	3		6 0
									16	S		84	5.8 TI/L	3		6 0
									17	U		91	5.7 TI/L	3		6 0
									17	U		98	6 TI/L	3		6 0
									17	U		105	5.8 TI/L	3		6 0
									17	S		112	6.1 TI/L	3		6 1
									18	U		119	5.9 TI/L	3		6 0
									18	U		126	6.2 TI/L	3		6 1
									18	U		133	6.3 TI/L	3		6 1
									18	S		140	6 TI/L	3		6 0
									19	U		148	5.9 TI/L	3		6 0
									19	U		155	6 TI/L	3		6 0
									19	U		161	6 TI/L	3		6 0
									19	S		168	6 TI/L	3		6 0
									20	C		175	6 TI/L	3		6 0
									20	S		195	6.1 TI/L	3		6 1
									21	U		203	5.9 TI/L	3		6 0
									21	U		211	6 TI/L	3		6 0
									21	U		217	5.6 TI/L	3		6 0
									21	C		224	5.7 TI/L	3		6 0
									22	U		232	5.5 TI/L	3		6 0
									22	U		239	5.9 TI/L	3		6 0
									22	U		245	5.8 TI/L	3		6 0
									22	S		252	5.7 TI/L	3		6 0
									23	U		259	5.9 TI/L	3		6 0
									23	U		266	5.6 TI/L	3		6 0
									23	U		273	5.6 TI/L	3		6 0
									23	S		280	5.7 TI/L	3		6 0
									24	U		287	5.5 TI/L	3		6 0

RMP.FIDSTG.S1.SASPGM(LABNTJX) 85266

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

850 7065 M 01z A03 ERYTHROCYTE COUNT

DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
24	U	294	5.7 TI/L	3	6	0
24	U	302	5.6 TI/L	3	6	0
24	S	309	5.7 TI/L	3	6	0
25	U	315	5.6 TI/L	3	6	0
25	U	323	5.7 TI/L	3	6	0
25	U	330	5.6 TI/L	3	6	0
25	S	337	6 TI/L	3	6	0
26	U	344	5.8 TI/L	3	6	0
26	S	351	5.4 TI/L	3	6	0
27	U	358	5.6 TI/L	3	6	0
27	U	365	5.5 TI/L	3	6	0
27	U	372	5.6 TI/L	3	6	0
27	U	379	5.7 TI/L	3	6	0
27	U	385	5.6 TI/L	3	6	0
27	U	393	5.8 TI/L	3	6	0
27	U	400	5.8 TI/L	3	6	0
27	S	407	5.7 TI/L	3	6	0
28	U	414	5.7 TI/L	3	6	0
28	U	421	5.7 TI/L	3	6	0
28	U	428	5.8 TI/L	3	6	0

850 7080 M Ha1 A03 ERYTHROCYTE COUNT HIGH

850 7080 M Ha1 E12 CREATINE PHOSPHOKINASE HIGH

1	S	-2	194 U/L	.	594	0
2	S	0	290 U/L	.	594	0
3	S	7	1180 U/L	.	594	1
4	U	9	1070 U/L	.	594	1
4	U	13	372 U/L	.	594	0
4	S	14	282 U/L	.	594	0
5	S	21	231 U/L	.	594	0
6	S	27	357 U/L	.	594	0

850 7080 M Ha1 F07 SODIUM LOW

1	S	-2	136 mmol/L	129	160	0
2	S	0	134 mmol/L	129	160	0
3	S	7	131 mmol/L	129	160	0
4	U	9	132 mmol/L	129	160	0
4	U	13	133 mmol/L	129	160	0
4	S	14	133 mmol/L	129	160	0
5	S	21	133 mmol/L	129	160	0
6	S	27	128 mmol/L	129	160	1

RMP.FIDTSS1.SASPGM(LABNTJX)

85266

13:18 Wednesday, July 5, 1995 136

ZY 1234 430

ZY 1234 431

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

850 7081	F	OLz	E03	ALT/SGPT	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
					HIGH	S	36	16 U/L	.	165	0
						S	43	105 U/L	.	165	0
						S	50	119 U/L	.	165	0
						S	57	105 U/L	.	165	0
						S	65	216 U/L	.	165	1
						S	70	200 U/L	.	165	1
						S	76	160 U/L	.	165	0
						U	84	122 U/L	.	165	0
						S	91	83 U/L	.	165	0
						U	104	171 U/L	.	165	1
						S	148	48 U/L	.	165	0
						S	205	24 U/L	.	165	0
						S	260	22 U/L	.	165	0
						S	-3	13.5 GI/L	2.8	16	0
					HIGH	S	0	10.09 GI/L	2.8	16	0
						S	7	10.42 GI/L	2.8	16	0
						S	16	9.29 GI/L	2.8	16	0
						S	23	8.55 GI/L	2.8	16	0
						S	28	13.31 GI/L	2.8	16	0
						S	32	5.68 GI/L	2.8	16	0
						S	44	12.07 GI/L	2.8	16	0
						S	58	6.1 GI/L	2.8	16	0
						S	64	9.36 GI/L	2.8	16	0
						S	72	9.46 GI/L	2.8	16	0
						S	78	12.81 GI/L	2.8	16	0
						S	85	14.22 GI/L	2.8	16	0
						U	93	7.27 GI/L	2.8	16	0
						S	99	7.88 GI/L	2.8	16	0
						U	107	7.78 GI/L	2.8	16	0
						U	113	8.7 GI/L	2.8	16	0
						U	120	6.22 GI/L	2.8	16	0
						S	123	6.95 GI/L	2.8	16	0
						U	128	5.73 GI/L	2.8	16	0
						U	142	10.05 GI/L	2.8	16	0
						U	147	11.3 GI/L	2.8	16	0
						U	154	7.99 GI/L	2.8	16	0
						C	155	7.27 GI/L	2.8	16	0
						S	163	7.2 GI/L	2.8	16	0
						U	169	17.25 GI/L	2.8	16	1
						U	177	16.43 GI/L	2.8	16	1
						U	184	7.93 GI/L	2.8	16	0
						S	189	7.83 GI/L	2.8	16	0
						U	198	7.48 GI/L	2.8	16	0
						U	205	5.35 GI/L	2.8	16	0
						U	212	7.65 GI/L	2.8	16	0
						S	219	13.04 GI/L	2.8	16	0

851 7072 F OLz A10 LEUCOCYTE COUNT 29

30

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
851	7072	F	01z	A10	LEUCOCYTE	COUNT	HIGH	21	U	224	9.03	GI/L	16
								21	U	232	10.54	GI/L	16
								21	U	238	8.21	GI/L	16
								22	U	260	9.56	GI/L	16
								22	U	268	8.93	GI/L	16
								22	C	245	13.33	GI/L	16
								22	S	275	9.53	GI/L	16
								23	U	281	8.2	GI/L	16
								23	U	288	6.86	GI/L	16
								23	U	295	14.44	GI/L	16
851	7090	F	01z	A02	HEMOGLOBIN		HIGH	1	S	29	10.1158	mmL/L-Fe	5.8957
								10	S	36	9.99166	mmL/L-Fe	5.8957
								11	S	43	9.24694	mmL/L-Fe	5.8957
								12	S	50	9.68136	mmL/L-Fe	5.8957
								13	S	57	9.9296	mmL/L-Fe	5.8957
								14	S	67	9.6193	mmL/L-Fe	5.8957
								15	S	71	9.49518	mmL/L-Fe	5.8957
								16	U	78	9.43312	mmL/L-Fe	5.8957
								16	S	85	9.74342	mmL/L-Fe	5.8957
								17	U	92	9.43312	mmL/L-Fe	5.8957
								17	U	99	9.74342	mmL/L-Fe	5.8957
								17	U	106	9.37106	mmL/L-Fe	5.8957
								18	U	120	9.43312	mmL/L-Fe	5.8957
								18	U	127	10.2399	mmL/L-Fe	5.8957
								18	U	134	9.9296	mmL/L-Fe	5.8957
								18	C	113	9.68136	mmL/L-Fe	5.8957
								18	S	140	9.9296	mmL/L-Fe	5.8957
								19	U	148	9.80548	mmL/L-Fe	5.8957
								19	U	155	10.302	mmL/L-Fe	5.8957
								19	U	162	10.302	mmL/L-Fe	5.8957
								20	U	169	10.1778	mmL/L-Fe	5.8957
								20	U	176	10.4261	mmL/L-Fe	5.8957
								20	U	182	10.2399	mmL/L-Fe	5.8957
								20	U	189	9.99166	mmL/L-Fe	5.8957
								20	S	197	10.4261	mmL/L-Fe	5.8957
								21	U	204	10.7364	mmL/L-Fe	5.8957
								21	U	211	10.1778	mmL/L-Fe	5.8957
								21	U	218	9.9296	mmL/L-Fe	5.8957
								22	U	231	10.364	mmL/L-Fe	5.8957
								22	C	225	10.1778	mmL/L-Fe	5.8957
851	7090	F	01z	E17	GGT	(GGPT/SGGT/YGGT)	HIGH	1	S	29	89	U/L	135
								10	S	36	126	U/L	135
								11	S	43	173	U/L	135
								12	S	50	166	U/L	135
								13	S	57	172	U/L	135

ZY 1234 433

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

851 7090	F	OLz	E17	GGT(GEPT/SGGT/YGGT)	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
					HIGH	S	67	225 U/L	.	135	1
					14	S	71	217 U/L	.	135	1
					15	S	78	210 U/L	.	135	1
					16	U	85	169 U/L	.	135	1
					16	S	92	130 U/L	.	135	0
					17	U	99	107 U/L	.	135	0
					17	U	106	92 U/L	.	135	0
					17	U	120	109 U/L	.	135	0
					18	U	127	115 U/L	.	135	0
					18	U	134	97 U/L	.	135	0
					18	C	113	111 U/L	.	135	0
					18	S	140	115 U/L	.	135	0
					19	U	148	100 U/L	.	135	0
					19	U	155	120 U/L	.	135	0
					19	U	162	142 U/L	.	135	1
					20	U	169	162 U/L	.	135	1
					20	U	176	145 U/L	.	135	1
					20	U	182	141 U/L	.	135	1
					20	U	189	160 U/L	.	135	1
					20	S	197	127 U/L	.	135	0
					21	U	204	162 U/L	.	135	1
851 7107	M	OLz	A10	LEUCOCYTE COUNT	HIGH	S	-5	10.03 GI/L	2.8	16	0
					2	S	0	11.89 GI/L	2.8	16	0
					3	S	7	10.82 GI/L	2.8	16	0
					4	S	14	8.77 GI/L	2.8	16	0
					5	S	20	13.28 GI/L	2.8	16	0
					6	S	24	9.68 GI/L	2.8	16	0
					7	S	34	9.42 GI/L	2.8	16	0
					8	S	42	10.77 GI/L	2.8	16	0
					9	C	49	11.44 GI/L	2.8	16	0
					9	C	56	9.27 GI/L	2.8	16	0
					9	C	63	10.28 GI/L	2.8	16	0
					9	S	70	12.77 GI/L	2.8	16	0
					16	U	77	10.77 GI/L	2.8	16	0
					16	U	84	12.15 GI/L	2.8	16	0
					16	U	91	9.54 GI/L	2.8	16	0
					16	S	98	8.76 GI/L	2.8	16	0
					17	U	105	9.3 GI/L	2.8	16	0
					17	U	112	7.36 GI/L	2.8	16	0
					17	U	119	10.16 GI/L	2.8	16	0
					18	U	134	9.96 GI/L	2.8	16	0
					18	U	140	11.23 GI/L	2.8	16	0
					18	U	148	8.68 GI/L	2.8	16	0
					18	C	126	8.87 GI/L	2.8	16	0
					18	S	155	10.7 GI/L	2.8	16	0
					19	U	161	8.78 GI/L	2.8	16	0

ZY 1234 434

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

851 7107	M	Olz	A10	A10	LEUCOCYTE COUNT	DIRECTN VISIT UNVISIT RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
						168	11.79 GI/L	2.8		0
						175	8.06 GI/L	2.8		0
						183	8.43 GI/L	2.8		0
						189	8.1 GI/L	2.8		0
						196	17.06 GI/L	2.8		1
990 7724	F	Olz	C11	UA-RBC	INC2	-7	0 NO UNITS	.		3
						0	0 NO UNITS	.		3
						12	0 NO UNITS	.		3
						21	0 NO UNITS	.		3
						28	0 NO UNITS	.		3
						35	0 NO UNITS	.		3
						54	0 NO UNITS	.		3
						61	0 NO UNITS	.		3
						68	0 NO UNITS	.		3
						75	0 NO UNITS	.		3
						82	1 NO UNITS	.		3
						89	0 NO UNITS	.		3
						103	0 NO UNITS	.		3
						159	0 NO UNITS	.		3
						215	0 NO UNITS	.		3
						222	4 NO UNITS	.		3
						225	4 NO UNITS	.		1
990 7727	F	Ha1	C11	UA-RBC	INC2	-7	0 NO UNITS	.		3
						7	0 NO UNITS	.		3
						14	0 NO UNITS	.		3
						21	0 NO UNITS	.		3
						28	0 NO UNITS	.		3
						35	0 NO UNITS	.		3
						42	4 NO UNITS	.		3
990 7727	F	Ha1	C15	UA-RBC	INC2	-7	0 NO UNITS	.		3
						7	0 NO UNITS	.		3
						14	0 NO UNITS	.		3
						21	0 NO UNITS	.		3
						28	0 NO UNITS	.		3
						35	0 NO UNITS	.		3
						42	4 NO UNITS	.		3
990 7754	M	Olz	A16	EOSINOPHILS	HIGH	-5	6.05381 % WBC	.		10
						0	5.91966 % WBC	.		10
						9	8.41121 % WBC	.		10
						14	6.11855 % WBC	.		10
						21	7.03518 % WBC	.		10
						28	17.6183 % WBC	.		10
						35	18.6589 % WBC	.		10

(✓)

ZY 1234 435

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

991 7748	F	01z	C11	UA-RBC	INC2	DIRECTN VISIT UNVISIT REIDAYS	RESULT UNIT	LOLIM	HILIM ABRNM
						-5	4 NO UNITS	.	3 1
						0	0 NO UNITS	.	3 0
						7	0 NO UNITS	.	3 0
						14	0 NO UNITS	.	3 0
						21	1 NO UNITS	.	3 0
						28	0 NO UNITS	.	3 0
						35	0 NO UNITS	.	3 0
						42	0 NO UNITS	.	3 0
						70	0 NO UNITS	.	3 0
						73	0 NO UNITS	.	3 0
						98	4 NO UNITS	.	3 1
991 7748	F	01z	C15	UA-WBC	INC2	-5	4 NO UNITS	.	3 1
						0	0 NO UNITS	.	3 0
						7	1 NO UNITS	.	3 0
						14	1 NO UNITS	.	3 0
						21	1 NO UNITS	.	3 0
						28	1 NO UNITS	.	3 0
						35	1 NO UNITS	.	3 0
						42	0 NO UNITS	.	3 0
						70	1 NO UNITS	.	3 0
						73	1 NO UNITS	.	3 0
						98	4 NO UNITS	.	3 1
992 7745	F	01z	E12	CREATINE PHOSPHOKINASE	HIGH	-6	183 U/L	.	507 0
						0	38 U/L	.	507 0
						8	81 U/L	.	507 0
						15	1092 U/L	.	507 1
						22	1091 U/L	.	507 1
						28	429 U/L	.	507 0
						35	65 U/L	.	507 0
						42	54 U/L	.	507 0
						58	110 U/L	.	507 0
992 7774	F	01z	A16	EOSINOPHILS	HIGH	-2	9.30979 % WBC	.	10 0
						0	7.38137 % WBC	.	10 0
						7	10.772 % WBC	.	10 1
						14	2.31023 % WBC	.	10 0
						21	9.12477 % WBC	.	10 0
						28	13.1261 % WBC	.	10 1
						35	11.619 % WBC	.	10 1
						42	13.5135 % WBC	.	10 1
						71	8.10811 % WBC	.	10 0
992 7774	F	01z	C11	UA-RBC	INC2	-2	0 NO UNITS	.	3 0
						0	0 NO UNITS	.	3 0
						7	0 NO UNITS	.	3 0

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

LOLIM HILIM ABNRM

992 7774	F	01z	C11	UA-RBC	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
					INC2	4	S	14	2 NO UNITS	.	3	0
						5	S	21	4 NO UNITS	.	3	1
						6	S	28	4 NO UNITS	.	3	1
						7	S	35	0 NO UNITS	.	3	0
						8	S	42	0 NO UNITS	.	3	0
						9	S	71	0 NO UNITS	.	3	0

992 7774	F	01z	C15	UA-WBC	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
					INC2	1	S	-2	0 NO UNITS	.	3	0
						2	S	0	0 NO UNITS	.	3	0
						3	S	7	0 NO UNITS	.	3	0
						4	S	14	4 NO UNITS	.	3	1
						5	S	21	4 NO UNITS	.	3	1
						6	S	28	4 NO UNITS	.	3	1
						7	S	35	0 NO UNITS	.	3	0
						8	S	42	0 NO UNITS	.	3	0
						9	S	71	0 NO UNITS	.	3	0

993 7761	M	Ha1	E17	GGT(GGPT/SGGT/YGGT)	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
					HIGH	1	S	-2	177 U/L	.	195	0
						2	S	0	154 U/L	.	195	0
						3	S	6	123 U/L	.	195	0
						4	S	13	150 U/L	.	195	0
						5	S	20	216 U/L	.	195	1
						6	S	27	246 U/L	.	195	1
						7	S	35	158 U/L	.	195	0

994 7792	F	01z	A01	HEMATOCRIT	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
					HIGH	1	S	-3	0.45 1	0.32	0.5	0
						2	S	0	0.45 1	0.32	0.5	0
						3	S	5	0.51 1	0.32	0.5	1
						4	S	12	0.51 1	0.32	0.5	1
						5	S	18	0.49 1	0.32	0.5	0
						6	S	25	0.49 1	0.32	0.5	0
						10	S	34	0.47 1	0.32	0.5	0
						11	S	41	0.47 1	0.32	0.5	0
						12	S	48	0.49 1	0.32	0.5	0
						13	S	54	0.47 1	0.32	0.5	0
						14	S	61	0.46 1	0.32	0.5	0
						15	S	68	0.46 1	0.32	0.5	0
						16	S	81	0.45 1	0.32	0.5	0
						18	S	144	0.44 1	0.32	0.5	0
						20	S	202	0.46 1	0.32	0.5	0

994 7793	F	01z	A10	LEUCOCYTE COUNT	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
					HIGH	1	S	-7	11.76 GI/L	2.8	16	0
						2	S	0	14.23 GI/L	2.8	16	0
						3	S	7	10.59 GI/L	2.8	16	0
						4	S	14	9.6 GI/L	2.8	16	0
						5	S	21	11.21 GI/L	2.8	16	0
						7	S	35	9.41 GI/L	2.8	16	0

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

994 7793	F	Olz	A10	LEUCOCYTE COUNT	HIGH	8	S	42	9.45 GI/L	2.8	16	0
						10	S	50	10.27 GI/L	2.8	16	0
						11	S	57	10.52 GI/L	2.8	16	0
						12	S	63	10.89 GI/L	2.8	16	0
						13	S	69	12.52 GI/L	2.8	16	0
						14	S	76	12.06 GI/L	2.8	16	0
						15	S	83	12.84 GI/L	2.8	16	0
						16	S	93	18.85 GI/L	2.8	16	1
994 7796	M	Olz	E12	CREATINE PHOSPHOKINASE	HIGH	1	S	-3	65 U/L	.	594	0
						2	S	0	63 U/L	.	594	0
						3	S	5	71 U/L	.	594	0
						4	S	7	1682 U/L	.	594	1
994 7797	F	Ha1	A01	HEMATOCRIT	HIGH	1	S	-6	0.48 1	0.32	0.5	0
						2	S	0	0.5 1	0.32	0.5	0
						3	S	7	0.49 1	0.32	0.5	0
						4	S	14	0.5 1	0.32	0.5	0
						5	S	22	0.49 1	0.32	0.5	0
						6	S	29	0.47 1	0.32	0.5	1
						7	S	37	0.52 1	0.32	0.5	1
						8	S	44	0.51 1	0.32	0.5	1
						16	S	105	0.48 1	0.32	0.5	0
						18	S	161	0.48 1	0.32	0.5	0
						20	S	213	0.46 1	0.32	0.5	0
994 7797	F	Ha1	F40	URIC ACID	HIGH	1	S	-6	480 umol/L	.	505.58	0
						2	S	0	502 umol/L	.	505.58	0
						3	S	7	441 umol/L	.	505.58	0
						4	S	14	461 umol/L	.	505.58	0
						5	S	22	451 umol/L	.	505.58	0
						6	S	29	432 umol/L	.	505.58	0
						7	S	37	481 umol/L	.	505.58	0
						8	S	44	515 umol/L	.	505.58	1
						16	S	105	511 umol/L	.	505.58	1
						18	S	161	481 umol/L	.	505.58	0
						20	S	213	469 umol/L	.	505.58	0
994 7827	F	Olz	A01	HEMATOCRIT	HIGH	1	S	-5	0.45 1	0.32	0.5	0
						2	S	0	0.47 1	0.32	0.5	0
						3	S	7	0.46 1	0.32	0.5	0
						4	S	14	0.49 1	0.32	0.5	0
						5	S	22	0.51 1	0.32	0.5	1
						6	S	29	0.51 1	0.32	0.5	1
						7	S	34	0.52 1	0.32	0.5	1
						10	S	41	0.47 1	0.32	0.5	0
						11	S	48	0.5 1	0.32	0.5	0

ZY 1234 438

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

997 7882	F	01z	C15	UA-MBC	INC2	26	S	366	2 NO UNITS	LOLIM	HILIM	ABNRM
997 7883	M	Ha1	C11	UA-RBC	INC2	27	S	421	0 NO UNITS	.	.	.
						1	S	-2	0 NO UNITS	.	.	3 0
						2	S	0	0 NO UNITS	.	.	3 0
						3	S	7	0 NO UNITS	.	.	3 0
						4	S	14	2 NO UNITS	.	.	3 0
						5	S	21	4 NO UNITS	.	.	3 1
						6	S	27	4 NO UNITS	.	.	3 1
						7	S	33	0 NO UNITS	.	.	3 0
						8	S	40	0 NO UNITS	.	.	3 0
						9	U	42	1 NO UNITS	.	.	3 0
						9	S	62	0 NO UNITS	.	.	3 0
997 7891	F	01z	C15	UA-MBC	INC2	1	S	-2	0 NO UNITS	.	.	3 0
						2	S	0	0 NO UNITS	.	.	3 0
						3	S	7	0 NO UNITS	.	.	3 0
						4	S	13	0 NO UNITS	.	.	3 0
						5	S	20	0 NO UNITS	.	.	3 0
						6	S	27	0 NO UNITS	.	.	3 0
						7	S	34	0 NO UNITS	.	.	3 0
						8	S	41	0 NO UNITS	.	.	3 0
						16	S	99	0 NO UNITS	.	.	3 0
						18	S	153	1 NO UNITS	.	.	3 0
						19	S	182	4 NO UNITS	.	.	3 1
997 7891	F	01z	E03	ALT/SGPT	HIGH	1	S	-2	23 U/L	.	.	165 0
						2	S	0	23 U/L	.	.	165 0
						3	S	7	18 U/L	.	.	165 0
						4	S	13	14 U/L	.	.	165 0
						5	S	20	17 U/L	.	.	165 0
						6	S	27	19 U/L	.	.	165 0
						7	S	34	16 U/L	.	.	165 0
						8	S	41	17 U/L	.	.	165 0
						16	S	99	9 U/L	.	.	165 0
						18	S	153	18 U/L	.	.	165 0
						19	S	182	234 U/L	.	.	165 1
997 7891	F	01z	E17	GGT(GGPT/SGGT/UGGT)	HIGH	1	S	-2	17 U/L	.	.	135 0
						2	S	0	16 U/L	.	.	135 0
						3	S	7	16 U/L	.	.	135 0
						4	S	13	12 U/L	.	.	135 0
						5	S	20	14 U/L	.	.	135 0
						6	S	27	14 U/L	.	.	135 0
						7	S	34	12 U/L	.	.	135 0
						8	S	41	12 U/L	.	.	135 0
						16	S	99	15 U/L	.	.	135 0

ZY 1234 439

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS
INV PATIENT GENDER THERAPY ANALYTCD ANALYTE

994	7827	F	01z	A01	HEMATOCRIT	DIRECTN VISIT	UNVISIT	RELDAYS	RESULT UNIT	LOLIM	HILIM	ABNRM
						HIGH	12	S	55 0.49 I	0.32	0.5	0
							13	S	62 0.43 I	0.32	0.5	0
996	7872	F	01z	C11	UA-RBC	INC2	1	S	-7 0 NO UNITS	.	.	3 0
							2	S	0 NO UNITS	.	.	3 0
							3	S	7 4 NO UNITS	.	.	3 1
							4	S	14 0 NO UNITS	.	.	3 0
							6	S	28 4 NO UNITS	.	.	3 1
							7	S	35 4 NO UNITS	.	.	3 1
							8	S	42 1 NO UNITS	.	.	3 0
							16	U	70 0 NO UNITS	.	.	3 0
							16	S	98 2 NO UNITS	.	.	3 0
							18	U	126 0 NO UNITS	.	.	3 0
							19	U	183 4 NO UNITS	.	.	3 1
							20	S	210 1 NO UNITS	.	.	3 0
							22	S	261 1 NO UNITS	.	.	3 0
996	7901	F	Ha1	C11	UA-RBC	INC2	1	S	-4 0 NO UNITS	.	.	3 0
							4	S	12 0 NO UNITS	.	.	3 0
							5	U	18 0 NO UNITS	.	.	3 0
							6	S	25 0 NO UNITS	.	.	3 0
							7	S	32 0 NO UNITS	.	.	3 0
							8	S	38 0 NO UNITS	.	.	3 0
							16	S	94 4 NO UNITS	.	.	3 1
							18	S	150 3 NO UNITS	.	.	3 1
							20	S	206 1 NO UNITS	.	.	3 0
							22	S	262 0 NO UNITS	.	.	3 0
997	7882	F	01z	C15	UA-RBC	INC2	1	S	-8 0 NO UNITS	.	.	3 0
							2	S	0 1 NO UNITS	.	.	3 0
							3	S	7 0 NO UNITS	.	.	3 0
							4	S	13 4 NO UNITS	.	.	3 1
							5	S	20 4 NO UNITS	.	.	3 1
							6	S	27 0 NO UNITS	.	.	3 0
							7	S	33 1 NO UNITS	.	.	3 0
							8	S	40 0 NO UNITS	.	.	3 0
							10	S	50 0 NO UNITS	.	.	3 0
							11	S	57 0 NO UNITS	.	.	3 0
							12	S	64 0 NO UNITS	.	.	3 0
							13	S	71 0 NO UNITS	.	.	3 0
							14	S	78 0 NO UNITS	.	.	3 0
							15	S	85 0 NO UNITS	.	.	3 0
							16	S	99 0 NO UNITS	.	.	3 0
							18	S	155 0 NO UNITS	.	.	3 0
							20	S	211 0 NO UNITS	.	.	3 0
							22	S	267 0 NO UNITS	.	.	3 0
							24	S	322 1 NO UNITS	.	.	3 0

ZY 1234 440

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	E17	E17	F40	GGT(GGPT/SGPT/YGGT)	URIC ACID	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
997 7891	F	Olz								HIGH	18	S	153	14	U/L	.	135	0
											19	S	182	168	U/L	.	135	1
997 7914	F	Olz								HIGH	1	S	-7	262	umol/L	.	505.58	0
											2	S	0	179	umol/L	.	505.58	0
											3	S	7	224	umol/L	.	505.58	0
											4	S	14	245	umol/L	.	505.58	0
											5	S	21	238	umol/L	.	505.58	0
											6	S	27	248	umol/L	.	505.58	0
											7	S	35	429	umol/L	.	505.58	0
											8	S	42	320	umol/L	.	505.58	0
											9	S	70	537	umol/L	.	505.58	1
997 7925	M	Olz			A16					HIGH	1	S	-7	1.90583	% WBC	.	10	0
											2	S	0	1.25224	% WBC	.	10	0
											3	S	7	2.52525	% WBC	.	10	0
											4	S	14	2.17114	% WBC	.	10	0
											5	S	20	2.90698	% WBC	.	10	0
											6	S	28	1.81818	% WBC	.	10	0
											7	S	35	2.71116	% WBC	.	10	0
											8	S	42	5.38793	% WBC	.	10	0
											10	S	56	13.3753	% WBC	.	10	1
											11	S	63	31.0367	% WBC	.	10	1
											12	S	70	17.1095	% WBC	.	10	1
											13	S	77	9.35351	% WBC	.	10	0
											14	S	83	9.48992	% WBC	.	10	0
											15	S	91	3.80079	% WBC	.	10	0
											16	S	105	5.62771	% WBC	.	10	0
											18	S	161	2.58824	% WBC	.	10	0
											20	S	217	0.91185	% WBC	.	10	0
997 7936	F	Olz			E17					HIGH	1	S	-5	42	U/L	.	135	0
											2	S	0	40	U/L	.	135	0
											3	S	7	157	U/L	.	135	1
											4	S	14	149	U/L	.	135	1
											5	S	21	98	U/L	.	135	0
											6	S	28	136	U/L	.	135	1
											7	S	35	125	U/L	.	135	0
											8	S	42	138	U/L	.	135	1
											16	U	73	57	U/L	.	135	0
											16	S	98	44	U/L	.	135	0
											18	S	154	58	U/L	.	135	0
997 7938	M	Olz			E03					HIGH	1	S	-4	13	U/L	.	165	0
											2	S	0	13	U/L	.	165	0
											3	S	7	20	U/L	.	165	0
											4	S	14	25	U/L	.	165	0

13:18 Wednesday, July 5, 1995 147

ZY 1234 441

ELI LILLY AND COMPANY
FID-MC-HGAJ (ALL PHASES)

NOTABLE PATIENTS' LABS
ABNORMAL AT ENDPOINT OR 2 CONSECUTIVE LABS

INV PATIENT	GENDER	THERAPY	ANALYTCD	ANALYTE	HIGH	DIRECTN	VISIT	UNVISIT	RELDAYS	RESULT	UNIT	LOLIM	HILIM	ABNRM
997	M	01z	E03	ALT/SOPT			5	S	21	88	U/L	.	165	0
							6	S	28	216	U/L	.	165	1
							7	U	31	222	U/L	.	165	1
							7	S	35	167	U/L	.	165	1
							8	S	42	116	U/L	.	165	0
							16	S	98	73	U/L	.	165	0
							18	S	154	94	U/L	.	165	0

haloperidol treatment group. Patients in the Olz10.0 treatment group had the largest incidence of high ALT/SGPT values. This incidence was statistically significantly greater than that in the Olz1.0 treatment group, but not in the placebo treatment group. Several urinary analytes were also statistically significantly different among treatment groups. However, the placebo treatment group had the highest incidence of elevations for these analytes.]]

Table HGAJ.7.1. [[E]]. Statistically Significant (p<.05) Treatment-Emergent Abnormal, High, or Low Laboratory Values at Any Time
F1D-MC-HGAJ Acute Phase

Laboratory Analyte	Abnormal, High, or Low	Treatment Group		p-Value
		Olz (1336) N n (%)	Hal (660) N n (%)	
5 Eosinophils	High	1272. 61 (4.8)	616. 7 (1.1)	<.001 ✓
3 AST/SGOT	High	1290. 56 (4.3)	632. 9 (1.4)	.001 ✓
2 ALT/SGPT	High	1284. 13 (1.0)	630. 9 (1.4)	<.001 ✓
1 Albumin	High	1291. 2 (0.2)	626. 7 (1.1)	.004 ✓
6 Glucose, n.f.	High	1284. 34 (2.6)	625. 7 (1.1)	.031 ✓
4 Cholesterol	High	1272. 29 (2.3)	622. 5 (0.8)	.023 ✓
7 Prolactin	High	704. 339 (33.9)	265. 172 (64.9)	<.001 ✓
3 MCHC	Low	1271. 55 (4.3)	610. 15 (2.5)	.045 ✓
4 Phosphorus (i)	Low	1267. 46 (3.6)	619. 10 (1.6)	.015 ✓
1 Albumin	Low	1275. 80 (6.3)	624. 15 (2.4)	<.001 ✓
5 Uric acid	Low	1282. 4 (0.3)	626. 9 (1.4)	.005 ✓
2 Bicarbonate	Low	1117. 214 (19.2)	542. 68 (12.5)	.001 ✓
3 Urine protein	Abnormal	1122. 143 (12.7)	539. 89 (16.5)	.038 ✓

LAB 4
Old Ankle

1289. 102 (7.9) 629. 7 (1.1)

Take out Jones

Abbreviations: Olz1.0 = olanzapine 1.0 mg/day; Olz10.0 = olanzapine 10.0 mg/day; vs = versus; ALT/SGPT = alanine transaminase; UA = urinalysis.

AST/SGOT = aspartate transaminase
n.f. = non fasting

*N = total number of at-risk patients with the lab test.
n = total number of sub-patients with the specific abnormality (e.g. high)*

1.5.6. Individual Marked Laboratory Abnormalities

Table HGAJ.7.1. [[F]] displays the low and high limits used to identify patients with individual marked abnormalities in selected clinical chemistry, hematology, and urinalysis analytes. These criteria are different from the reference ranges (Lilly and SciCor) used to determine abnormal laboratory values. A high-marked abnormality was defined as a change from a value less than or equal to the high limit at all baseline visits to a value greater than the high limit at endpoint or for two consecutive measures during the acute phase. A low-marked abnormality was defined as a change from a value greater than or equal to the low limit at all baseline visits to a value less than the low limit at endpoint or for two consecutive measures during the acute phase. The exception to

Table HGAJ.7.1.35 summarizes the analysis of treatment-emergent high or low laboratory values at any time during the acute phase. Patients in the Olz treatment group had a significantly higher incidence of high eosinophil (p<.001), ALT/SGPT (p<.001), AST/SGOT (p=.001), phosphorous (p=.046), non-fasting glucose (p=.031), and cholesterol (p=.023) concentrations than patients in the Hal treatment group. Patients in the Hal treatment group had a significantly higher incidence of high albumin (p=.004) and prolactin (p<.001) concentrations than patients in the Olz treatment group. Patients in the Olz treatment group had a significantly higher incidence of low MCHC (p=.045), phosphorus (p=.015), albumin (p<.001), and bicarbonate (p=.001) concentrations than patients in the Hal treatment group. Patients in the Hal treatment group had a significantly higher incidence of low uric acid (p=.005) and abnormal urine protein (p=.023).

Table HGAJ.7.1.35. Statistically Significant (p≤.05) Treatment-Emergent Abnormal, High, or Low Laboratory Values at Any Time F1D-MC-HGAJ Acute Phase

Laboratory Analyte	Abnormal, High, or Low	Treatment Group		p-Value		
		Olz (1336 pats)	Hal(660 pats)			
		N	n (%)	N	n (%)	p-value
Eosinophils	High	1272	62 (4.9)	616	7 (1.1)	<.001
AST/SGOT	High	1290	57 (4.4)	632	9 (1.4)	.001
ALT/SGPT	High	1289	102 (7.9)	629	7 (1.1)	<.001
Phosphorous	High	1269	64 (5.0)	624	19 (3.0)	.046
Albumin	High	1291	2 (0.2)	626	7 (1.1)	.004
Glucose, n.f.	High	1284	34 (2.6)	625	7 (1.1)	.031
Cholesterol	High	1272	29 (2.3)	622	5 (0.8)	.023
Prolactin	High	718	244 (34.0)	278	180 (64.7)	<.001
MCHC	Low	1271	56 (4.3)	610	15 (2.5)	.045
Phosphorus	Low	1267	46 (3.6)	619	10 (1.6)	.015
Albumin	Low	1275	80 (6.3)	624	15 (2.4)	<.001
Uric acid	Low	1282	4 (0.3)	626	9 (1.4)	.005
Bicarbonate	Low	1117	216 (19.3)	542	68 (12.5)	.001
Urine protein	Abnormal	1122	143 (12.7)	539	91 (16.9)	.023

Abbreviations: Olz = olanzapine 5, 10, 15, or 20 mg/day, Hal = haloperidol 5, 10, 15, or 20 mg/day, pats = patients, N = total number of at-risk patients with this lab test, n = total number of at-risk patients with the specific lab result, ALT/SGPT = alanine transaminase, AST/SGOT = aspartate transaminase, n. f. = non fasting, MCHC = mean corpuscular hemoglobin concentration.

ZY 1234 870